KOL | Rikard HolmdahlNational and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China | Medical ... |
Kol Lebenslauf für Rikard Holmdahl
| Year | |
|---|---|
| 2022 | National and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China Medical Inflammation Research, MediCity Research Laboratory, University of Turku, Turku, Finland |
| 2021 | The Second Affiliated Hospital of Xi’an Jiaotong University (Xibei Hospital), Xi’an, China Department Medical Biochemistry and Biophysics, Division Medical Inflammation Research, Karolinska Institute, 171 77 Stockholm, Sweden;, (M.A.);, (X.C.);, (B.X.);, (G.F.L.);, (M.Y.B.);, (Y.H.);, (L.B.) Division of Medical Inflammation Research, Dept. of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden |
| 2020 | Dept. of Medical Inflammation Research, Section of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm Section for Medical Inflammation Research, BMCI11, Lund University, Lund, Sweden National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital, Xi'an Jiaotong University, 710004 Xi’an, China Karolinska Institutet |
| 2019 | Section for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Solnavägen 9, 171 65, Solna, Sweden Center for Medical Inflammation Research, Southern Medical University, Guangzhou, China R. Holmdahl and C.I. Svensson contributed equally to this paper. |
| 2018 | School of Pharmaceutical Science, Southern Medical University, Guangzhou, China Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 17177, Sweden. Electronic address: Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden Medicity Research Laboratory, University of Turku, Turku, Finland |
| 2017 | Karolinska Institutet Division of Medical Inflammation Research Stockholm Sweden Center for Medical Immunopharmacology Research, Southern Medical University, 510515 Guangzhou, China. Medicity Research Laboratory, University of Turku, Turku, Finland, . |
Rikard Holmdahl: Einflussstatistik
Bericht ausführen
| Concept | World rank |
|---|---|
| cii dendritic cells | #1 |
| dth nzb mice | #1 |
| arthritis encephalomyelitis | #1 |
| arthritis severity rats | #1 |
| peritonitis transgenic | #1 |
| function nox2 | #1 |
| pia disease | #1 |
| collagen reactivity cxi | #1 |
| day acute arthritis | #1 |
| caia lps | #1 |
| comp arthritis models | #1 |
| ciif4 ciic1 | #1 |
| arthritis | #1 |
| caia monoclonal | #1 |
| single monoclonal | #1 |
| tnfα tlr3 expression | #1 |
| insulitis strains | #1 |
| reactivity cb268 | #1 |
| ncf1 polymorphism | #1 |
| oxazolone inflammatory response | #1 |
| innate‐associated disease | #1 |
| arthritis qtl pia7 | #1 |
| collagen antibodies | #1 |
| keratinocytes dth reaction | #1 |
| role ncf1 | #1 |
| lps caia | #1 |
| beta 10b beta | #1 |
| interacting subloci | #1 |
| realtime pcr flss | #1 |
| reproductive performance identification | #1 |
| lack arthritis | #1 |
| rheumatoid arthritis immunization | #1 |
| chromosome congenic strains | #1 |
| sialadenitis strains | #1 |
| severity cia | #1 |
| macrophages mannans | #1 |
| mice ros | #1 |
| mem lglutamine | #1 |
| ncf1 mice wt | #1 |
| chronic arthritis development | #1 |
| maintenance arthritis | #1 |
| fcbinding | #1 |
| 339 polymorphism | #1 |
| induction cii | #1 |
| promoter regions antigens | #1 |
| nzb mice trait | #1 |
| cii ros | #1 |
| polymorphism autoimmune diseases | #1 |
| double deficiency qa2 | #1 |
| h2p h2q | #1 |
| eae2 | #1 |
| collagen induced | #1 |
| glycosylated cii259 | #1 |
| abetachains | #1 |
| effects fab2 | #1 |
| strains b10q | #1 |
| cell specificity cii | #1 |
| hexadecane induce arthritis | #1 |
| arthritis castration | #1 |
| pristane macrophages | #1 |
| expression liver receptor | #1 |
| effector phase arthritis | #1 |
| developed arthritis | #1 |
| cia reduction | #1 |
| spontaneous tissue inflammation | #1 |
| pristane hexadecane | #1 |
| immunization rat | #1 |
| exacerbation arthritis | #1 |
| antigenic adjuvant | #1 |
| mice salt concentrations | #1 |
| preformed cartilage | #1 |
| autoimmune accelerating | #1 |
| 6 cii | #1 |
| cia experimental arthritis | #1 |
| adjuvanticity autoimmunity | #1 |
| arthritogenic antibody | #1 |
| arthritis autoantibody | #1 |
| cii259 273 | #1 |
| 15a11 | #1 |
| fpr1 agonist neutrophils | #1 |
| cii severe arthritis | #1 |
| pia11 | #1 |
| il10 cia | #1 |
| new loci controlling | #1 |
| epitopes cb10 fragment | #1 |
| induce arthritis | #1 |
| nox2derived ros | #1 |
| elisagenetyping | #1 |
| plasminogen deficiency cia | #1 |
| function acpas | #1 |
| polymorphic fragment | #1 |
| mgpi325 | #1 |
| polymorphism ncf1 | #1 |
| cii articular cartilage | #1 |
| collagen citrullination | #1 |
| pristane cell death | #1 |
| induced relapsing | #1 |
| effects cia | #1 |
| cia cii | #1 |
| therapeutic cleavage igg | #1 |
| rns type collagen | #1 |
| cells cii | #1 |
| pia3 | #1 |
| peptides aq | #1 |
| anticardiolipin antibodies p005 | #1 |
| incidence nod | #1 |
| h2p susceptibility | #1 |
| immunospecific reactions | #1 |
| nfr origin | #1 |
| tlr3 upregulation flss | #1 |
| minor cartilage proteins | #1 |
| cii immunization treatment | #1 |
| ros continental ancestry | #1 |
| topoisomerase antagonist | #1 |
| ifnbeta experimental arthritis | #1 |
| functional ncf1 | #1 |
| male mice arthritis | #1 |
| anticcp2negative patients | #1 |
| administration antibodies hyaluronanreceptor | #1 |
| collagen langerhans cells | #1 |
| pregq2 fragment | #1 |
| engagement fcgammar | #1 |
| b10q h2q | #1 |
| protein expression genes | #1 |
| olive oil arthritis | #1 |
| representative swedish | #1 |
| frequency chronic arthritis | #1 |
| ethylene isostere | #1 |
| inflammation caia | #1 |
| protective role cia | #1 |
| ciispecific cells day | #1 |
| cii comp | #1 |
| homologous type collagen | #1 |
| cii induced | #1 |
| cii heterologous cii | #1 |
| type collagen cia | #1 |
| major epitopes patients | #1 |
| reactivity cii | #1 |
| arthritis autoimmune | #1 |
| ccp2 negative | #1 |
| cia32 | #1 |
| arthritis synovial tlr3 | #1 |
| bal cells work | #1 |
| h‐2b | #1 |
| inclusion negative predictive | #1 |
| ciic1scfv | #1 |
| cb268 | #1 |
| ciic1 ciif4 | #1 |
| dancf1da rats | #1 |
| cartilage antibody | #1 |
| cia chromosome | #1 |
| cartilage explants mabs | #1 |
| major locus cia | #1 |
| cia recognition | #1 |
| transgenic tolerance tlymphocytes | #1 |
| gene ncf1 | #1 |
| lewis oia | #1 |
| bb2bb3 regulation | #1 |
| rabeximod treatment | #1 |
| immunization mouse | #1 |
| rheumatoid disease models | #1 |
| eae2 chromosome | #1 |
| ala261gly262 | #1 |
| tlr3 expression flss | #1 |
| nox2 complex–derived ros | #1 |
| cia swr mouse | #1 |
| frequency igaproducing cells | #1 |
| monoclonal cartilage cattle | #1 |
| acpa discriminate | #1 |
| fumia | #1 |
| ii‐induced arthritis | #1 |
| experimental arthritis antibodies | #1 |
| 256 270 | #1 |
| collagen epitope expression | #1 |
| ox8 antibodies | #1 |
| functional ncf1 macrophages | #1 |
| sod3 peritonitis | #1 |
| nox2 complex ncf4 | #1 |
| type cii | #1 |
| cii259 | #1 |
| established sialadenitis | #1 |
| dependent autoimmune arthritis | #1 |
| b10qacb | #1 |
| rat pia | #1 |
| caia experimental arthritis | #1 |
| paamcryogel | #1 |
| genetic encephalomyelitis autoimmune | #1 |
| comp cxi | #1 |
| liver histone deacetylase | #1 |
| cii cix | #1 |
| cia pathogenesis | #1 |
| genetic association ncf1 | #1 |
| oxoethyl6h | #1 |
| igg response cii | #1 |
| immunologic animals arthritis | #1 |
| melatonin release pinealectomy | #1 |
| cia rat | #1 |
| mbp c5a | #1 |
| kgf chondrocytes | #1 |
| locus arthritis | #1 |
| mice functional ncf1 | #1 |
| nodq×b10q | #1 |
| peripheral cells alphachains | #1 |
| autoimmune arthritis activation | #1 |
| cia h2p | #1 |
| rats pristaneinduced arthritis | #1 |
| cartilage‐specific antibodiesis | #1 |
| cia tsc transgenic | #1 |
| tolerance collagen | #1 |
| caia mab | #1 |
| h2w3 | #1 |
| cii experimental autoantigens | #1 |
| arthritis tlr3 | #1 |
| ciiinduced | #1 |
| ccp positive patients | #1 |
| cii rat cii | #1 |
| b10qnfr | #1 |
| antibodies pc4 | #1 |
| nephritis nodq | #1 |
| nox2 functionality | #1 |
| multiple sclerosis rabeximod | #1 |
| treatment physiological doses | #1 |
| new arthritis therapy | #1 |
| heterologous cii | #1 |
| cii mabs | #1 |
| cii259273 peptide | #1 |
| macrophages cii degradation | #1 |
| models rheumatoid | #1 |
| phenotypes ncf1m1j mice | #1 |
| peptide characterisation | #1 |
| cii epitopes | #1 |
| cii triple | #1 |
| downregulating oestradiol | #1 |
| major antigenic epitope | #1 |
| stages arthritis | #1 |
| rat type collagen | #1 |
| placental mhc class | #1 |
| cii ciif4 | #1 |
| polychondritis mice | #1 |
| ncf4 gene | #1 |
| inbred strains severity | #1 |
| pia model rats | #1 |
| pristaneprimed cells | #1 |
| cia antigens haplotypes | #1 |
| phagocytic nox2 complex | #1 |
| clonal expansion arthritis | #1 |
| c3bireceptors | #1 |
| tumor models ncf1 | #1 |
| authors hgpi325339 peptide | #1 |
| aq molecule | #1 |
| ftirm ciic1 | #1 |
| psich2nh2 | #1 |
| ciif4 cartilage explants | #1 |
| findings new therapy | #1 |
| dth nzb | #1 |
| pristaneinduced arthritis | #1 |
| rats cxi | #1 |
| surface redox levels | #1 |
| susceptible strain cross | #1 |
| animal epitopes | #1 |
| ncf1 | #1 |
| p47phoxv232 | #1 |
| streptococcal endo | #1 |
| dth response mrl | #1 |
| arthritis ides | #1 |
| type disease | #1 |
| mcaia | #1 |
| re04001activatedfpr1 | #1 |
| region eae2 | #1 |
| chick cii cii | #1 |
| mice anticd4 treatment | #1 |
| susceptible collagen | #1 |
| rheumatoid arthritis eae | #1 |
| cb268 cii | #1 |
| hfdmets | #1 |
| ppt medium | #1 |
| oxidative burst inducers | #1 |
| inbred dba prolactin | #1 |
| genetic regions | #1 |
| rt1u lew1w | #1 |
| mice b10q | #1 |
| cia locus | #1 |
| expressions cyp7a1 | #1 |
| mhc genetic region | #1 |
| oils induce | #1 |
| riiis alleles eae2 | #1 |
| cxi cii | #1 |
| 4 histone deacetylases | #1 |
| eae b10riii mice | #1 |
| pia3 pia4 | #1 |
| citrulline collagen | #1 |
| rat cb10 cb11 | #1 |
| rt1bβ | #1 |
| collagen ii‐induced | #1 |
| denatured cii | #1 |
| vivo treatment | #1 |
| compia | #1 |
| skg mutation | #1 |
| mice ncf4 | #1 |
| transgenic nadph | #1 |
| cii cartilage explants | #1 |
| avridine arthritis | #1 |
| collagen‐induced arthritis | #1 |
| rat cii cii | #1 |
| chromosomes eae loci | #1 |
| mcaia ncf1 | #1 |
| arthritis pnipaam | #1 |
| pparγ cbrh7919 cells | #1 |
| mice th1 cytokines | #1 |
| immune cartilage | #1 |
| driven psoriatic arthritis | #1 |
| thymectomy transgenes | #1 |
| arthritis estrogen treatment | #1 |
| development inflammatory attack | #1 |
| damage type collagen | #1 |
| loci sialadenitis | #1 |
| nod nss1 | #1 |
| impact topoisomerase antagonist | #1 |
| cells rat cii | #1 |
| fls ppt medium | #1 |
| gergaagiagpk | #1 |
| terpenes toll | #1 |
| chronic arthritis mice | #1 |
| mmc transgene | #1 |
| dba 1 | #1 |
| ciid3 | #1 |
| vivo monoclonal | #1 |
| pia rats arthritis | #1 |
| peritonitis sod3 | #1 |
| arthritogenic mabs | #1 |
| obs electrophoresis | #1 |
| wo2012127214 | #1 |
| genetic crossbreeding | #1 |
| cii development | #1 |
| cryogel column antibodies | #1 |
| rats synthetic peptide | #1 |
| cartilage stability cartilage | #1 |
| impact etoposide | #1 |
| role eosinophilia | #1 |
| pinealectomy exposure | #1 |
| ciispecific | #1 |
| heterologous cii cells | #1 |
| rheumatoid arthritis complexity | #1 |
| cii specific | #1 |
| activation cii | #1 |
| cia rheumatoid arthritis | #1 |
| ym1 pneumonitis | #1 |
| relapsing arthritis | #1 |
| epitopes cii | #1 |
| chromosome caia | #1 |
| c57bl strains loci | #1 |
| cia melatonin | #1 |
| b10riii | #1 |
| cii256270 | #1 |
| cii cb fragments | #1 |
| arthritis pepsin | #1 |
| disease genotype immunoglobulin | #1 |
| collagen type‐ii epitope | #1 |
| phemagelatin | #1 |
| ability gut protection | #1 |
| cii peptides | #1 |
| sensitive wkymvm | #1 |
| ncf1da | #1 |
| congenic mice vdr | #1 |
| adjuvant oils | #1 |
| severe polyarthritis | #1 |
| cii pia | #1 |
| emulsions induction | #1 |
| innate immunity mip | #1 |
| cia cells | #1 |
| established pia disease | #1 |
| arthritis rat | #1 |
| ncf1 gene | #1 |
| arthritis adjuvants | #1 |
| disease lew | #1 |
| comp experimental autoantibodies | #1 |
| ncf1deficient mice | #1 |
| mir144 tlr2 expression | #1 |
| genes animal models | #1 |
| synovial membranes joints | #1 |
| function p47phox | #1 |
| chromosome arthritis severity | #1 |
| cd4 treatment | #1 |
| cia caia | #1 |
| phagocyte oxidative burst | #1 |
| arthritis rat strains | #1 |
| rats severity | #1 |
| qa2 natural mutations | #1 |
| collagen iiinduced arthritis | #1 |
| melatonin cia | #1 |
| arthritis b6n mice | #1 |
| concentrations mouse cii | #1 |
| riiis segment chromosome | #1 |
| c3hq mice | #1 |
| cia b10q | #1 |
| drb10401 col2259 | #1 |
| illness terpenes | #1 |
| disease dba 1jpfp | #1 |
| immunodominant cii | #1 |
| rat pristaneinduced arthritis | #1 |
| cia11 | #1 |
| autoimmune diseases identification | #1 |
| nox2 complex | #1 |
| tolerance arthritis susceptibility | #1 |
| glycosylated cii | #1 |
| rats pia | #1 |
| new therapy arthritis | #1 |
| models rheumatoid arthritis | #1 |
| arthritis development severity | #1 |
| eae3 chromosome | #1 |
| arthritogenic mabs cii | #1 |
| arthritis chronic | #1 |
| cia compdeficient mice | #1 |
| arthritis caia | #1 |
| experimental arthritis autoimmune | #1 |
| immunization type | #1 |
| hladrβ10402 | #1 |
| ncf1 nos2 | #1 |
| bb2bb3 | #1 |
| cii 6 | #1 |
| anticii abs | #1 |
| position cii256270 | #1 |
| comp cii | #1 |
| muscle nox2 | #1 |
| physiological doses development | #1 |
| ncf1 copy variation | #1 |
| tcell experimental cartilage | #1 |
| ifnbeta arthritis | #1 |
| cii antibodies | #1 |
| caia kgf | #1 |
| synovium pia rats | #1 |
| liver contributes hfdmets | #1 |
| estrogeninduced suppression | #1 |
| type epitopes | #1 |
| l012 vivo imaging | #1 |
| ros immunohistochemistry implants | #1 |
| human immunopeptidome lung | #1 |
| ciic1 mabs | #1 |
| mannan immune | #1 |
| celldependent disease | #1 |
| plasminogendeficient mice arthritis | #1 |
| fcγr3 | #1 |
| ncf1m1j mice function | #1 |
| hydrolyzed igg | #1 |
| h2q mice | #1 |
| fecq3 locus | #1 |
| oestrogen treated | #1 |
| ros nox2 complex | #1 |
| targeted mutation ncf4 | #1 |
| act389949 fpr | #1 |
| rats rt1f mhc | #1 |
| response splenocytes | #1 |
| cia homologous cii | #1 |
| pepsin cii | #1 |
| arthritis collagen | #1 |
| arthritis amino | #1 |
| chemiluminescent probe l012 | #1 |
| oestrogen lupus disease | #1 |
| protein ncf1m1j mice | #1 |
| salivary glands antigen | #1 |
| arthritis susceptibility rats | #1 |
| rheumatoid arthritis cii | #1 |
| mouse cii | #1 |
| autologous peptide cells | #1 |
| antitype collagen | #1 |
| rats congenic arthritis | #1 |
| cells arthritogenicity | #1 |
| cells cia | #1 |
| ncf1 mutated | #1 |
| ncf4 mip | #1 |
| cii treatment | #1 |
| backcrosses nzb mice | #1 |
| antibodies cii | #1 |
| ncf1 ptpn22 | #1 |
| selected anti‐t‐cell | #1 |
| experimental collagen | #1 |
| arthritis driven | #1 |
| cells dba mouse | #1 |
| cells arthritis progression | #1 |
| chronicity arthritis | #1 |
| cathelicidin expression blood | #1 |
| autoimmune response cii | #1 |
| tissue attack | #1 |
| chronic stage arthritis | #1 |
| saline arthritis | #1 |
| immunization heterologous peptide | #1 |
| eae2 locus | #1 |
| bcell activities | #1 |
| nod nss1 loci | #1 |
| emerging glyco‐based strategies | #1 |
| genome b10riii | #1 |
| tlr3 rna interference | #1 |
| sialadenitis cell phenotypes | #1 |
| epitope type | #1 |
| severity pia | #1 |
| ncf1 lyme arthritis | #1 |
| ftirm mice | #1 |
| ncf4 mice | #1 |
| rat cii response | #1 |
| regulates severity | #1 |
| genes ncf1 | #1 |
| hg6pi325 | #1 |
| collagen 256 | #1 |
| eae39 locus cia | #1 |
| ncf1 allele | #1 |
| alphachains cell surface | #1 |
| native cii | #1 |
| methodspurified | #1 |
| differential susceptibility cia | #1 |
| cartilage damage vivo | #1 |
| cii immunisation | #1 |
| phytol arthritis | #1 |
| prevents arthritis | #1 |
| controlling onset | #1 |
| chronic development | #1 |
| therapeutic c4bp | #1 |
| act389949 agonist | #1 |
| presence mhv | #1 |
| congenic arthritis rats | #1 |
| inbred dba cii | #1 |
| ncf1 ros | #1 |
| igg1 igg2b isotypes | #1 |
| ul1 ciif4 mab | #1 |
| p47phox mutant | #1 |
| cxi pia | #1 |
| cartilage‐specific | #1 |
| cd43expressing cells | #1 |
| joint inflammatory phase | #1 |
| cells ncf1 | #1 |
| cii acpa | #1 |
| h‐2q | #1 |
| kupffer cells mir144 | #1 |
| dba 1 background | #1 |
| hyaluronanreceptor cd44 | #1 |
| adaptive immunity fcγrs | #1 |
| tlr3 pristane | #1 |
| severe arthritis immunization | #1 |
| cia congenic arthritis | #1 |
| identification genetic regions | #1 |
| cii lewis | #1 |
| development chronic arthritis | #1 |
| homologous cii | #1 |
| cii mab | #1 |
| collagen cxi | #1 |
| induction postpartum flare | #1 |
| urokinase enzyme | #1 |
| dba mouse epitopes | #1 |
| daxlewf1 | #1 |
| pc4 pc8 | #1 |
| psoriasis single locus | #1 |
| collagen arthritis progesterone | #1 |
| experimental carcinogens | #1 |
| immunization autologous peptide | #1 |
| nodq nod nodp | #1 |
| arthritis intraperitoneal injection | #1 |
| function targeted deletion | #1 |
| citrullinated cii | #1 |
| tolerance arthritis | #1 |
| cii peptide molecules | #1 |
| cii citrullinated | #1 |
| molecule aq | #1 |
| synthetic peptides cii | #1 |
| restricted role fcγr | #1 |
| tolerance induction cii | #1 |
| cii sera | #1 |
| m1j | #1 |
| phase cia | #1 |
| new arthritis | #1 |
| cii severity | #1 |
| rheumatoid collagen | #1 |
| ncf4 nox2 complex | #1 |
| haplotype ltab | #1 |
| b10riii riiis | #1 |
| pepsin arthritis | #1 |
| nonglycosylated peptide | #1 |
| cii260 | #1 |
| ncf1 spread | #1 |
| deficient ncf1 | #1 |
| mice cii immunization | #1 |
| b10dr4ncf1 mice cii | #1 |
| active arthritis complex | #1 |
| ncf1 association | #1 |
| 17βestradiolregulation | #1 |
| b10b | #1 |
| dependent autoimmune | #1 |
| monoclonal arthritis arthritis | #1 |
| mouse chromosome eae39 | #1 |
| disease th1 immunity | #1 |
| oxa backcrosses | #1 |
| ncf1m1j mutation | #1 |
| pristane induced | #1 |
| cartilage collagen type | #1 |
| cii human | #1 |
| pia eae | #1 |
| spread psoriasis | #1 |
| cii ncf1 | #1 |
| cb11 fragment | #1 |
| arthritis onset severity | #1 |
| diabetes sialadenitis | #1 |
| headache paradigm | #1 |
| autoimmune priming | #1 |
| b10q mice | #1 |
| increased salt exposure | #1 |
| early onset development | #1 |
| pia cii | #1 |
| cb11 sequence cii | #1 |
| suppression collagen arthritis | #1 |
| dth dominant hypersensitivity | #1 |
| incidence arthritis | #1 |
| blocking arthritis | #1 |
| glycosylation cell recognition | #1 |
| h2p cia | #1 |
| development pristaneinduced arthritis | #1 |
| phase arthritis | #1 |
| methods | #1 |
| pc117 | #1 |
| dimethyl6n | #1 |
| mice l012 | #1 |
| citrullinated collagen arthritis | #1 |
| autoantibody responses cii | #1 |
| tlr3 flss | #1 |
| ncf1 knockout | #1 |
| tolerance arthritis protection | #1 |
| ncf1 ncf1 mice | #1 |
| histology vaccination | #1 |
| cia eae39 | #1 |
| illness cia | #1 |
| psicoch2 | #1 |
| arthritis control mice | #1 |
| ym1 alternative activation | #1 |
| ncf1m1j mice ncf1 | #1 |
| cia21 lymph nodes | #1 |
| injection adjuvant oils | #1 |
| h2g7 haplotype nod | #1 |
| cii antigen presentation | #1 |
| major cii | #1 |
| hiit nox2 activity | #1 |
| nox2complex | #1 |
| hyaluronanreceptor | #1 |
| glycoprotein alpha1microglobulin | #1 |
| cartilage cii | #1 |
| rats chronic disease | #1 |
| polychondritis autoimmune disease | #1 |
| dth mice trait | #1 |
| p47phox ncf1 | #1 |
| myelomonocytic arthritis interleukin2 | #1 |
| cia caia model | #1 |
| qtl positional cloning | #1 |
| collagen reactive | #1 |
| pia3 chromosome | #1 |
| pristaneinduced arthritis rats | #1 |
| congenic fragment | #1 |
| cia rheumatoid autoantibodies | #1 |
| rabeximod arthritis | #1 |
| collagen epitopes | #1 |
| mrl mice estrogen | #1 |
| dba 1j | #1 |
| beta 812 | #1 |
| response cii | #1 |
| cartilage specific | #1 |
| pia cia13 pia7 | #1 |
| cii pepsin | #1 |
| encephalomyelitis arthritis | #1 |
| antibodies consensus motif | #1 |
| u1 epitope | #1 |
| macrophages autoimmune priming | #1 |
| h2q c3hnb | #1 |
| pia blocking arthritis | #1 |
| eae strains severity | #1 |
| daf2cross | #1 |
| arthritis cia | #1 |
| inflammatory arthritis assessment | #1 |
| ciispecific cell responses | #1 |
| cells caia | #1 |
| epitopes collagen | #1 |
| cia dominant epitope | #1 |
| estrogen physiological doses | #1 |
| inbred dba pepsin | #1 |
| rabeximod | #1 |
| position 264 | #1 |
| eae2 eae3 | #1 |
| maintained pregnancy levels | #1 |
| cia il10 | #1 |
| genetic control sialadenitis | #1 |
| cii256 | #1 |
| serum chromosome | #1 |
| socalled collagen antibody | #1 |
| rat comp arthritis | #1 |
| animal models acpa | #1 |
| chronic arthritis rats | #1 |
| epitopes cb11 fragment | #1 |
| macrophages cii | #1 |
| disease cd8 deficiency | #1 |
| cxi rats | #1 |
| minimal glycopeptide core | #1 |
| cii arthritis | #1 |
| cia22 | #1 |
| healthy nzw | #1 |
| severity arthritis | #1 |
| dominant traits | #1 |
| arthritis naive mice | #1 |
| citrullinated variants | #1 |
| positional identification | #1 |
| collagen cii | #1 |
| endos hydrolyzed igg | #1 |
| etoposide topoisomerase antagonist | #1 |
| cii cells | #1 |
| sialadenitis incidence | #1 |
| mhc‐congenic mouse strains | #1 |
| cix disease | #1 |
| cxi comp | #1 |
| csfspecific | #1 |
| cells autologous cii | #1 |
| targeted deletion ncf1 | #1 |
| functional selective fpr1 | #1 |
| susceptibility collagen | #1 |
| joint proteins | #1 |
| cia5 region | #1 |
| cii caia | #1 |
| ifa rats | #1 |
| cii chronic | #1 |
| b10qc5δ | #1 |
| arthritis qtl chip | #1 |
| oestradiol suppression | #1 |
| autoantibodies collagen | #1 |
| ciic1 m2139 | #1 |
| rats antibody response | #1 |
| beta haplotype | #1 |
| oia induction | #1 |
| selfcii | #1 |
| striking phenotypic similarities | #1 |
| pc8 pc117 | #1 |
| cia5 cia21 | #1 |
| immunisation cells | #1 |
| models collagen | #1 |
| cii | #1 |
| kgf cia | #1 |
| tcell hybridomas cells | #1 |
| collagen arthritis iii | #1 |
| citrullinated type | #1 |
| strains nodq | #1 |
| clec4b | #1 |
| h‐2q mice | #1 |
| pia2–8 | #1 |
| rs201802880 | #1 |
| mip cia | #1 |
| mice cryogels | #1 |
| eae mtx | #1 |
| tcell congenic arthritis | #1 |
| lnchc cholesterol metabolism | #1 |
| macrophage ros | #1 |
| ciic1 antibody | #1 |
| role nox2derived ros | #1 |
| collagen chains antibody | #1 |
| cii u1 | #1 |
| ncf1 mutation | #1 |
| flss polyi | #1 |
| rp autoimmune disease | #1 |
| autoimmunogenic hydrocarbon oils | #1 |
| pathway arthritis | #1 |
| arthritis pia | #1 |
| presence sex hormones | #1 |
| suppressive development | #1 |
| ciif4 adverse effects | #1 |
| ifa cii ifa | #1 |
| arthritis injection | #1 |
| rat placenta uterus | #1 |
| chondrocytes kgf | #1 |
| comp mabs | #1 |
| cxi chronic arthritis | #1 |
| disease susceptibility castration | #1 |
| caia cia | #1 |
| signaling characterization | #1 |
| cryogel matrix cells | #1 |
| cia oia | #1 |
| kgf treatment onset | #1 |
| cii recognition | #1 |
| arthritis estrogen | #1 |
| hladrbound peptides | #1 |
| cii immunization mice | #1 |
| cii cross reactivity | #1 |
| psoriasis spread | #1 |
| pregq2 | #1 |
| genetic variants ncf1 | #1 |
| animal models arthritis | #1 |
| animal models polychondritis | #1 |
| nox2 complex addition | #1 |
| mice salt intake | #1 |
| cii polymer | #1 |
| arthritis susceptibility mice | #1 |
| collageninduced arthritis | #1 |
| ifn signature mice | #1 |
| fecq3 | #1 |
| periodontitis rats pia | #1 |
| nrc ova | #1 |
| arthritis genetics | #1 |
| disease glycoproteins | #1 |
| e3xda | #1 |
| ros adaptive immunity | #1 |
| autologous type collagen | #1 |
| pia4 chromosome | #1 |
| developed severe | #1 |
| ncf1 mutant | #1 |
| collagen hybridomas | #1 |
| cd200 btla | #1 |
| col2259 | #1 |
| autoimmune diseases cnvs | #1 |
| cii mhc | #1 |
| copy variation ncf1 | #1 |
| ul1 vivo | #1 |
| reduced oxidative burst | #1 |
| cholera toxin study | #1 |
| bond requirements | #1 |
| siliac | #1 |
| disease transgenic models | #1 |
| b10q mice authors | #1 |
| phytol molecular pathways | #1 |
| h2q h2r | #1 |
| immune response mbp | #1 |
| arthritis incidence | #1 |
| anticii response | #1 |
| specificity ros rns | #1 |
| b10qbalb | #1 |
| congenic cia40 | #1 |
| position ros production | #1 |
| rats rt1 | #1 |
| isolated fragment chromosome | #1 |
| arthritis‐susceptibility loci | #1 |
| congenic polymorphism illness | #1 |
| synovial cells macrophages | #1 |
| antibody binding vivo | #1 |
| neonatal mortality milk | #1 |
| lymphocytes collagen | #1 |
| extraarticular cartilage | #1 |
| heterologous collagen | #1 |
| cia rat cii | #1 |
| immune priming events | #1 |
| rats rheumatoid | #1 |
| mutated ncf1 | #1 |
| antibody response cii | #1 |
| cii induced arthritis | #1 |
| disease development effects | #1 |
| idd5 loci | #1 |
| position ciilysdnp | #1 |
| transgenic nadph oxidase | #1 |
| injection mannan | #1 |
| mhc aq | #1 |
| mice ncf1m1j mutation | #1 |
| sialadenitis congenic mice | #1 |
| mice darkness | #1 |
| cia cartilage | #1 |
| oestradiol exacerbation | #1 |
| rheumatoid arthritis autoimmunity | #1 |
| igg2a vivo | #1 |
| caia acute arthritis | #1 |
| acpa general population | #1 |
| experimental autoantibodies | #1 |
| contrast nodq | #1 |
| cia f1 males | #1 |
| cell‐deficient mice | #1 |
| tlr3 expression fls | #1 |
| caia cii | #1 |
| da1u rat liver | #1 |
| arthritismodulating | #1 |
| pia8 | #1 |
| spread induced psoriasis | #1 |
| collageninduced arthritis loci | #1 |
| ciif4 mab | #1 |
| severity ides | #1 |
| h2q haplotype | #1 |
| estrogen immune responses | #1 |
| nodq locus | #1 |
| acpas specificity | #1 |
| formation arthritis | #1 |
| chromosome f1 males | #1 |
| ltabncr3 | #1 |
| cia development | #1 |
| vridine‐induced arthritis | #1 |
| c57bl 10q | #1 |
| anti cii acpa | #1 |
| pathogenesisis | #1 |
| oestrogen induced | #1 |
| arthritis male | #1 |
| cia antibody response | #1 |
| polyi arthritis | #1 |
| satellite encephalomyelitis | #1 |
| acute arthritis neutrophils | #1 |
| mhv runting neonates | #1 |
| arthritis protection | #1 |
| ftirm cii | #1 |
| susceptibility collageninduced arthritis | #1 |
| ncf1339 allele | #1 |
| predominant selection | #1 |
| cii anticd4 treatment | #1 |
| presentation arthritis | #1 |
| ncf1 deficient | #1 |
| oxidases receptors | #1 |
| strains polychondritis | #1 |
| dnp epitopes lysine | #1 |
| development humanized models | #1 |
| citrullinated collagen | #1 |
| features arthritis | #1 |
| cd68‐expressing cells | #1 |
| mice cii epitopes | #1 |
| cii mouse | #1 |
| epitopes arthritis | #1 |
| experimental chromosomes | #1 |
| c4bp alternative pathway | #1 |
| cia experimental autoantibodies | #1 |
| collagen‐induced | #1 |
| nod incidence | #1 |
| mbq mouse macrophages | #1 |
| arthritis animals | #1 |
| cia | #1 |
| g6pi acute arthritis | #1 |
| mediating arthritis | #1 |
| chronic pristane | #1 |
| b10dr4ncf1 | #1 |
| caia riiis segment | #1 |
| cii olive oil | #1 |
| argltgrpgda | #1 |
| cia mip | #1 |
| arthritis b10q mice | #1 |
| c1iii type collagen | #1 |
| cia13 pia7 | #1 |
| arthritis development immunisation | #1 |
| tolerance cia | #1 |
| snat proteins | #1 |
| arthritis estrus cycle | #1 |
| qa2 ncf1 | #1 |
| spe acute phase | #1 |
| oestrogen‐induced | #1 |
| genes antibodies | #1 |
| human α‐enolase | #1 |
| arthritis ncf1 | #1 |
| decreasing activation | #1 |
| hladr1transgenic mice | #1 |
| complex cia | #1 |
| intracellular processing cii | #1 |
| qtl animal genes | #1 |
| mice mutated type | #1 |
| defined polymeric adjuvant | #1 |
| genetic control pia | #1 |
| day cii immunisation | #1 |
| congenic | #1 |
| functional nox2 | #1 |
| sialadenitis arthritis | #1 |
| mice burkholderia cepacia | #1 |
| galactosylated peptide | #1 |
| arthritis animal | #1 |
| cia ul1 | #1 |
| cix cii | #1 |
| recognition lysine | #1 |
| humans animals arthritis | #1 |
| pia9 | #1 |
| model rheumatoid arthritis | #1 |
| upregulation tlr3 | #1 |
| cii swr mice | #1 |
| oestrogen‐induced suppression | #1 |
| induction phase cia | #1 |
| manifestations lupus disease | #1 |
| h2p mice cia | #1 |
| ciiglycopeptides | #1 |
| eae39 | #1 |
| inbred strains cia | #1 |
| rat rt1ba genes | #1 |
| arthritis toe stiffness | #1 |
| pia cia | #1 |
| marginal ankylosis | #1 |
| chlorophyll component | #1 |
| effects ciif4 | #1 |
| ros antigens | #1 |
| anti type | #1 |
| locus cia development | #1 |
| 2 months beta | #1 |
| cii rats | #1 |
| swr mice immunization | #1 |
| arthritis pristane | #1 |
| immunization mouse cii | #1 |
| anticii antibodies | #1 |
| sialadenitis nodq | #1 |
| ox8 monoclonal | #1 |
| olive oil cii | #1 |
| psiechch | #1 |
| animal models complexity | #1 |
| severe arthritis | #1 |
| lymphocytes cartilage | #1 |
| haplotypes h2q | #1 |
| dth dba 1 | #1 |
| ros glucose transporter | #1 |
| pia7 | #1 |
| autologous cii | #1 |
| arthritis congenic | #1 |
| human cii cartilage | #1 |
| type collagen cii256−270 | #1 |
| rats antibody cartilage | #1 |
| leukosialin rats | #1 |
| cells cb11 | #1 |
| inflammatory tissue attack | #1 |
| autoantibodies cartilage | #1 |
| day ciispecific cells | #1 |
| animal histocompatibility | #1 |
| il10 mmc | #1 |
| induced arthritis | #1 |
| toxin‐1‐producing staphylococci | #1 |
| disease c4bp | #1 |
| inability collagen | #1 |
| valphachain | #1 |
| naive experimental chromosomes | #1 |
| cia ul1 mab | #1 |
| glycosylated epitope structures | #1 |
| nox2 agonists | #1 |
| idiotype‐specific binding | #1 |
| loci eae39 | #1 |
| pristane tlr3 expression | #1 |
| arthritis mutant strains | #1 |
| ncf1 p47phox | #1 |
| plcpip | #1 |
| cia lysine | #1 |
| hla–dr1 | #1 |
| phytol rna | #1 |
| cxiia | #1 |
| ecm mab | #1 |
| homologous type | #1 |
| animal genes cia | #1 |
| b10q | #1 |
| epitopes vivo | #1 |
| chemical cartilage | #1 |
| pia5 | #1 |
| arthritis mhc | #1 |
| cii epitope | #1 |
| dba 1jpfp cia | #1 |
| susceptibility cia | #1 |
| mhc cii | #1 |
| cells heterologous cii | #1 |
| data act389949 | #1 |
| c3hnb | #1 |
| chromosome cia | #1 |
| substrains ztmrhd | #1 |
| cartilage explants ciic1 | #1 |
| autoantibodies cii | #1 |
| nzw parental | #1 |
| congenic strains cia | #1 |
| ros experimental arthritis | #1 |
| β1helix | #1 |
| cell determinants cii | #1 |
| antibody ciic1 | #1 |
| dth antibody response | #1 |
| pia rats tlr3 | #1 |
| ncf1 genes | #1 |
| cii induce | #1 |
| rats pia9 alleles | #1 |
| ctbcii | #1 |
| congenic mice genes | #1 |
| mab ecm | #1 |
| protective alleles eae2 | #1 |
| development collagen | #1 |
| carbohydrates cii | #1 |
| type collagens rats | #1 |
| strong response epitopes | #1 |
| dominant susceptibility loci | #1 |
| differences ncf1 | #1 |
| cia model strains | #1 |
| lpr mice granulocytes | #1 |
| diagnostic accuracy acpa | #1 |
| cia31 | #1 |
| cia animal epitopes | #1 |
| mip ncf4 | #1 |
| beta 10b mrl | #1 |
| genistein collagen | #1 |
| ros autoimmune diseases | #1 |
| established arthritis | #1 |
| antigen presentation cii | #1 |
| genetically segregating crosses | #1 |
| h2r h2q | #1 |
| disease monitoring rats | #1 |
| pia model | #1 |
| rats ncf1 | #1 |
| arthritis immunisation | #1 |
| type collagen cxi | #1 |
| ides treatment severity | #1 |
| tracheolaryngeal | #1 |
| da1f | #1 |
| pepsin immunization | #1 |
| vivo experimental arthritis | #1 |
| inflammatory phase arthritis | #1 |
| cii carbohydrates | #1 |
| cia pia | #1 |
| spleen cluster | #1 |
| congenic c57bl mice | #1 |
| mab mab ciic1 | #1 |
| f1 hybrids disease | #1 |
| arthritis immunization | #1 |
| pathogenesis cia | #1 |
| treatment pia | #1 |
| mice developed | #1 |
| mhc influence | #1 |
| patients china cohort | #1 |
| eae chromosomes | #1 |
| nodq nod | #1 |
| glycopeptide stimulation | #1 |
| injection lewis rat | #1 |
| polymorphism mitochondrial genome | #1 |
| cii cia | #1 |
| milk titers | #1 |
| animal immunosuppressive agents | #1 |
| potent disease accelerator | #1 |
| cii lewis rats | #1 |
| hfdmets expression | #1 |
| mice mutated cii | #1 |
| denidritic cells | #1 |
| ros mip | #1 |
| ll37 rcramp | #1 |
| lew avridineinduced arthritis | #1 |
| cii responsiveness | #1 |
| ciif4 cartilage damage | #1 |
| nasal treatment ctbcii | #1 |
| clec4b activation | #1 |
| rat cii arthritis | #1 |
| macrophages hladr1transgenic mice | #1 |
| myeloid effector functions | #1 |
| caia effects | #1 |
| cia12 | #1 |
| ncf1m1j | #1 |
| rabeximod inflammatory cells | #1 |
| arthritis traits | #1 |
| recombinant vaccine inflammation | #1 |
| dominant hypersensitivity dth | #1 |
| nzb dth | #1 |
| estrogenmediated suppression | #1 |
| comp lack | #1 |
| chronic relapsing arthritis | #1 |
| mumt mice oestrogen | #1 |
| ncf1 polymorphisms | #1 |
| immunization lathyritic cii | #1 |
| disease collagen | #1 |
| ifnbeta deficiency | #1 |
| mouse cii reactivity | #1 |
| cii261 | #1 |
| anti comp | #1 |
| thps cii | #1 |
| cells chronic arthritis | #1 |
| ncf1 339 | #1 |
| ncf1 sle | #1 |
| humanized models disease | #1 |
| development collageninduced arthritis | #1 |
| vpba pnipaam | #1 |
| b10q mice ncf1 | #1 |
| fibroblast induced arthritis | #1 |
| major epitopes | #1 |
| elevated th17 cells | #1 |
| fecq4 | #1 |
| c3hq | #1 |
| nzw parental strain | #1 |
| arthritis males | #1 |
| partial advanced | #1 |
| mir144 tlr2 | #1 |
| arthritis collagen arthritis | #1 |
| scarce clinical samples | #1 |
| compdeficient mice | #1 |
| glut4dependent glucose transport | #1 |
| ciilysdnp | #1 |
| rt1f haplotype | #1 |
| insulitis nodq | #1 |
| qtl chip | #1 |
| mutant p47phox | #1 |
| immunological transmitter | #1 |
| recombinants rt1u | #1 |
| cia molecular basis | #1 |
| chemical collagen | #1 |
| mabs monoclonal arthritis | #1 |
| fibroblasts ifnbetadeficient mice | #1 |
| emission tomography mannan | #1 |
| eae39 control disease | #1 |
| caia model | #1 |
| mannan mice | #1 |
| b10q b10riii | #1 |
| arthritis induced | #1 |
| function ncf1 gene | #1 |
| cii immunodominant | #1 |
| loci cia2 | #1 |
| anticii autoantibodies | #1 |
| act389949 fpr2 | #1 |
| autoantibody formation cia | #1 |
| estrogen differential outcome | #1 |
| normal cartilage arthritis | #1 |
| m1s1a | #1 |
| large numbers hybridomas | #1 |
| ul1 ciif4 | #1 |
| arthritis incidence severity | #1 |
| pristane hydrocarbon oils | #1 |
| qa2 gene clusters | #1 |
| rt1l haplotypes | #1 |
| pia experimental arthritis | #1 |
| dominant hypersensitivity | #1 |
| citrullinated type collagen | #1 |
| rat cii | #1 |
| cia comp | #1 |
| arthritis suppression | #1 |
| nucleotide reactive | #1 |
| development cia | #1 |
| j1 epitope | #1 |
| pc4 pc117 | #1 |
| hybridomas multispecific antibodies | #1 |
| aq glycopeptide | #1 |
| rats mhc genes | #1 |
| ciispecific cells | #1 |
| cia induced arthritis | #1 |
| murine psoriasis model | #1 |
| aq class | #1 |
| swr nfr | #1 |
| fab2 ciic1 | #1 |
| 237 females | #1 |
| biodegradation cryogels | #1 |
| arthritis anticii abs | #1 |
| antibody induced | #1 |
| cii vaccination | #1 |
| lew mol strain | #1 |
| superovulation rate | #1 |
| mice h2q | #1 |
| concentrations cii | #1 |
| transgenic mice mhcii | #1 |
| mhc cia | #1 |
| function single | #1 |
| w33t | #1 |
| respiratory burst severity | #1 |
| wild type ncf1 | #1 |
| arthritis ncf1 allele | #1 |
| tregs ros | #1 |
| fecq4 fragment | #1 |
| mbpc5a | #1 |
| rat congenic data | #1 |
| collagens antibody | #1 |
| cia21 | #1 |
| fecq4 locus | #1 |
| cd2 human cells | #1 |
| mice chronic arthritis | #1 |
| concentrations rat cii | #1 |
| hg6pi | #1 |
| arthritis loci | #1 |
| autoimmunity mineral oils | #1 |
| cii monoclonal arthritis | #1 |
| rats arthritis | #1 |
| animals arthritis | #1 |
| rheumatoid arthritis cia | #1 |
| nonglycosylated epitope | #1 |
| lewis rat cia | #1 |
| cii h2p | #1 |
| arthritogenicity cells | #1 |
| collagen type cii | #1 |
| da1u rats expression | #1 |
| cells mouse cii | #1 |
| congenic polymorphism | #1 |
| fpr act389949 | #1 |
| cii response | #1 |
| arthritis humans | #1 |
| cell recognition carbohydrates | #1 |
| mice interferon gamma | #1 |
| position mouse cii | #1 |
| oxidases polymers | #1 |
| role major epitopes | #1 |
| t‐cell epitope cii260‐270 | #1 |
| nss1 | #1 |
| cia12 pia4 | #1 |
| greater osteoclasts | #1 |
| ciipeptide cells | #1 |
| female preponderance development | #1 |
| lathyritic cii | #1 |
| lpscaia | #1 |
| tumors immunosuppressive leukocytes | #1 |
| vivo imaging l012 | #1 |
| arthritis independent | #1 |
| gia expansion | #1 |
| loci controlling diabetes | #1 |
| mannaninduced | #1 |
| cii 256270 peptide | #1 |
| presence arthritogenic mabs | #1 |
| oxidative burst disease | #1 |
| cii260‐270 | #1 |
| drb10401positive | #1 |
| cii256 270 | #1 |
| cia2 cia9 | #1 |
| arthritis aim | #1 |
| cii cxi | #1 |
| functional nox2 complex | #1 |
| partial advanced intercross | #1 |
| suggestive locus chromosome | #1 |
| c3hnb mice | #1 |
| comp disease monitoring | #1 |
| cells synthetic glycopeptides | #1 |
| ros ncf1 | #1 |
| cix cartilage | #1 |
| 1 ncf1 | #1 |
| cia13 | #1 |
| arthritogenic antibodies | #1 |
| arthritis arthritis loci | #1 |
| inconsistent susceptibility | #1 |
| cia opportunities | #1 |
| dba1 mice | #1 |
| inflammation living mice | #1 |
| confers arthritis susceptibility | #1 |
| psa mip | #1 |
| acute phase arthritis | #1 |
| chromosome 17 mhc | #1 |
| induced arthritis cia | #1 |
| ciispecific antibodies | #1 |
| ncf1m1j mice | #1 |
| sterically privileged | #1 |
| cii experimental arthritis | #1 |
| cii ecm | #1 |
| stromal cells osteoclasts | #1 |
| f1 males influence | #1 |
| tumor colonization | #1 |
| mcii707 | #1 |
| innate rats | #1 |
| m1j mice | #1 |
| arthritis ul1 | #1 |
| cia olive oil | #1 |
| estrogen manifestations | #1 |
| rat comp | #1 |
| 270 peptide | #1 |
| clever1 type macrophages | #1 |
| experimental collagen type | #1 |
| rats ncf1 gene | #1 |
| b10q dba 1f1 | #1 |
| experimental autoantigens | #1 |
| lew1w rt1u | #1 |
| ciipeptide | #1 |
| bqncf1m1j | #1 |
| flss tlr3 expression | #1 |
| ncf1 mutant mice | #1 |
| animal epitopes injections | #1 |
| sle‐prone mrl | #1 |
| glycosylated determinant peptides | #1 |
| cii cell | #1 |
| oestrogen cia | #1 |
| cii256−270 | #1 |
| rats adjuvant oil | #1 |
| breeding capacity | #1 |
| dr4 glycopeptides | #1 |
| cxi | #1 |
| caia mutant mice | #1 |
| arthritis mcaia | #1 |
| antitlr3 antibody | #1 |
| nodp nod | #1 |
| m2139 ciic1 | #1 |
| carcinoma tumors ros | #1 |
| arthritis antibody | #1 |
| cia5 qtl | #1 |
| hydrocarbon oil structure | #1 |
| genetic background rats | #1 |
| inflammatory phase cia | #1 |
| oestradiol dth | #1 |
| aq molecules | #1 |
| pia cix | #1 |
| cells galactosylated peptide | #1 |
| mutation ptdins3pbinding site | #1 |
| cia animal models | #1 |
| cxb10qf2 | #1 |
| c3hq mice cii | #1 |
| mhc class injections | #1 |
| pristane primed | #1 |
| collagen immunization | #1 |
| tlr2 tlr2 regulation | #1 |
| arthritis locus | #1 |
| alpha type collagen | #1 |
| dba 1 mouse | #1 |
| m2139 arthritogenic mab | #1 |
| dapia3 | #1 |
| cuiiidaligands | #1 |
| δ228 | #1 |
| elimination carbohydrates | #1 |
| genes arthritis | #1 |
| cii major epitope | #1 |
| mice arthritis | #1 |
| cia oestrogen | #1 |
| mbq mouse | #1 |
| cxi arthritis | #1 |
| lower capacity ros | #1 |
| arthritis animal mice | #1 |
| rat cb11 immunization | #1 |
| cii histocompatibility complex | #1 |
| enhanced autoimmunity arthritis | #1 |
| ncf4 | #1 |
| cii vivo | #1 |
| congenic arthritis | #1 |
| rats ncf1 allele | #1 |
| antibody responses cii | #1 |
| environments mice | #1 |
| h2p h2q haplotype | #1 |
| tlr3 expression tnfα | #1 |
| ciiinduced arthritis | #1 |
| 371115tetramethyl2hexadecene1ol | #1 |
| ncf1 mice | #1 |
| tlr3 tlr3 expression | #1 |
| ncf1 ncf1m1j mutation | #1 |
| experimental arthritis articular | #1 |
| phosphatase 22 | #1 |
| h2w17 | #1 |
| ciic1 fab | #1 |
| cii immunization | #1 |
| homologous type pia | #1 |
| native comp | #1 |
| mice ncf1 | #1 |
| cii antibody | #1 |
| pristane stimulation | #1 |
| cia21 cia22 | #1 |
| cnbr‐fragment | #1 |
| cia ros | #1 |
| pia experimental chromosomes | #1 |
| autoimmune arthritis apcs | #1 |
| cells mgps | #1 |
| rats established pia | #1 |
| lewis rats pepsin | #1 |
| immunization heterologous | #1 |
| compsufficient mice | #1 |
| proteins gay | #1 |
| induced arthritis rats | #1 |
| cell tolerance cii | #1 |
| transient joint inflammation | #1 |
| arthritis transfer | #1 |
| antiidiotypic antibodies cd4 | #1 |
| dapia6 | #1 |
| expression ncf1 | #1 |
| pv cd4 cells | #1 |
| oxa nzb mice | #1 |
| arthritis rheumatoid arthritis | #1 |
| cia collagen | #1 |
| tracheolaryngeal cartilage | #1 |
| strains developed | #1 |
| therapeutic cleavage | #1 |
| ncf1 mutation mice | #1 |
| wt ncf1 | #1 |
| b10dr4ncf1 mice | #1 |
| epitope cartilage | #1 |
| cxi 6 | #1 |
| daiu | #1 |
| cageeffects | #1 |
| specific antibody protection | #1 |
| nox2 function | #1 |
| arthritis promoting | #1 |
| presentation cii | #1 |
| b10q strain | #1 |
| glycosylation hla | #1 |
| caia gene segments | #1 |
| development oia | #1 |
| disease suggestive locus | #1 |
| major role rp | #1 |
| controlling collagen | #1 |
| arthritis cell | #1 |
| rats comp | #1 |
| critical restriction site | #1 |
| model rheumatoid | #1 |
| arthritis darkness | #1 |
| deficient neonatal | #1 |
| anti collagen | #1 |
| animal genetic predisposition | #1 |
| ciilysdnp mice | #1 |
| 22 variant r620w | #1 |
| cii saline | #1 |
| pristaneinduced arthritis pia | #1 |
| cia ifa | #1 |
| c3hnb h2p | #1 |
| dendritic cells collagen | #1 |
| ym1deficient mice | #1 |
| development aureus arthritis | #1 |
| pc117 extracellular structures | #1 |
| increase ncf1 | #1 |
| arthritis monoclonal arthritis | #1 |
| antibodies citrullinated peptide | #1 |
| tlr expression synovium | #1 |
| cia induced | #1 |
| ciispecific monoclonal | #1 |
| non‐mhc genes | #1 |
| cii disease | #1 |
| visual signs arthritis | #1 |
| arthritogenic mab ciic1 | #1 |
| arthritis rabeximod | #1 |
| arthritis experimental | #1 |
| complex aq molecules | #1 |
| 2 nox2 | #1 |
| rats hfdmets | #1 |
| constant light order | #1 |
| nadph activation | #1 |
| immunization cii | #1 |
| mcia1 | #1 |
| region eae3 | #1 |
| cii h2q | #1 |
| immunization heterologous cii | #1 |
| tolerance immunodominant | #1 |
| nox2derived ros mice | #1 |
| existence periodontitis | #1 |
| mice c3h background | #1 |
| collagen dendritic cells | #1 |
| hdac3 pparγ | #1 |
| rheumatoid drug evaluation | #1 |
| rt1ba | #1 |
| anticd4 treatment immunization | #1 |
| clec4b ncf1 | #1 |
| immunization rat cii | #1 |
| susceptible cia | #1 |
| tlr3 synovium | #1 |
| c1iii | #1 |
| cia vivo priming | #1 |
| rats phytol | #1 |
| g6pi peptide | #1 |
| arthritis development cross | #1 |
| peptide agonist fmlf | #1 |
| ros rheumatoid humans | #1 |
| periodontitis pristaneinduced arthritis | #1 |
| u1 antibodies patients | #1 |
| arthritis tlr3 upregulation | #1 |
| rats terpenes | #1 |
| cell recognition cii | #1 |
| specific cii | #1 |
| rat recombinants | #1 |
| ros rns inflammation | #1 |
| mab ciif4 ciic1 | #1 |
| hufcgammariia | #1 |
| anticii antibody response | #1 |
| ztmrhd | #1 |
| eae2 resistant locus | #1 |
| chronic intervention | #1 |
| act389949 | #1 |
| experimental autoimmunity cells | #1 |
| mucosal tolerance cii | #1 |
| mechanism autoimmune | #1 |
| cii cartilage | #1 |
| congenic strains rats | #1 |
| pepsin lewis | #1 |
| human gpi protein | #1 |
| cartilagespecific protein | #1 |
| ncf1m1j m1j mice | #1 |
| post‐partum exacerbation | #1 |
| cia2 arthritis | #1 |
| g6pi chronic arthritis | #1 |
| modified glycopeptides | #1 |
| cia mhc | #1 |
| cii rheumatoid autoantibodies | #1 |
| proteolipoprotein peptide | #1 |
| region ncf1 | #1 |
| mice deficient ncf1 | #1 |
| loci arthritis | #1 |
| nod loci genes | #1 |
| evokes peptide | #1 |
| dba 1jpfp | #1 |
| caia induced | #1 |
| cii molecule | #1 |
| cia9 | #1 |
| chromosome pia | #1 |
| glycosylated epitope | #1 |
| citc1iiip | #1 |
| treatment cii immunization | #1 |
| onset animals arthritis | #1 |
| citrullination cii | #1 |
| mhc mbp | #1 |
| ciiderived | #1 |
| rfig lambda | #1 |
| resistance collageninduced arthritis | #1 |
| b10qnss1 | #1 |
| enhanced autoimmunity | #1 |
| vivo monoclonal mouse | #1 |
| lys264 | #1 |
| cxi collagen fibers | #1 |
| cii matrix protein | #1 |
| cia7 chromosome | #1 |
| spleen pristane injection | #1 |
| kgf thymus | #1 |
| aplec locus | #1 |
| chronic active arthritis | #1 |
| polyi pia rats | #1 |
| collagen arthritis hyaluronanreceptor | #1 |
| mab cb268 | #1 |
| mannan joints | #1 |
| ncf1mutation | #1 |
| collagen antibody arthritis | #1 |
| cii 256 | #1 |
| rats clec4b | #1 |
| pia rheumatoid arthritis | #1 |
| arthritis gene regions | #1 |
| publication animals arthritis | #1 |
| serum interferon activity | #1 |
| polymer adjuvant activity | #1 |
| congenic fragments | #1 |
| lew ztm ncf1 | #1 |
| anticlever1 antibody treatment | #1 |
| rats pristane | #1 |
| satellite encephalomyelitis autoimmune | #1 |
| arthritis multiple | #1 |
| eae39 study | #1 |
| induction oia | #1 |
| cartilage explants m2139 | #1 |
| pia4 | #1 |
| ncf1 m1j | #1 |
| genes congenic | #1 |
| specificity arthritis | #1 |
| heterologous peptide response | #1 |
| mediate pulmonary inflammation | #1 |
| cia mtx | #1 |
| receptor γ pparγ | #1 |
| b10q1 | #1 |
| suppression collagen | #1 |
| arthritis monoclonal | #1 |
| cartilaginous joints | #1 |
| disease affinity | #1 |
| mabs cii | #1 |
| arthritis epitopes | #1 |
| ciic1 mab ciif4 | #1 |
| increased incidence cia | #1 |
| cia40 | #1 |
| collagen autoantibody | #1 |
| antibody cartilage blymphocyte | #1 |
| single bout hiit | #1 |
| disease arthritis | #1 |
| chain l10d9 antibody | #2 |
| rp animal ear | #2 |
| nadph oxidase 2 | #2 |
| mycobacteria granulomas | #2 |
| type collagen cii | #2 |
| rats da1u rats | #2 |
| immunization mbp89 | #2 |
| monodeoxygenation | #2 |
| vaccination strategy c5a | #2 |
| h2q response | #2 |
| liver histone | #2 |
| antibodies fibß62 | #2 |
| integrin‐binding‐domain | #2 |
| increased severity development | #2 |
| cartilage respiratory tract | #2 |
| arthritogenic | #2 |
| antibodies development | #2 |
| matrilin vivo | #2 |
| alp monoclonal arthritis | #2 |
| nox2 complex sle | #2 |
| percentage peripheral cells | #2 |
| rats ifngamma | #2 |
| eae caia | #2 |
| b10g | #2 |
| citc1359 | #2 |
| aetiology2–4 | #2 |
| macrophages enhances | #2 |
| sera rheumatoid arthritis | #2 |
| circulating medium | #2 |
| oestradiol induction phase | #2 |
| smash recommendations | #2 |
| ros tregs | #2 |
| α3xi | #2 |
| animal model arthritis | #2 |
| oestrogen ean | #2 |
| c5ay35 | #2 |
| arthritis g6pi | #2 |
| lymphocytes animals | #2 |
| ides treatment | #2 |
| glycan activation | #2 |
| macrophagespecific nox2 development | #2 |
| arthritis mice | #2 |
| mbp peptide eae | #2 |
| immunization sch | #2 |
| lymphoproliferative gene | #2 |
| cell tolerance c5a | #2 |
| hkatpasecontaining vesicles | #2 |
| liver mice rna | #2 |
| binding sites autoimmune | #2 |
| osteoclasts flow cytometry | #2 |
| microscopic scoring arthritis | #2 |
| arthritis models rats | #2 |
| mbp89 peptides | #2 |
| l10d9 antibody | #2 |
| cii citrullination | #2 |
| design glycopeptides | #2 |
| m2139 ciif4 | #2 |
| anti cii | #2 |
| antibody fine | #2 |
| development combination | #2 |
| glycopeptide complexes | #2 |
| pia rat | #2 |
| das28 acpa reactivities | #2 |
| granulocytes alp | #2 |
| class immunoenzyme | #2 |
| hydroxyethylene | #2 |
| oestrogen suppressive | #2 |
| iaexpressing cells | #2 |
| dxeb strain immunization | #2 |
| symptoms antibodies | #2 |
| dancf1da | #2 |
| tcells recognition | #2 |
| c57bl 10 background | #2 |
| ptpn22 disulfide | #2 |
| pristane rats | #2 |
| collageninduced arthritis mice | #2 |
| cia arthritis | #2 |
| osteoclastogenesis endogenous dna | #2 |
| b10qncf1 mice | #2 |
| autoimmune membrane proteins | #2 |
| 18ffluoromannan | #2 |
| antibody cartilage | #2 |
| cd19 cells egfp | #2 |
| anticii antibody | #2 |
| cells arthritis | #2 |
| intrinsic tolerance | #2 |
| antitoxin immunoglobulin | #2 |
| sle cgd | #2 |
| da1u rats | #2 |
| cep1 fibß62 | #2 |
| ala261 | #2 |
| mrl joints stages | #2 |
| immunological requirements | #2 |
| arthritogenic challenge | #2 |
| mabs collagen | #2 |
| wildtype mice macrophages | #2 |
| mice susceptible | #2 |
| tlymphocyte arthritis arthritis | #2 |
| antibody response development | #2 |
| new immunomodulatory drug | #2 |
| rats heterologous cii | #2 |
| eno5 | #2 |
| tregs mph ros | #2 |
| ability arthritis | #2 |
| sle nadph oxidase | #2 |
| mph ros | #2 |
| ovx ncf1 mice | #2 |
| nox2 neuropathological alterations | #2 |
| congenic polychondritis | #2 |
| immunosuppressive leukocytes | #2 |
| c2ta genetic polymorphisms | #2 |
| arthritis scoring | #2 |
| cia anti | #2 |
| antibodies disease onset | #2 |
| diseases collagen | #2 |
| igke promoter expression | #2 |
| chronic relapsing disease | #2 |
| granulomas cgd mice | #2 |
| granulomas macrophages | #2 |
| lack ifngamma | #2 |
| cia day | #2 |
| h12919 | #2 |
| autoimmune congenic arthritis | #2 |
| arthritis treatment | #2 |
| sialadenitis mice | #2 |
| w3 13 | #2 |
| raloxifene estradiol treatment | #2 |
| macrophagespecific nox2 | #2 |
| incidence nephritis | #2 |
| m2139 | #2 |
| arthritis raloxifene | #2 |
| titres ccp2 | #2 |
| anticcp2negative | #2 |
| ß62 | #2 |
| conditions igke promoter | #2 |
| pristane injection | #2 |
| ptpn22 ncf1 | #2 |
| igsecretors | #2 |
| l10d9 | #2 |
| fibβ36 | #2 |
| endoglycosidase treatment | #2 |
| snecs neutrophils | #2 |
| ros peroxide | #2 |
| multiple sclerosis maps | #2 |
| egfp cd19 cells | #2 |
| allelic variant type | #2 |
| p47phoxmutated | #2 |
| alterations neuroendocrine profile | #2 |
| tgfbeta spinal cord | #2 |
| mbp peptides immunization | #2 |
| tracheolaryngeal cartilage rp | #2 |
| influence chromosome | #2 |
| neutrophil fpr2 | #2 |
| mog79 | #2 |
| rats disease onset | #2 |
| ncf1 mutants | #2 |
| genotypes ovx | #2 |
| ros granulomas | #2 |
| nox2 macrophages | #2 |
| linomide homologous cia | #2 |
| cxi l10d9 antibody | #2 |
| autoimmunity autoantibodies | #2 |
| derived ros | #2 |
| gender rats | #2 |
| cia mice mice | #2 |
| mice bacterial infections | #2 |
| sequences mbp89 | #2 |
| c2ta genetic | #2 |
| adjuvant rats | #2 |
| animal granulomatous disease | #2 |
| kinloch | #2 |
| ean6 | #2 |
| rats arthritogenic challenge | #2 |
| collagen arthritis cii | #2 |
| nadph oxidase deficiency | #2 |
| elastaseinduced emphysema nox2 | #2 |
| ifngamma spinal cord | #2 |
| antibodies cep1 | #2 |
| matrilin 1 | #2 |
| cia monkeys | #2 |
| castrated mice day | #2 |
| oestrogen myelin | #2 |
| rats polymorphism | #2 |
| collagen citrullination adhesion | #2 |
| collagen ii‐induced arthritis | #2 |
| arthritis oia | #2 |
| collagen antibody | #2 |
| 18fbicyclo610nonyne | #2 |
| rats lymphocytes | #2 |
| ccp2 diagnostic accuracy | #2 |
| salt intake vivo | #2 |
| citrullinated peptides development | #2 |
| experimental cloning | #2 |
| mrl mice stages | #2 |
| g6pi arthritis | #2 |
| mph induction | #2 |
| arthritogenic mab cii | #2 |
| arthritis heterologous cia | #2 |
| transgenic oxidases zymosan | #2 |
| mice genistein treatment | #2 |
| severity collagen | #2 |
| human animal models | #2 |
| immunocap isac performance | #2 |
| binding cartilage | #2 |
| arthritis gender | #2 |
| bmd caia | #2 |
| neutrophil functions modulation | #2 |
| antibody‐mediated arthritis | #2 |
| das28 values p001 | #2 |
| ptpn22 protein disulfide | #2 |
| transgenic osteoporosis oestradiol | #2 |
| galactosyl moiety | #2 |
| positive anticcp2 test | #2 |
| igkeegfp lentivirus expression | #2 |
| comp titers | #2 |
| pia rats | #2 |
| h2q mice mice | #2 |
| glut4dependent | #2 |
| heterologous collagens arthritis | #2 |
| i‐a molecule | #2 |
| enhanced arthritis | #2 |
| fibα563 | #2 |
| severity collagen arthritis | #2 |
| eae dxea strain | #2 |
| chronic autoimmune polyarthritis | #2 |
| arthritis development rats | #2 |
| mbp 87110 peptide | #2 |
| dr4 cii259 | #2 |
| arthritis female | #2 |
| antileukoproteinase alp | #2 |
| genetic regions psoriasis | #2 |
| dominant suppressive | #2 |
| higher levels anas | #2 |
| analyses comp | #2 |
| rats da1u | #2 |
| cii depletion | #2 |
| early onset severity | #2 |
| dxea strain tgfbeta | #2 |
| neuroendocrine profile | #2 |
| disease 111 | #2 |
| adjuvant oils arthritis | #2 |
| rt1bb | #2 |
| fibroblast induced | #2 |
| mhciii | #2 |
| maintenance induced resistance | #2 |
| dxeb | #2 |
| animal haplotypes | #2 |
| raloxifene oestradiol | #2 |
| homologous cia | #2 |
| b10qf1 | #2 |
| comp cia | #2 |
| exclusive reactivity | #2 |
| arthritis antibody response | #2 |
| das28 24 months | #2 |
| rheumatoid binding | #2 |
| cytosolic ros production | #2 |
| disease humanized mice | #2 |
| flow cytometry ovx | #2 |
| oxidation increased severity | #2 |
| suggestive locus | #2 |
| granulomas ros | #2 |
| multiple antibody reactivities | #2 |
| utility comp | #2 |
| models autoimmune | #2 |
| hladr2dq6 | #2 |
| rats utility | #2 |
| ptpn22 c129s | #2 |
| chitosanagarosegelatin | #2 |
| disease promoting | #2 |
| caia effector phase | #2 |
| mannan induced | #2 |
| l10d9 antibody cartilage | #2 |
| skg model | #2 |
| agonist fpr2 | #2 |
| citcii311 | #2 |
| cpg2088 | #2 |
| fibα580 | #2 |
| ros source | #2 |
| fibß62 | #2 |
| mabs comp | #2 |
| induction cia | #2 |
| arthritis ethanol | #2 |
| selective fpr1 | #2 |
| vivo cii | #2 |
| lack functional nox2 | #2 |
| autoimmune recognition | #2 |
| disease genotype hybridization | #2 |
| species susceptible haplotypes | #2 |
| cii injection | #2 |
| cartilage respiratory | #2 |
| synovial immune reactions | #2 |
| hiit skeletal muscle | #2 |
| mbp89 | #2 |
| matrilin cartilage proteins | #2 |
| anticd4 treatment | #2 |
| induction p47phoxmutated mph | #2 |
| snp position | #2 |
| control subjects samples | #2 |
| mhc congenic | #2 |
| epitope glycosylation | #2 |
| arthritis fb | #2 |
| igg glycosylation arthritis | #2 |
| fpr1 neutrophils | #2 |
| cia mechanisms | #2 |
| fil307 | #2 |
| single nucleotide rats | #2 |
| arthritogenic capacity | #2 |
| micro dams transgenic | #2 |
| cms eae | #2 |
| oestrogen pregnancy | #2 |
| acpa reactivities | #2 |
| sialadenitis animals | #2 |
| mog rats | #2 |
| functional ncf1 variants | #2 |
| suppressive oestrogen | #2 |
| altered formation | #2 |
| caia oestradiol | #2 |
| 12 590 | #2 |
| ncf1 oxidation | #2 |
| c2ta mhcii expression | #2 |
| etoposide serum concentrations | #2 |
| oxidation c129s | #2 |
| terpenes animals | #2 |
| psychosocial stress hpaaxis | #2 |
| celldependent phase | #2 |
| cii ciic1 | #2 |
| symptoms anti ccp2 | #2 |
| mhcii experimental arthritis | #2 |
| clever1 tumor | #2 |
| implanted melanoma | #2 |
| injection w3 13 | #2 |
| shared epitope cxi | #2 |
| myelin ppd | #2 |
| 034positive | #2 |
| c129s mutant disulfide | #2 |
| citcii | #2 |
| igke | #2 |
| cii311 | #2 |
| toe stiffness | #2 |
| glycopeptides histocompatibility | #2 |
| mitochondria polymorphism | #2 |
| chronic arthritis treatment | #2 |
| mab cii | #2 |
| putative vulnerability locus | #2 |
| agonist study | #2 |
| c1epitope | #2 |
| fpr1 signaling | #2 |
| receptor‐specific manner | #2 |
| redox regulation ptpn22 | #2 |
| antileukoproteinase modulation | #2 |
| wtc5a | #2 |
| anticcp2negative presence | #2 |
| ere activation treatment | #2 |
| ciif4 | #2 |
| pnipaam vpba | #2 |
| cgd mice kynurenine | #2 |
| genetic encephalomyelitis | #2 |
| nadph oxidase elevations | #2 |
| h2q | #2 |
| b10qncf1 mice cia | #2 |
| incidence insulitis | #2 |
| lew mol | #2 |
| disease development presence | #2 |
| psoriatic disease models | #2 |
| cell dependent | #2 |
| murine locus eae2 | #2 |
| transgenic protein processing | #2 |
| congenic mice autoimmune | #2 |
| ncf1 ean6 | #2 |
| igke promoter | #2 |
| eosinophilia arthritis | #2 |
| nodq | #2 |
| epitopes rat | #2 |
| fpr1 agonist | #2 |
| knockout illness | #2 |
| pathogenic igg antibodies | #2 |
| cartilage proteins sera | #2 |
| paws mice | #2 |
| mice collagen | #2 |
| dxea strain | #2 |
| cartilage‐specific autoimmunity | #2 |
| cia animals | #2 |
| staphylococcal infections mice | #2 |
| immunization mouse collagen | #2 |
| antibodies cartilage | #2 |
| disease cyclosporin treatment | #2 |
| rno12 | #2 |
| apc naïve cells | #2 |
| prophylactic treatment linomide | #2 |
| human lung nox2 | #2 |
| comp cartilage | #2 |
| l10d9 antibody cxi | #2 |
| re04 | #2 |
| ncf1gene | #2 |
| da1u | #2 |
| arthritis progression | #2 |
| tolerance cii | #2 |
| igkeegfp lentivirus | #2 |
| antipan | #2 |
| peptides chronic eae | #2 |
| hiit skeletal | #2 |
| oestradiol cia | #2 |
| tregs mph | #2 |
| eae protein rna | #2 |
| epitope‐specific recognition | #2 |
| biologicals 24 months | #2 |
| caia eae | #2 |
| sequence analysis indel | #2 |
| collagen arthritis immunization | #2 |
| mhc iii | #2 |
| 111 vivo treatment | #2 |
| cia disease | #2 |
| caia | #2 |
| lymphocytelike | #2 |
| beta 10b | #2 |
| eae cia | #2 |
| cd8 cells incidence | #2 |
| chromosome rats | #2 |
| ciic1 | #2 |
| rtlu | #3 |
| allogeneic pregnancy | #3 |
| arthritis effects | #3 |
| hfdmets rats | #3 |
| mice development | #3 |
| disease w3 13 | #3 |
| differences citrullinated peptides | #3 |
| mice copolymers | #3 |
| targeting toll | #3 |
| fibα573 | #3 |
| ifnbetadeficient mice | #3 |
| antibodies vim60 | #3 |
| cryogel bioreactor | #3 |
| points acs | #3 |
| height disease | #3 |
| 81b | #3 |
| cystatin cdeficient mice | #3 |
| animal glycosylation humans | #3 |
| h2qbearing | #3 |
| acpas twins | #3 |
| rats disease | #3 |
| spe dce | #3 |
| dce spe | #3 |
| acpapositive twins | #3 |
| nerve terminallike profiles | #3 |
| wildtype mice granulomas | #3 |
| arthritis autoimmunity | #3 |
| cvrelated death | #3 |
| advanced intercross eae5 | #3 |
| complex genetic control | #3 |
| 95 cvrelated death | #3 |
| loci antibodies | #3 |
| ifngamma neurons | #3 |
| development acpas | #3 |
| monoclonal cartilage sections | #3 |
| hdac1 pathogenesis | #3 |
| cep1 filaggrin | #3 |
| rheumatoid cloning | #3 |
| arthritis susceptible | #3 |
| cii reactive | #3 |
| genetic influence susceptibility | #3 |
| vivo control mice | #3 |
| arthritis resistance | #3 |
| nox2 cgd | #3 |
| experimental cell | #3 |
| eae17 | #3 |
| acpa combination | #3 |
| cia strains | #3 |
| mnc salivary glands | #3 |
| vim60 | #3 |
| disease genotype immunity | #3 |
| ncf4 rs729749 | #3 |
| glycosylated type | #3 |
| crossreactive idiotope | #3 |
| subspecificities associations | #3 |
| induced immunospecific tolerance | #3 |
| models arthritis | #3 |
| cd8 cells ean | #3 |
| ncf1 cldn4 | #3 |
| genotype knowledge | #3 |
| disease immunization | #3 |
| cvrelated death adjustment | #3 |
| oxidase 2 | #3 |
| endogenous ifnbeta | #3 |
| restricted role | #3 |
| common mouse model | #3 |
| disease disease development | #3 |
| rt1a tap2 | #3 |
| eae1 | #3 |
| arthritis susceptibility | #3 |
| citrullinated peptides multiplex | #3 |
| lupus nets | #3 |
| genes disease development | #3 |
| allopregnancy | #3 |
| arthritis review | #3 |
| mhc class betachain | #3 |
| cia animals arthritis | #3 |
| antibodies specific sets | #3 |
| cii species | #3 |
| keratinocytes langerhans cells | #3 |
| cyp7a1 abca1 | #3 |
| cells naïve mice | #3 |
| ifngammali | #3 |
| onset combination | #3 |
| ean mca | #3 |
| type collagen vivo | #3 |
| antigen presentation mhcii | #3 |
| type c2ta | #3 |
| dancf1e3 | #3 |
| reactive idiotope | #3 |
| neutrophils eae | #3 |
| eae17 chromosome | #3 |
| cartilage proteins | #3 |
| fibβ74 | #3 |
| rheumatoid autoimmune | #3 |
| dnfb ears | #3 |
| early phase disease | #3 |
| disease height | #3 |
| autoimmune models | #3 |
| species lymphocytes | #3 |
| dxea | #3 |
| sialadenitis | #3 |
| development arthritis | #3 |
| fibα573 fibβ74 | #3 |
| isotypes acpas | #3 |
| citrulline inflammation | #3 |
| eae31 | #3 |
| anti‐type | #3 |
| twins acpas | #3 |
| development collagen arthritis | #3 |
| fibβ62 81b | #3 |
| h2p mice | #3 |
| citc1iii | #3 |
| clever1 macrophages | #3 |
| citc1iii fibα573 | #3 |
| autoimmunity pia | #3 |
| treatment arthritis | #3 |
| bcg ros | #3 |
| mice constant light | #3 |
| minimal adjuvant requirement | #3 |
| antigens keratinocytes | #3 |
| rheumatoid crosses | #3 |
| fibα591 | #3 |
| rs729749 | #3 |
| arthritis levels | #3 |
| mice rheumatoid | #3 |
| h2aalpha | #3 |
| female preponderance | #3 |
| rats rheumatoid arthritis | #3 |
| cytotoxic t‐lymphocyte | #3 |
| oxidases reactive | #3 |
| cdk6 padi4 | #3 |
| incidence antinuclear antibodies | #3 |
| apc cia | #3 |
| lew ztm | #3 |
| autoimmunity cartilage | #3 |
| acpas fine specificities | #3 |
| arthritogenicity | #3 |
| twins acpapositive | #3 |
| processing cii | #3 |
| ros deficiency | #3 |
| arthritogenic mab | #3 |
| experimental arthritis | #3 |
| db1 treatment | #3 |
| cd4∶cd8 lineage | #3 |
| acpa subspecificities | #3 |
| cia hdac1 | #3 |
| antibodies induce | #3 |
| pristane‐induced arthritis | #3 |
| carriers hladrb104 | #3 |
| arthritis model | #3 |
| cd4∶cd8 lineage commitment | #3 |
| hdac1 rheumatoid arthritis | #3 |
| origin suggestive linkage | #3 |
| acpas plasma | #3 |
| citcii355 | #3 |
| c57bl mice illness | #3 |
| eae5 pia4 | #3 |
| acpa specificities presence | #3 |
| ctla4 deletion | #3 |
| citrullinated peptides time | #3 |
| lew1f | #3 |
| swedish patients antibodies | #3 |
| mice environments | #3 |
| citrullinated cyclic | #3 |
| stroke cvrelated death | #3 |
| fibβ74 onset | #3 |
| arthritis animal model | #3 |
| immuniozation | #3 |
| dthreaction | #3 |
| fibα573 fibα591 | #3 |
| mmc mice | #3 |
| acpa multiplex | #3 |
| rs729749 ncf4 | #3 |
| igl genes | #3 |
| aureus arthritis mice | #3 |
| antibodies citrullinated | #3 |
| chronic collagen | #3 |
| disease anti lymphocyte | #3 |
| antigens collagen | #3 |
| disease development contribution | #3 |
| inflamed synovial tissues | #3 |
| ifngammali neurons | #3 |
| transgenic osteoporosis | #3 |
| eae16 | #3 |
| osteoclasts release | #3 |
| rats mog | #3 |
| combination acpa | #3 |
| db1 treatment day | #3 |
| recombination rt1a | #3 |
| nox2 pathogenesis | #3 |
| pia6 | #3 |
| macroporous gel particles | #3 |
| eae5 ncf1 | #3 |
| binding aq | #3 |
| fibα591 vim60 | #3 |
| female immunoenzyme | #3 |
| natural alleles genes | #3 |
| immunization addition | #3 |
| anticollagen antibody | #3 |
| model arthritis | #3 |
| human cii | #3 |
| complex autoimmune diseases | #3 |
| anticollagen antibodies | #3 |
| rheumatoid arthritis complement | #3 |
| antigen monoclonal arthritis | #3 |
| macrophages involvement | #3 |
| pia | #3 |
| c2ta | #3 |
| antibodies citc1iii | #3 |
| patients monoclonal chimeric | #3 |
| ciic1 cii | #3 |
| hydrocarbon oils | #3 |
| pnippam | #3 |
| disease risk subsets | #3 |
| hladrb104 cochranmantelhaenszel test | #3 |
| neutrophil cytosolic factor | #3 |
| class antigens keratinocytes | #3 |
| chromosome eae17 | #3 |
| cbrh7919 cells | #3 |
| low production | #3 |
| presence drb104 | #3 |
| dual manner | #3 |
| ctla4 adult mice | #3 |
| rodents6 | #3 |
| hladrb104 mann whitney | #3 |
| citc1iii filaggrin | #3 |
| pathogenesis pia | #3 |
| pfp mice | #3 |
| response immune response | #3 |
| levels fibα591 | #3 |
| acpa titers | #3 |
| eae17 genetic heterogeneity | #3 |
| activated cells mice | #3 |
| day disease duration | #3 |
| nadph oxidase complex | #3 |
| acpas human serum | #3 |
| multiple sclerosis hladr2 | #3 |
| occurrence subspecificities | #3 |
| cvrelated death association | #3 |
| rt11 rats | #3 |
| eae5r1 | #3 |
| cii elisa | #3 |
| subspecificities occurrence | #3 |
| total abrogation | #3 |
| major cell epitope | #3 |
| mca ean | #3 |
| role ros | #3 |
| acpas genetic factors | #3 |
| il‐4‐deficient mice | #4 |
| cells maternal origin | #4 |
| placental mhc | #4 |
| citrullinated peptides autoantibodies | #4 |
| α1ii chain | #4 |
| ethylene isosteres | #4 |
| interaction monoclonal antibody | #4 |
| tcell activation development | #4 |
| positional cloning genes | #4 |
| parathyroid antibodies | #4 |
| type collagen arthritis | #4 |
| experimental arthritis cii | #4 |
| cia6 | #4 |
| cia mouse | #4 |
| sh3gl1 | #4 |
| mhc eae | #4 |
| fibβ62 | #4 |
| mrl dth | #4 |
| congenic c57bl | #4 |
| affinity case | #4 |
| immunodominant cell | #4 |
| bxsb chromosome | #4 |
| cellular transfer | #4 |
| epitope collagen | #4 |
| arthritis severity | #4 |
| immune response cii | #4 |
| cia b10q mice | #4 |
| elevated th1 | #4 |
| citrullinated protein antibodies | #4 |
| rheumatoid arthritis rats | #4 |
| cryogel matrix | #4 |
| mice etoposide | #4 |
| adjuvant oil | #4 |
| pathogenic antibody | #4 |
| antigen sequence deletion | #4 |
| variance animals arthritis | #4 |
| shared autoimmunity | #4 |
| mip mice | #4 |
| genetic association vav1 | #4 |
| k8 k8 mice | #4 |
| autoimmune experimental phenotype | #4 |
| dead cell remnants | #4 |
| onset clinical arthritis | #4 |
| diseases rheumatoid | #4 |
| cyclic software | #4 |
| type collagen rat | #4 |
| strains arthritis | #4 |
| lnchc | #4 |
| catabolism kynurenine | #4 |
| estrus cycling | #4 |
| glend2 | #4 |
| stages disease development | #4 |
| macrophages mycobacteria | #4 |
| anti‐t‐cell | #4 |
| antitype collagen antibodies | #4 |
| treg cells ctla4 | #4 |
| type collagen autoimmunity | #4 |
| collagen rheumatoid | #4 |
| cd4 cells stage | #4 |
| dae3 | #4 |
| elimination cd8 cells | #4 |
| rs682626 | #4 |
| cia suppression | #4 |
| smoking antibodies | #4 |
| immunoglobulin deficient | #4 |
| experimental genetic | #4 |
| collagen type | #4 |
| normal mouse igg | #4 |
| vav1 rheumatoid arthritis | #4 |
| autoantibodies type collagen | #4 |
| acpas serum | #4 |
| pathogenesis histone | #4 |
| arthritis mouse | #4 |
| fcγr regulation | #4 |
| cells cryogel column | #4 |
| cell response immunization | #4 |
| tsc mice | #4 |
| arthritis comp | #4 |
| cii animal epitopes | #4 |
| estrogen levels levels | #4 |
| autoimmune mrl | #4 |
| rp sle | #4 |
| dth reaction | #4 |
| fpr2 recognition | #4 |
| collagen glycopeptides | #4 |
| response arthritis | #4 |
| dth mrl | #4 |
| knowledge genetic association | #4 |
| autoimmunity rats | #4 |
| collagen immune | #4 |
| experimental cattle cells | #4 |
| cii peptide | #4 |
| pristane‐induced | #4 |
| arthritis collageninduced arthritis | #4 |
| multispecific antibodies | #4 |
| peptide mbp | #4 |
| glands sialadenitis | #4 |
| krönke | #4 |
| endos igg | #4 |
| mutation ncf1 | #4 |
| cb10 fragment | #4 |
| strain eae | #4 |
| arthritis defined | #4 |
| cells cryogel | #4 |
| antibodies citrullinated peptides | #4 |
| cytosolic ros | #4 |
| synovial endothelium | #4 |
| mp‐lpr | #4 |
| candidate genes rats | #4 |
| potent immunomodulator | #4 |
| tnfα p38 mapk | #4 |
| antibody response mog | #4 |
| genistein addition | #4 |
| estrogen cia | #4 |
| subsets presence | #4 |
| inpp4b474r 548p | #4 |
| ox8 | #4 |
| development sialadenitis | #4 |
| type‐ii collagen | #4 |
| lxrα pparγ | #4 |
| cia lia | #4 |
| species regulate | #4 |
| inbred dba peptides | #4 |
| cii ifa | #4 |
| c129s | #4 |
| congenic rats rats | #4 |
| experimental arthritis humans | #4 |
| cathelicidins ll37 | #4 |
| mrl b6 | #4 |
| locus mouse chromosome | #4 |
| rs12979659 | #4 |
| ii‐induced | #5 |
| measurement nox activity | #5 |
| chick cii | #5 |
| patients acpa levels | #5 |
| streptococcus pyogenes ides | #5 |
| ovalbumin pepsin | #5 |
| b‐cell epitope | #5 |
| classical adjuvant | #5 |
| arthritis onset | #5 |
| tsst1producing | #5 |
| raloxifene disease activity | #5 |
| interaction cartilage | #5 |
| symptoms rheumatoid arthritis | #5 |
| biomarkers 2 polyradiculoneuropathy | #5 |
| backcrossed | #5 |
| apc cii | #5 |
| oxidative radicals | #5 |
| immunized animals controls | #5 |
| regulating rat | #5 |
| subsets rheumatoid arthritis | #5 |
| field nox | #5 |
| arthritogenic cells | #5 |
| cartilage type | #5 |
| multiplex analyses | #5 |
| pathogenesis autoimmune arthritis | #5 |
| immunization type collagen | #5 |
| cbrh7919 | #5 |
| experimental breeding | #5 |
| cia type collagen | #5 |
| multiparous mice | #5 |
| lipidomic remodeling | #5 |
| lew1n | #5 |
| dba 1 mice | #5 |
| nox complex | #5 |
| commonly model | #5 |
| epitope cii | #5 |
| cgd mice | #5 |
| oestradiol vehicle | #5 |
| exercise hiit | #5 |
| ly female | #5 |
| c‐glycoside analogue | #5 |
| autologous type | #5 |
| symptom onset frequency | #5 |
| asparaginelinked glycan | #5 |
| autoimmune disease models | #5 |
| overexpression hdac3 | #5 |
| swr mouse | #5 |
| tcell mrl | #5 |
| collageninduced arthritis cia | #5 |
| delayed immunization rats | #5 |
| severe arthritis mice | #5 |
| position type collagen | #5 |
| painlike behavior | #5 |
| eae5 | #5 |
| pineal gland development | #5 |
| glycopeptide | #5 |
| lethal inflammatory disorder | #5 |
| tcell hybridomas | #5 |
| nox o2• h2o2 | #5 |
| il4deficient mice | #5 |
| type collagen cix | #5 |
| ros mca | #5 |
| egfp flow cytometry | #5 |
| cgd hyperinflammation | #5 |
| beta 11 cells | #5 |
| tlr3 macrophages | #5 |
| nox animal models | #5 |
| arthritis rats | #5 |
| puccetti | #5 |
| wellknown role | #5 |
| tlr3 expression | #5 |
| mice acpa | #5 |
| osteoclasts stromal cells | #5 |
| igg endos | #5 |
| ros macrophages | #5 |
| citrullinated peptides ccp | #5 |
| rt1eu | #5 |
| cia model | #5 |
| chromosome cia7 | #5 |
| multiplex array | #5 |
| uterus cells | #5 |
| dba mouse | #5 |
| glycopeptidomimetics | #5 |
| severe sialadenitis | #5 |
| antibodies filaggrin | #5 |
| oia | #5 |
| symptoms development | #5 |
| recovery ean | #5 |
| rats developed | #5 |
| congenic nod | #5 |
| α10i | #5 |
| resistance cia | #5 |
| glycopeptide fragment | #5 |
| aureus arthritis | #5 |
| higher levels melatonin | #5 |
| mrvalues | #5 |
| development acpa | #5 |
| cd8 deficiency | #5 |
| antileukoproteinase | #5 |
| immunization male | #5 |
| smoking prior | #5 |
| avridineinduced arthritis | #5 |
| absence c5 | #5 |
| o2• h2o2 nox | #5 |
| monoclonal antibody alpha | #5 |
| tbb infection | #5 |
| low dose tolerance | #5 |
| collagen anti | #5 |
| citrullinated peptides | #5 |
| tubule cells kidney | #5 |
| hydroxynorvaline | #5 |
| immunological involvement | #5 |
| cia cd4 cells | #6 |
| acpa specificities | #6 |
| peptides arthritis | #6 |
| mice investigated | #6 |
| immunization peptides | #6 |
| cells affinity surface | #6 |
| dominant suppression | #6 |
| cd4∶cd8 | #6 |
| hdac1 class | #6 |
| autoimmune experimental genes | #6 |
| murine loci | #6 |
| female lymphocyte | #6 |
| acpa anti | #6 |
| glycoproteins nadph | #6 |
| recombinant rat interferongamma | #6 |
| betaoestradiol | #6 |
| experimental postmenopausal | #6 |
| c57bl 6 background | #6 |
| nox2 mediates | #6 |
| macrophages mph | #6 |
| activity neuroinflammation | #6 |
| ltab | #6 |
| pyramidal neurons loss | #6 |
| mice congenic | #6 |
| loci controlling | #6 |
| igg autoantibodies sera | #6 |
| mice sialadenitis | #6 |
| eae mhc | #6 |
| pv loss | #6 |
| pristane squalene | #6 |
| contrasting roles | #6 |
| joints rats | #6 |
| rheumatoid arthritis collagen | #6 |
| transgenic mice arthritis | #6 |
| collagen cia | #6 |
| k8 mice | #6 |
| induced psoriasis | #6 |
| relapsing polychondritis rp | #6 |
| mhcii alleles | #6 |
| develop arthritis | #6 |
| cartilage collagens | #6 |
| tsst1 mice | #6 |
| data ros | #6 |
| collagen arthritis | #6 |
| rheumatoid arthritis comp | #6 |
| mrna tgfbeta | #6 |
| glycopeptide specificity | #6 |
| collagen cells | #6 |
| active arthritis | #6 |
| erosive polyarthritis | #6 |
| heterogeneous stock mice | #6 |
| affinity ligand protein | #6 |
| monoclonal encephalomyelitis autoimmune | #6 |
| controls arthritis | #6 |
| animal genetic | #6 |
| functional selective | #6 |
| staphylococcus aureus arthritis | #6 |
| autoimmunity arthritis | #6 |
| isotypes patients | #6 |
| anti ccp2 | #6 |
| arthritis autoantibodies | #6 |
| treatment oestradiol | #6 |
| metabolic nuclear receptors | #6 |
| ccp2 positive | #6 |
| disease protective | #6 |
| b10 mouse | #6 |
| rcramp | #6 |
| cia26 | #6 |
| arthritis antibodies | #6 |
| l3t4positive cells | #6 |
| lys270 | #6 |
| cell recognition | #6 |
| complex mhc | #6 |
| knockout receptors igg | #6 |
| arthritis models | #6 |
| rheumatoid arthritis model | #6 |
| pathogenic events | #6 |
| impact cia | #7 |
| congenic mouse | #7 |
| type collagen | #7 |
| locus chromosome | #7 |
| symptoms disease onset | #7 |
| nonarthritogenic | #7 |
| collagen arthritis cia | #7 |
| antibodies citrullinated antigens | #7 |
| cia mice | #7 |
| response immunization | #7 |
| raassociated molecules | #7 |
| cii anti | #7 |
| autoimmunity collagen | #7 |
| effector phase | #7 |
| polychondritis relapsing | #7 |
| cryogel column | #7 |
| macrophages alternative activation | #7 |
| induction arthritis | #7 |
| castrated females | #7 |
| ean animals | #7 |
| hydrolases polymorphism | #7 |
| antibodyinduced arthritis | #7 |
| rats phases | #7 |
| isomerase peptide | #7 |
| cia5 | #7 |
| snecs | #7 |
| psoriasiform skin disease | #7 |
| g6pi | #7 |
| mice constant darkness | #7 |
| oestrogen rats | #7 |
| impaired induction | #7 |
| mbp peptide | #7 |
| arthritis type collagen | #7 |
| citrullinated peptide antigens | #7 |
| congenic strains | #7 |
| rheumatoid arthritis role | #7 |
| ciireactive cells | #7 |
| animal immunization injections | #7 |
| yaa gene | #7 |
| autoantibodies citrullinated peptides | #7 |
| collagen epitope | #7 |
| acpa titres | #7 |
| autoantibodies lymphocytes | #7 |
| aplec | #7 |
| conventional environment | #7 |
| periodontitis arthritis | #7 |
| 3xi | #7 |
| cii apc | #7 |
| cab3 | #7 |
| strains disease | #7 |
| regulatory cells macrophages | #7 |
| arthritis genes | #7 |
| mediated vasculitis | #7 |
| transgenic class | #7 |
| collagen arthritis rats | #7 |
| autoimmune human | #7 |
| analysis crosses | #7 |
| murine psoriasis | #7 |
| responses cii | #7 |
| role raloxifene | #7 |
| arthritis strains | #7 |
| glycosylated collagen | #7 |
| region syntenic | #7 |
| chronic phase arthritis | #7 |
| cognate activation | #7 |
| chronic experimental | #7 |
| mouse collagen | #7 |
| protective influences | #7 |
| antigens differentiation arthritis | #7 |
| experimental autoimmune disease | #8 |
| polymeric cryogels | #8 |
| sialadenitis mrl | #8 |
| clinical signs ean | #8 |
| non‐mhc | #8 |
| antibody vivo | #8 |
| neutrophil cytosolic | #8 |
| autoimmune congenic mice | #8 |
| medium mem | #8 |
| t‐cell priming | #8 |
| autoantibodies subset | #8 |
| cosphox | #8 |
| typeii collagen | #8 |
| fcγr2b | #8 |
| autologous peptide | #8 |
| antigenspecific priming | #8 |
| cia2 | #8 |
| eae3 | #8 |
| incidence cia | #8 |
| chronic autoimmune arthritis | #8 |
| mumt mice | #8 |
| b10 background | #8 |
| hladrb11001 | #8 |
| persistent joint pain | #8 |
| oxidized peptides | #8 |
| rt1f | #8 |
| ptpn22620w | #8 |
| experimental binding | #8 |
| α1‐microglobulin | #8 |
| supermacroporous cryogel | #8 |
| destructive effects | #8 |
| humans experimental arthritis | #8 |
| onset incidence | #8 |
| chromosomes loci | #8 |
| diseases loci | #8 |
| heterologous peptide | #8 |
| treatment monoclonal | #8 |
| ifa cii | #8 |
| hlase alleles | #8 |
| mice ifnbeta | #8 |
| ros interplay | #8 |
| cia animal model | #8 |
| hdac3 expression | #8 |
| arthritis lymphocytes | #8 |
| mice techniques | #8 |
| dominant cell epitope | #8 |
| onset day day | #8 |
| 42 rats | #8 |
| rheumatoid chromosome | #8 |
| mbp mog | #8 |
| induced neuropathology | #8 |
| antibodies acpas | #8 |
| illness igg | #8 |
| underlying genes | #8 |
| rheumatoid autoimmunity | #8 |
| parathyroid glands receptors | #8 |
| murinised | #8 |
| rats mhc | #8 |
| inflamed synovia | #8 |
| haematogenously | #8 |
| hybridomas antibodies | #8 |
| expression hdac3 | #8 |
| eae genetic encephalomyelitis | #8 |
| patients type collagen | #8 |
| oia2 | #8 |
| 297 cases | #8 |
| lyme arthritis severity | #8 |
| murine locus | #8 |
| autoantibodies collagen type | #8 |
| collagen female | #9 |
| eae immunization | #9 |
| experimental genes | #9 |
| rt1u | #9 |
| mammalian disease models | #9 |
| murine collagen | #9 |
| arthritis cross | #9 |
| arthritis skg mice | #9 |
| differentiation autoimmune | #9 |
| posttranslational glycosylation | #9 |
| hgpi325 | #9 |
| idiotype‐specific | #9 |
| nodp | #9 |
| illness receptor | #9 |
| oil adjuvants | #9 |
| avridine | #9 |
| antibody alpha | #9 |
| response mouse | #9 |
| serum interferon | #9 |
| il10 role | #9 |
| reduced arthritis | #9 |
| early joint erosions | #9 |
| bound carbohydrates | #9 |
| loci rats | #9 |
| rats rat | #9 |
| acpas | #9 |
| human immunopeptidome | #9 |
| collagen complement | #9 |
| induced metabolic syndrome | #9 |
| antibodies vivo | #9 |
| b10riii mice | #9 |
| animal models urgent | #9 |
| psychological tyrosine | #9 |
| hitr | #9 |
| disease strains | #9 |
| cia transgenic mice | #9 |
| mouse peptide | #9 |
| rheumatoid autoantibodies | #9 |
| variants acpa | #9 |
| acpas patients | #9 |
| bovine cii | #9 |
| inbred dba mice | #9 |
| specific nox2 | #9 |
| pristane | #9 |
| intranasal animals arthritis | #9 |
| experimental arthritis rats | #9 |
| histone 1 hdac1 | #9 |
| development autoimmune arthritis | #9 |
| adaptive inflammation | #9 |
| ox19 | #9 |
| alpha1inhibitor3 | #9 |
| ean myelin | #9 |
| rheumatoid joints | #9 |
| specific sets | #9 |
| oligomeric matrix | #9 |
| postmenopausal arthritis | #9 |
| effects mabs | #9 |
| inbred lew tlymphocytes | #9 |
| 2 nadph | #9 |
| class allele | #9 |
| patients acpas | #9 |
| autoimmunogenic | #9 |
| mutated mice | #10 |
| alpha collagen chains | #10 |
| h2ap | #10 |
| o2• h2o2 | #10 |
| inbred dba | #10 |
| cartilage collagen fibrils | #10 |
| antibodies specific | #10 |
| cartilage oligomeric | #10 |
| mice nadph | #10 |
| monoclonal arthritis | #10 |
| mbp peptides | #10 |
| nih heterogeneous stock | #10 |
| tertbutylacrylamide | #10 |
| oestrogen | #10 |
| acpa diagnosis | #10 |
| monoclonal antigens rats | #10 |
| rheumatoid arthritis dr4 | #10 |
| presence acpa | #10 |
| cartilage arthritis | #10 |
| activation male | #10 |
| stock mice | #10 |
| development severity | #10 |
| ifnbeta mice | #10 |
| collagen autoimmunity | #10 |
| animal models | #10 |
| experimental cartilage | #10 |
| cells increased production | #10 |
| severe erosive | #10 |
| citrullinated antigen | #10 |
| beta 11 | #10 |
| endogenous collagen | #10 |
| pain animal models | #10 |
| immunization rats | #10 |
| axotomized motor neurons | #10 |
| passive transfer experiments | #10 |
| extracellular cartilage | #10 |
| mice genistein | #10 |
| dense fractions | #10 |
| antibody collagen | #10 |
| mice cii | #10 |
| cells development | #10 |
| cd4 cells spleen | #10 |
| cii mice | #10 |
| acutephase response rats | #10 |
| knockout nadph | #10 |
| rats lewis rats | #10 |
| hlase smoking | #10 |
| genetic experiments | #10 |
| autoimmune disease humans | #10 |
| cell‐deficient | #10 |
| abp gene | #10 |
| onset chromosome | #10 |
| reactivity acpas | #10 |
| native collagen type | #10 |
| prl effects | #10 |
| development rheumatoid | #11 |
| gad6 | #11 |
| isotypes | #11 |
| rat liver rats | #11 |
| mice mhc | #11 |
| ptpn22 smoking | #11 |
| chronic arthritis | #11 |
| potential autoantigens | #11 |
| species respiratory | #11 |
| tailbase | #11 |
| nodb10h2b mice | #11 |
| cia7 | #11 |
| dss wt | #11 |
| naïve cells cells | #11 |
| loci regulating | #11 |
| mice cd1 | #11 |
| antigen variability | #11 |
| liver receptor lxrα | #11 |
| cia30 | #11 |
| 2xi | #11 |
| rat arthritis | #11 |
| chondrocytes ecm | #11 |
| antibody type collagen | #11 |
| inflammatory arthritis role | #11 |
| rat collagen | #11 |
| individuals onset | #11 |
| monoclonal rheumatoid factors | #11 |
| cells pia | #11 |
| 84–102 | #11 |
| stromal cells macrophages | #11 |
| antibodies association | #11 |
| fragments anti | #11 |
| arthritis absence | #11 |
| mhc control | #11 |
| lentiviral vector expression | #11 |
| autoimmune monoclonal antigens | #12 |
| nonselfdiscrimination | #12 |
| pia1 | #12 |
| chronic erosive arthritis | #12 |
| natural polymorphism | #12 |
| role arthritis | #12 |
| encephalomyelitis induced | #12 |
| major haplotype | #12 |
| cell responses cii | #12 |
| cross rats | #12 |
| qa2 | #12 |
| psoriasis arthritis | #12 |
| myelin ean | #12 |
| icmediated | #12 |
| rats cia | #12 |
| stages pathogenesis | #12 |
| structure antibodies | #12 |
| cii patients | #12 |
| natural loss | #12 |
| serum concentrations comp | #12 |
| antibodies structures | #12 |
| loci disease | #12 |
| backgroundantibodies | #12 |
| mice comp | #12 |
| animal immunohistochemistry | #12 |
| matrilin | #12 |
| mbp response | #12 |
| peptide study | #12 |
| onset symptoms | #12 |
| treatment experimental arthritis | #12 |
| associations antibodies | #12 |
| stage cia | #12 |
| immunodominant | #12 |
| genetic contamination | #12 |
| frequencies antibodies | #12 |
| rats expression | #12 |
| increased litter size | #12 |
| riiis | #12 |
| mutation nadph | #12 |
| mutated mouse | #12 |
| hydroxylysines | #12 |
| lung macrophages mice | #12 |
| illness sex characteristics | #12 |
| lymphoid cells development | #12 |
| type collagen immunization | #12 |
| bovine type collagen | #12 |
| α1ii | #12 |
| study arthritis | #12 |
| psoriasis mouse model | #12 |
| reduces severity | #12 |
| fpr2 agonists | #12 |
| immunohistochemistry interferon | #13 |
| idd5 | #13 |
| joints blood | #13 |
| advanced intercross | #13 |
| mannan | #13 |
| bcelldeficient mice | #13 |
| l012 | #13 |
| rfigg | #13 |
| ho4 | #13 |
| genes mouse chromosome | #13 |
| macroscopic scoring | #13 |
| species deficiency | #13 |
| mouse strains | #13 |
| levels nabs | #13 |
| anticii | #13 |
| μ chain | #13 |
| citrullinated | #13 |
| b10p | #13 |
| cell epitope | #13 |
| mtec aire | #13 |
| antibodies citrullinated proteins | #13 |
| t‐cell epitope | #13 |
| 24dinitro1fluorobenzene | #13 |
| cells salivary glands | #13 |
| native type collagen | #13 |
| lew1w | #13 |
| expression egfp | #13 |
| arthritis knowledge | #13 |
| complement complement activation | #13 |
| strains incidence | #13 |
| epitope immunization | #13 |
| development type collagen | #13 |
| behavioral alterations rats | #13 |
| nos2derived | #13 |
| cyclic citrullinated | #13 |
| oxidase nox2 | #13 |
| doses ici | #13 |
| ccp2 antibodies | #13 |
| major loci | #13 |
| dr1 transgenic | #13 |
| sequence collagen | #13 |
| oxidative regulation | #13 |
| nonobese diabetic mouse | #13 |
| multispecific | #13 |
| hladrb1 ptpn22 | #13 |
| factor isotypes | #13 |
| dba molecular | #13 |
| macrophages immune response | #14 |
| osteoclasts vivo | #14 |
| nasal inhalation | #14 |
| candidate autoantigens | #14 |
| arlacel | #14 |
| blymphocyte female humans | #14 |
| smallmolecule compound | #14 |
| cia expression | #14 |
| murine collageninduced arthritis | #14 |
| specific inflammation | #14 |
| arthritic paws | #14 |
| protein collagen | #14 |
| sirt1 mmp9 | #14 |
| antifilaggrin antibodies | #14 |
| presence mcv | #14 |
| autoimmunity animals | #14 |
| molecular disease models | #14 |
| collagen comp | #14 |
| immunized rat | #14 |
| peptides anti | #14 |
| mhc class region | #14 |
| efficient promotion | #14 |
| humans nadph | #14 |
| loci interaction | #14 |
| loci rheumatoid | #14 |
| collagen disease | #14 |
| gut protection | #14 |
| aggregated nets | #14 |
| deficient production | #14 |
| thr233 | #14 |
| experimental interferon | #14 |
| immune regulators | #14 |
| autoimmune arthritis | #14 |
| involvement cells | #14 |
| b6n mice | #14 |
| rheumatoid arthritis presence | #15 |
| type collagen development | #15 |
| rt1a | #15 |
| rat genetics | #15 |
| dcii | #15 |
| involvement pathogenesis | #15 |
| regulation adaptive immunity | #15 |
| translationally modified | #15 |
| ros cii | #15 |
| arthritis role | #15 |
| exaggerates | #15 |
| antigenic epitope | #15 |
| monoclonal arthritis rats | #15 |
| lentiviral gene delivery | #15 |
| osteoporosis development | #15 |
| polychondritis | #15 |
| anticollagen | #15 |
| raloxifene estradiol | #15 |
| arthritis development | #15 |
| mhc class molecule | #15 |
| presence anticarp antibodies | #15 |
| citrullinated peptides patients | #15 |
| mice type collagen | #15 |
| congenic rats | #15 |
| murine cia | #15 |
| 2 weight | #15 |
| cultured human chondrocytes | #15 |
| immune complex formation | #15 |
| rats monoclonal antigens | #15 |
| experimental allergic neuritis | #15 |
| treatment cia | #15 |
| cdr regions | #15 |
| tflask | #15 |
| antibodies arthritis | #15 |
| nodb10h2b | #15 |
| mice immunization | #15 |
| amps development | #15 |
| monolithic cryogel | #15 |
| neuritis rats | #15 |
| integrated bioprocess | #15 |
| apcs macrophages | #15 |
| aire mtec | #15 |
| epitopes mice mice | #16 |
| anti‐t | #16 |
| development rheumatoid arthritis | #16 |
| matrilin proteins | #16 |
| rt1 | #16 |
| males onset | #16 |
| fewer osteoclasts | #16 |
| rno10 | #16 |
| mhcii ciita | #16 |
| h2p | #16 |
| antinuclear autoimmunity | #16 |
| cep1 | #16 |
| levels natural antibodies | #16 |
| indirect genetic predisposition | #16 |
| n305 | #16 |
| lethal inflammatory | #16 |
| rats experimental arthritis | #16 |
| hla–drb1 shared epitope | #16 |
| autologous collagen | #16 |
| pparγ lxrα | #16 |
| class transplantation | #16 |
| rheumatoid factor production | #16 |
| subspecificities | #16 |
| oligomeric matrix protein | #16 |
| disease mice mice | #16 |
| acute inflammation mice | #16 |
| mumt | #16 |
| genes animals | #16 |
| nonglycosylated form | #16 |
| congenic mice mice | #16 |
| staphylococcal arthritis | #16 |
| mhc genes | #16 |
| rheumatoid arthritis genes | #16 |
| lew1 | #16 |
| arthritis cii | #16 |
| arthritis severity mice | #16 |
| allergic neuritis | #17 |
| polyphosphate4 | #17 |
| cartilage collagen | #17 |
| mice rheumatoid arthritis | #17 |
| leuphe | #17 |
| arthritis rheumatoid autoantibodies | #17 |
| human fcγriia | #17 |
| cells collagen | #17 |
| ethanol development | #17 |
| genistein mice | #17 |
| clever1 | #17 |
| periodontitis antibodies | #17 |
| spleen peyers patches | #17 |
| rats lewis | #17 |
| nox2 derived | #17 |
| rt1av1 | #17 |
| animals congenic | #17 |
| inbred lew | #17 |
| progesterone development | #17 |
| native denatured | #17 |
| cab4 | #17 |
| skg | #17 |
| cells female mice | #17 |
| rheumatoid arthritis subsets | #17 |
| collagen induced arthritis | #17 |
| collagen specific | #17 |
| strains lymphocytes | #17 |
| triplehelical conformation | #17 |
| onset rheumatoid arthritis | #17 |
| cells presenting cells | #17 |
| hybridomas mice mice | #18 |
| moginduced eae | #18 |
| short‐term administration | #18 |
| joint inflammatory | #18 |
| genes spleen | #18 |
| salivary glands mice | #18 |
| h2z | #18 |
| phenotypic feature | #18 |
| addition ros | #18 |
| disease duration onset | #18 |
| dra0101 | #18 |
| day arthritis | #18 |
| langerhans cells cells | #18 |
| cuiiida | #18 |
| ealkene | #18 |
| purified anti | #18 |
| anti cd44 | #18 |
| ros data | #18 |
| humanized transgenic mice | #18 |
| keratinocytes induction | #18 |
| autoimmune illness | #18 |
| adjuvant arthritis rats | #18 |
| arthritis anti | #18 |
| galactose moiety | #18 |
| day immunization | #18 |
| collagen autoantibodies | #18 |
| expression lxrα | #18 |
| cartilage type collagen | #18 |
| defined epitope | #18 |
| elisa cia | #19 |
| citrullinated proteins acpa | #19 |
| suppression dth | #19 |
| supermacroporous | #19 |
| future utility | #19 |
| vivo elimination | #19 |
| tbetarii gene | #19 |
| rats snp | #19 |
| cia eae | #19 |
| inflammatory attack | #19 |
| collagen response | #19 |
| mice develop | #19 |
| gly262 | #19 |
| blood monocytes neutrophils | #19 |
| beta oestradiol | #19 |
| cd4 transgenic | #19 |
| new avenues | #19 |
| trimolecular complex | #19 |
| peyers patches spleen | #19 |
| mrl mp mice | #19 |
| single intradermal injection | #19 |
| protective alleles | #19 |
| three‐dimensional culture | #19 |
| castrated female rats | #19 |
| patients polychondritis | #19 |
| mice congenic mice | #19 |
| protein comp | #19 |
| ncr3 | #20 |
| imaging reactive | #20 |
| mbp rats | #20 |
| progesterone oestrogen | #20 |
| mice cia | #20 |
| role nox | #20 |
| knockout mice transgenic | #20 |
| pvg1av1 | #20 |
| rt1d | #20 |
| serm raloxifene | #20 |
| development disease | #20 |
| 5p14 | #20 |
| monkeys rodents | #20 |
| highly susceptible | #20 |
| loci chromosomes | #20 |
| human rheumatoid arthritis | #20 |
| underlying gene | #20 |
| glycosylated | #20 |
| antibody treatment | #20 |
| mhc class alleles | #20 |
| prominent infiltration | #20 |
| littermate | #20 |
| enhanced tcr | #20 |
| 5r5 | #20 |
| ciita mhcii | #20 |
| nox1deficient mice | #20 |
| inflammation mice | #20 |
| stress phospholipids | #20 |
| experimental autoimmunity | #20 |
| matrilin1 | #20 |
| response mbp | #20 |
| fls tnfα | #20 |
| onset severity | #21 |
| rats development | #21 |
| ean rats | #21 |
| igg fcgammar | #21 |
| n141 | #21 |
| nitratenitriteno pathway | #21 |
| muscle ros | #21 |
| arthritis pregnancy | #21 |
| cells adaptive immune | #21 |
| chronic relapsing | #21 |
| α1acidglycoprotein | #21 |
| diseases lymphocytes | #21 |
| suppressor cytotoxic cells | #21 |
| linomide treatment | #21 |
| olahsd | #21 |
| serum levels comp | #21 |
| nox2 activity | #21 |
| pathogenesis rheumatoid | #21 |
| supermacroporous cryogels | #21 |
| cia treatment | #21 |
| individual acpa | #21 |
| granule mobilization | #21 |
| positional cloning | #21 |
| illness autoimmune | #21 |
| triplehelical peptides | #21 |
| nox2 mice | #21 |
| genes controlling | #21 |
| experimental rheumatoid | #21 |
| conserved haplotype | #21 |
| drb11001 | #21 |
| mice mutant strains | #21 |
| n286 | #21 |
| animal epitopes humans | #22 |
| identification susceptibility genes | #22 |
| samples onset | #22 |
| experimental phenotype | #22 |
| mice independent | #22 |
| cultured hepatic cells | #22 |
| antiidiotypic antibody | #22 |
| ccp negative | #22 |
| induced eae | #22 |
| rats nonalcoholic steatohepatitis | #22 |
| determinant selection | #22 |
| semiallogenic | #22 |
| rats loss | #22 |
| 270 | #22 |
| association pv | #22 |
| vh j558 | #22 |
| response myelin | #22 |
| c57bl mice subfamily | #22 |
| ul1 | #22 |
| 81a | #22 |
| citrullinated epitopes | #23 |
| citrullinated antigens | #23 |
| inflammation absence | #23 |
| cells b10 | #23 |
| mace association | #23 |
| arthritis type | #23 |
| lymphocytes amino | #23 |
| tgfbeta resistance | #23 |
| loss collagen | #23 |
| peptide activation | #23 |
| mbp eae | #23 |
| anti‐cd5 | #23 |
| onset cia | #23 |
| complex influences | #23 |
| citrullinated protein | #23 |
| 17 betaoestradiol | #23 |
| castration rats | #23 |
| phage clones | #23 |
| immunopeptides | #23 |
| comp | #23 |
| monoclonal antigens autoimmune | #23 |
| experimental autoimmune diseases | #23 |
| antibodies acpa | #23 |
| cryogel beads | #23 |
| diseases autoimmunity | #23 |
| cells presentation | #23 |
| animal genes | #23 |
| 4npa | #23 |
| rats inbred lew | #23 |
| b10r | #23 |
| experimental chromatography | #23 |
| levels comp | #24 |
| loci chromosome | #24 |
| ftirm | #24 |
| mediated arthritis | #24 |
| 339 | #24 |
| experimental lupus | #24 |
| mouse models development | #24 |
| c57bl 10 mice | #24 |
| mice nox2 | #24 |
| autoantibodies rheumatoid | #24 |
| inflammation arthritis | #24 |
| antinuclear apoptosis | #24 |
| rat induction | #24 |
| y35 | #24 |
| animal epistasis | #24 |
| secondary immune response | #24 |
| subloci | #24 |
| monoclonal anti | #24 |
| experimental cells | #24 |
| chronic autoimmune diseases | #24 |
| severity ali | #24 |
| controls anti | #24 |
| flss patients | #24 |
| severity chronicity | #24 |
| postpartum flare | #24 |
| new mouse | #24 |
| cells c3h | #24 |
| rno4 | #25 |
| collagen cartilage | #25 |
| congenic animals | #25 |
| inbred lew rats | #25 |
| monocytes nadph | #25 |
| b6 balb | #25 |
| massive infiltration | #25 |
| tolerized rats | #25 |
| immunodominant epitope | #25 |
| autoimmune diseases humans | #25 |
| production monoclonal | #25 |
| beta lymphocytes | #25 |
| 8 antibodies | #25 |
| murine lyme arthritis | #25 |
| bnda | #25 |
| specific epitopes | #25 |
| complex male | #25 |
| autoantibody response | #25 |
| common autoimmune disease | #25 |
| arthritis experimental arthritis | #25 |
| proteinarginine deiminase type | #25 |
| parasitemia survival | #25 |
| immunization development | #25 |
| ros | #25 |
| cix | #25 |
| arginine arthritis | #25 |
| rat mhc | #25 |
| autoimmune messenger | #25 |
| cell hybridomas | #25 |
| relapsing polychondritis | #25 |
| interleukin2 mice receptors | #25 |
| cells immunization | #25 |
| cells joints | #26 |
| cb11 | #26 |
| viable chondrocytes | #26 |
| eae development | #26 |
| autoantibodies citrullinated proteins | #26 |
| gene regions | #26 |
| anti citrullinated | #26 |
| nitrophenylalanine | #26 |
| igg2a mice | #26 |
| polychondritis rp | #26 |
| local exposure | #26 |
| mice gammadelta cells | #26 |
| post translationally | #26 |
| glutamax | #26 |
| helperinducer animals antibodies | #26 |
| granulocytes cells | #26 |
| hydrocarbon oil | #26 |
| disease immunoglobulin | #27 |
| ccp2 | #27 |
| interleukin21 tlymphocytes | #27 |
| rheumatoid factor isotypes | #27 |
| innate interleukin10 | #27 |
| individuals antibodies | #27 |
| c1i | #27 |
| perforin deficiency | #27 |
| physiological level | #27 |
| intercrossed | #27 |
| immunodominant response | #27 |
| trypsination | #27 |
| antibodies type | #27 |
| immunospecific | #27 |
| hladrb1 shared epitope | #27 |
| pointmutation | #27 |
| pannus tissue | #27 |
| nonmhc genes | #27 |
| protein peptides | #28 |
| w3 25 | #28 |
| chronicity | #28 |
| ros induction | #28 |
| eae susceptibility | #28 |
| rat strain | #28 |
| animal models neurodegeneration | #28 |
| antily6g | #28 |
| anti rat | #28 |
| lysine position | #28 |
| nr8383 | #28 |
| mediated effects | #28 |
| mrna ifngamma | #28 |
| cia3 | #28 |
| cartilage vivo | #28 |
| upregulation cytokines | #28 |
| onset day | #28 |
| antigenspecific tolerance | #28 |
| antibodies mab | #28 |
| severity day | #28 |
| autoimmune inflammatory | #28 |
| membrane lymphocytes | #29 |
| 246trinitrophenyl | #29 |
| immunopathogenicity | #29 |
| smoking presence | #29 |
| cfa cia | #29 |
| ls2616 | #29 |
| mice mab | #29 |
| hiit exercise | #29 |
| antibody producing cells | #29 |
| parotid secretory protein | #29 |
| presence synovial fluid | #29 |
| rfigm | #29 |
| ros production macrophages | #29 |
| phenomes | #29 |
| glucose transport capacity | #29 |
| suboptimal doses | #29 |
| chronic dss | #29 |
| acpa | #29 |
| absence inflammation | #29 |
| peptide anti | #29 |
| development experimental | #30 |
| chain collagen | #30 |
| hlase | #30 |
| alphabetat | #30 |
| linkage disease | #30 |
| synovial cells patients | #30 |
| paws | #30 |
| vgenes | #30 |
| vpba | #30 |
| adult thymectomy | #30 |
| treatment raloxifene | #30 |
| increased salt | #30 |
| ctla4 mice | #30 |
| disease immunity | #30 |
| 11 cells | #30 |
| translational rats | #30 |
| acpa fine | #30 |
| metabolic syndrome rats | #30 |
| vivo exercise | #30 |
| variable heavy chain | #30 |
| cultivation cells | #30 |
| dba mice | #30 |
| chronic autoimmune | #30 |
| plasminogendeficient mice | #30 |
| monoclonal antibody production | #31 |
| drugs addition | #31 |
| disease development | #31 |
| littermate controls | #31 |
| synovial fluid blood | #31 |
| phytol | #31 |
| psoriasis model | #31 |
| pristaneinduced lupus | #31 |
| nox2 nox1 | #31 |
| ige cd23 | #31 |
| acute‐phase response | #31 |
| trimolecular | #31 |
| rats autoimmune | #31 |
| common chain | #31 |
| selfprotein | #31 |
| human type collagen | #31 |
| comparative genetic analysis | #31 |
| hiit training | #31 |
| expressing cells | #31 |
| perpetuated | #31 |
| apc development | #31 |
| immunization | #31 |
| steen | #32 |
| cells uterus | #32 |
| beta mice | #32 |
| ros rns | #32 |
| epitope antibodies | #32 |
| presence acpas | #32 |
| cell ratio | #32 |
| nadph oxidases nox | #32 |
| bound peptides | #32 |
| genomewide genotyping | #32 |
| type antibody | #32 |
| mucosal tolerance | #32 |
| ra33 | #32 |
| methods serum samples | #32 |
| rt11 | #32 |
| differentiation arthritis | #32 |
| specificity function | #32 |
| 11 cell | #32 |
| h2aq | #32 |
| congenic mice | #32 |
| arthritis therapy | #32 |
| influence genes | #32 |
| polymorphic genes | #32 |
| hladrb104 | #32 |
| receptor preference | #32 |
| nonb cells | #32 |
| caia mice | #32 |
| acpa rheumatoid arthritis | #32 |
| role osteoclastogenesis | #32 |
| nodes mice | #32 |
| arthritic mice | #33 |
| cytosolic factor | #33 |
| multiplex analysis | #33 |
| autoantibody activity | #33 |
| delayed type | #33 |
| role vav1 | #33 |
| skews | #33 |
| tcell receptor | #33 |
| epitopes antibodies | #33 |
| rheumatoid joint | #33 |
| type cross | #33 |
| antigenpresenting cells cells | #33 |
| tolerance immunization | #33 |
| modified collagen | #33 |
| autoimmune demyelinating disease | #33 |
| induced immunization | #33 |
| c4bp | #34 |
| fpr1 | #34 |
| patients animal models | #34 |
| chronic polyarthritis | #34 |
| interferon activity | #34 |
| natural antibodies nabs | #34 |
| heterogeneous stock | #34 |
| cells dendritic cells | #34 |
| neurodegeneration role | #34 |
| promiscuous expression | #34 |
| joint pathology | #34 |
| nox2 deficiency | #34 |
| monoclonal rheumatoid | #35 |
| plasminogen deficiency | #35 |
| 1xi | #35 |
| hybridomas | #35 |
| major regulators | #35 |
| complex arthritis | #35 |
| autoreactive | #35 |
| nets neutrophils | #35 |
| antirat | #35 |
| psoriasiform skin | #35 |
| triple helical | #35 |
| destructive arthritis | #35 |
| acs stroke | #35 |
| accessible sites | #35 |
| development chronic | #35 |
| patients populations | #35 |
| infectious disease models | #35 |
| antiarthritis | #35 |
| arthritis disease | #35 |
| phagotope | #35 |
| vdr cells | #35 |
| techniques mice | #36 |
| female histocompatibility | #36 |
| cii cfa | #36 |
| oxidases rna | #36 |
| h2r | #36 |
| animals antigen | #36 |
| nk cells recognition | #36 |
| arthritis cartilage | #36 |
| tolerance tlymphocytes | #36 |
| induction tregs | #36 |
| cartilage joints | #36 |
| dth | #36 |
| flow cytometry expression | #36 |
| dinitro1 | #36 |
| phagocyte | #36 |
| specificity sera | #36 |
| h2g7 | #36 |
| comparative genetics | #36 |
| variance animals antibodies | #36 |
| protein specific | #36 |
| immunopathological features | #37 |
| spontaneous arthritis | #37 |
| synthetic glycopeptides | #37 |
| dba1 | #37 |
| acpa positive | #37 |
| role gamma interferon | #37 |
| cii protein | #37 |
| c129 | #37 |
| lymphocytes disease | #37 |
| rich lipid | #37 |
| encephalomyelitis | #37 |
| mif pathogenesis | #37 |
| joint cartilage | #37 |
| peptides binding | #37 |
| oxidases oxidation | #37 |
| recombinant vaccine | #37 |
| genetic control | #37 |
| susceptibility autoimmune diseases | #37 |
| cldn4 | #38 |
| target autoantigens | #38 |
| animal models pain | #38 |
| cochranmantelhaenszel test | #38 |
| antibodies animals | #38 |
| human blood neutrophils | #38 |
| nitrogen species | #38 |
| sialophorin | #38 |
| snat | #38 |
| innovative tools | #38 |
| clonal expansion cells | #39 |
| acpa response | #39 |
| oestrogen treatment | #39 |
| benoist | #39 |
| ccia | #39 |
| data myelin | #39 |
| resultsrats | #39 |
| cell tolerance | #39 |
| b6n | #39 |
| nzw | #39 |
| endoβnacetylglucosaminidase | #39 |
| nfr | #39 |
| ym1 | #39 |
| measurement activity | #39 |
| autoreactive cells | #39 |
| wasting syndrome | #39 |
| allogeneically | #39 |
| peptide cell | #40 |
| positive rheumatoid | #40 |
| isostere | #40 |
| addition impact | #40 |
| polyclonal cell activation | #40 |
| adjuvant induced | #40 |
| disease animal models | #40 |
| genetic complexity | #40 |
| rt1c | #40 |
| antigens arthritis | #40 |
| autoimmune inflammatory diseases | #41 |
| autoimmune | #41 |
| mhc haplotype | #41 |
| immunocap isac | #41 |
| priming phase | #41 |
| rats anti | #41 |
| aq | #41 |
| severity incidence | #41 |
| effects experiments | #41 |
| genes loci | #41 |
| rat myelin | #41 |
| congenic mapping | #41 |
| ncii | #41 |
| th17 axis | #42 |
| species receptors | #42 |
| expected onset | #42 |
| articular collagen | #42 |
| pineal gland melatonin | #42 |
| drb1 shared | #42 |
| mhc class class | #42 |
| spleen weight | #42 |
| p38 mapk nfκb | #42 |
| cartilage bone destruction | #42 |
| fibroblasts mice | #42 |
| antibody isotypes | #42 |
| ptpn22 locus | #42 |
| treatment autoimmune diseases | #43 |
| congeneic | #43 |
| type‐ii | #43 |
| cd11bly6g | #43 |
| lew lymphocytes | #43 |
| anticitrullinated | #43 |
| crosses genetic | #43 |
| arthritis data | #43 |
| kgf treatment | #43 |
| anticyclic | #43 |
| immunodominant epitopes | #43 |
| spinal glia | #43 |
| collagen | #43 |
| mice autoimmune | #43 |
| lew rats | #43 |
| autoreactive cell | #43 |
| rats sex | #43 |
| pc8 | #43 |
| provocations | #44 |
| mathis | #44 |
| mice adulthood | #44 |
| c4bbinding protein c4bp | #44 |
| peptide induced | #44 |
| chloro23 | #44 |
| defensins humans | #44 |
| genetic linkage analysis | #44 |
| inflammation animals | #44 |
| mice mice autoimmune | #44 |
| epitopes lymphocyte | #44 |
| addition order | #44 |
| neuritis ean | #44 |
| homozygous form | #44 |
| relapsing disease | #45 |
| potent suppression | #45 |
| susceptibility arthritis | #45 |
| phagotopes | #45 |
| nzb | #45 |
| genetic encoding | #45 |
| outbred rats | #45 |
| disease histocompatibility | #45 |
| chromosome development | #45 |
| disease induction | #46 |
| affinity purified | #46 |
| posttranslationally | #46 |
| lower severity | #46 |
| specific tolerance | #46 |
| c227 | #46 |
| cocrystallisation | #46 |
| eae mbp | #46 |
| rat2 | #46 |
| alphachains | #46 |
| neuritis autoimmune | #46 |
| carp antibodies | #46 |
| isosteres | #46 |
| locus controlling | #46 |
| mhc class humans | #46 |
| rheumatoid factors | #47 |
| diagnostic accuracy diagnosis | #47 |
| f1 hybrid mice | #47 |
| association hladrb1 alleles | #47 |
| antibody reactivities | #47 |
| intercrosses | #47 |
| idiotypic antibody | #47 |
| complex mediated | #47 |
| posttranslational rats receptors | #47 |
| protective allele | #47 |
| humanized model | #48 |
| peptide recognized | #48 |
| acetylchitobiose | #48 |
| experimental arthritis mice | #48 |
| f1 crosses | #48 |
| synovial lining layer | #48 |
| mice nzb | #48 |
| γchains | #48 |
| mice carrying | #48 |
| tlr12 | #48 |
| antibody specificity | #48 |
| cia rats | #48 |
| collagen glycosylation | #48 |
| collagen peptide | #48 |
| lupus disease | #48 |
| comp levels | #49 |
| tcell stimulation | #49 |
| experimental crosses | #49 |
| histone hdacs | #49 |
| class major | #49 |
| immune nervous | #49 |
| mouse cartilage | #49 |
| sex genes | #49 |
| monoclonal autoimmune diseases | #49 |
| mice caia | #49 |
| polyvinylcaprolactam | #49 |
| bystander activation | #49 |
| parathyroid cells | #50 |
| antigenantibody | #50 |
| inflammation kynurenine | #50 |
| animal cell culture | #50 |
| glycosylated form | #50 |
| glutamine uptake | #50 |
| complex region | #50 |
| disease rats | #50 |
| monoclonal epitopes | #50 |
| loci animals | #50 |
| cytometry analyses | #50 |
| anticarbamylated protein | #50 |
| dependent chronic | #50 |
| mice tolerance | #50 |
| alagly | #50 |
| ciiia | #50 |
| delayed immunization | #51 |
| runting | #51 |
| antibodies cells | #51 |
| evidence animal models | #51 |
| c57bl 6j background | #51 |
| inbred c57bl autoimmune | #51 |
| autoantibodies rheumatoid arthritis | #51 |
| lentiviral particles | #51 |
| tolerized | #51 |
| tracheal cartilage | #51 |
| rheumatoid factor activity | #51 |
| cells ova | #51 |
| fewer cells | #51 |
| aire mice | #51 |
| derived type | #51 |
| antigenpresenting cells | #52 |
| model collagen | #52 |
| macrophages skin | #52 |
| ptpn22 | #52 |
| xor activity | #52 |
| matrix protein | #52 |
| protein antibodies | #53 |
| antibodies epitopes | #53 |
| production reactive | #53 |
| lysosomal compartments | #53 |
| cartilage erosion | #53 |
| physiological doses | #53 |
| triple helical structure | #53 |
| carbamylated proteins | #53 |
| patients rheumatic conditions | #53 |
| melatonin day | #53 |
| arthritis induction | #53 |
| gastric parietal cell | #53 |
| induced autoimmunity | #53 |
| aged peptides | #53 |
| imitating | #54 |
| melatonin animals | #54 |
| strain rats | #54 |
| carbamylated protein | #54 |
| antigens myelomonocytic arthritis | #54 |
| rats social isolation | #54 |
| predating | #54 |
| development individuals | #54 |
| animals autoimmune | #54 |
| yaa | #54 |
| major epitope | #54 |
| nodes lymphocyte | #54 |
| crossbreeding | #54 |
| complex genetic disease | #55 |
| autoimmune reactions | #55 |
| susceptibility autoimmune disease | #55 |
| inflammatory manifestations | #55 |
| arthritis genetic | #55 |
| macrophage mannose receptor | #55 |
| autoimmune nzb | #55 |
| animals antibody | #56 |
| cells salivary | #56 |
| new animal | #56 |
| alpha1microglobulin | #56 |
| mhc | #56 |
| selfreactive cells | #56 |
| labels superoxide | #56 |
| cd1 mice | #57 |
| vivo depletion | #57 |
| animals antirheumatic | #57 |
| antibodies | #57 |
| arthritis pathogenesis | #57 |
| collagen sequence | #57 |
| development autoimmune | #57 |
| igg abs | #57 |
| antibodies bind | #57 |
| oestrogen progesterone | #58 |
| rat type | #58 |
| chronic eae | #58 |
| urokinase activity | #58 |
| schafer | #58 |
| peptide response | #58 |
| hydroxylase diet | #59 |
| anticarp antibodies | #59 |
| resistance eae | #59 |
| anti cd8 | #59 |
| genes mhc | #59 |
| oligoclonal igg bands | #59 |
| anti cell | #59 |
| articular joints | #59 |
| cartilage matrix protein | #59 |
| encephalitogenicity | #59 |
| joint erosions | #60 |
| assay epitopes | #60 |
| hpaaxis | #60 |
| macrophage mannose | #60 |
| inflammatory cells macrophages | #60 |
| alternative activation macrophages | #60 |
| protein peptide | #60 |
| dichotomous effects | #60 |
| immunohistopathology | #60 |
| experimental evoked potentials | #61 |
| differentiation myelomonocytic arthritis | #61 |
| epitope spreading | #61 |
| incidence severity | #61 |
| major histocompatibility | #61 |
| alpha1m | #61 |
| serum comp | #61 |
| experimental rats rats | #61 |
| cells innate immune | #61 |
| species reactive | #61 |
| syngeneically | #62 |
| cyclic sensitivity | #62 |
| reduced oxidative | #62 |
| basic characterization | #62 |
| fpr2 | #62 |
| interferon‐β | #62 |
| adaptive immune | #62 |
| antigens class histocompatibility | #62 |
| mice susceptibility | #62 |
| placenta uterus | #62 |
| autoantibody formation | #62 |
| toxin1 | #62 |
| specificity tumor | #63 |
| post‐partum | #63 |
| glycoprotein myelin | #63 |
| constant darkness | #63 |
| collagen cell | #63 |
| induced experimental | #63 |
| mice polyi | #63 |
| duval | #63 |
| protein disease | #63 |
| igaproducing cells | #63 |
| delayed interferon | #63 |
| specific stages | #63 |
| peptide specific | #63 |
| rats strain | #63 |
| mog1 | #63 |
| nadph oxidases | #63 |
| hypersensitivity dth | #63 |
| transfer animals | #63 |
| freund adjuvant | #64 |
| lower capacity | #64 |
| role apc | #64 |
| secondary immune | #64 |
| maternal origin | #64 |
| tolerance model | #64 |
| hindpaws | #65 |
| flss | #65 |
| weight variation | #65 |
| autoimmunity humans | #65 |
| induced suppression | #65 |
| histocompatibility complex | #65 |
| major subset | #65 |
| model chronic | #65 |
| thy1 antigen | #66 |
| hladr2 | #66 |
| spontaneous disease | #66 |
| experimental lymphocytes | #66 |
| negative rheumatoid | #66 |
| rheumatoid synovial cells | #66 |
| multispecificity | #66 |
| chromosomes mammalian | #66 |
| phagocytosis oxidative burst | #66 |
| peripheral joints | #66 |
| acute arthritis | #66 |
| resemblances | #66 |
| mice induced | #67 |
| endos | #67 |
| myelomonocytic arthritis | #67 |
| rheumatoid arthritis susceptibility | #67 |
| experimental allergic | #67 |
| development cell | #67 |
| dendritic cells epitopes | #67 |
| strains susceptible | #67 |
| mice cell | #67 |
| key interactions | #67 |
| experimental encephalomyelitis | #67 |
| fibrinogen genotype | #67 |
| class region | #68 |
| cells mhc class | #68 |
| sodium diethyldithiocarbamate | #68 |
| individuals positive | #68 |
| frequent infections | #68 |
| female sex hormones | #68 |
| complex class | #68 |
| tolerized mice | #68 |
| helper phenotype | #68 |
| anti carp | #68 |
| rheumatoid chromosomes | #68 |
| severity periodontitis | #68 |
| iggrf | #68 |
| direct damage | #69 |
| rheumatoid disease | #69 |
| relapsing | #69 |
| lymphocytes chronic | #69 |
| frequency antibodies | #69 |
| cells mouse | #69 |
| vertebrate immune | #69 |
| zap‐70 | #69 |
| translationally | #70 |
| presence rheumatoid factor | #70 |
| mrl mice | #70 |
| prolonged graft survival | #70 |
| response type | #70 |
| immunoglobulin interferon | #70 |
| role cells | #70 |
| swr | #71 |
| susceptibility female | #71 |
| expression pparγ | #71 |
| isolated rats | #71 |
| ztm | #71 |
| human psoriasis | #71 |
| cartilage mice | #71 |
| cb10 | #71 |
| study antibodies | #72 |
| autoimmunity lymphocytes | #72 |
| antibodies binding | #72 |
| interphalangeal joints | #72 |
| naïve mice | #72 |
| dark agouti rats | #72 |
| lathyritic | #72 |
| napdh | #72 |
| delayedtype hypersensitivity dth | #72 |
| knockout protein processing | #73 |
| treatment stages | #73 |
| type ifn signature | #73 |
| environmental lighting | #73 |
| oxidase complex | #73 |
| membrane animals | #73 |
| species ros | #73 |
| mrl lpr | #73 |
| bovine type | #73 |
| igarf | #74 |
| pregnancyinduced | #74 |
| cartilage explants | #74 |
| peptides sequences | #74 |
| antigens class | #74 |
| hypersensitivity delayed | #74 |
| cell reactivity | #75 |
| acpapositive | #75 |
| inbred dba receptors | #75 |
| effects development | #75 |
| diabetes arthritis | #75 |
| genetic disease models | #75 |
| dth mice | #75 |
| oestradiol | #75 |
| peptide mhc | #76 |
| type collagens | #76 |
| disease rheumatoid arthritis | #76 |
| anti carbamylated | #76 |
| rat splenocytes | #76 |
| pain inflammation | #77 |
| nerve conduction velocity | #77 |
| rats eae | #77 |
| inbred mouse strains | #77 |
| cyp7a1 | #77 |
| eae induced | #77 |
| regulatory vaccines | #77 |
| rt1n | #77 |
| cell deficient | #77 |
| collagen chains | #77 |
| new animal model | #77 |
| lpr mrl | #77 |
| oligomeric | #77 |
| development insulitis | #77 |
| rats respiratory | #78 |
| mhc expression | #78 |
| autoantigenic | #78 |
| pythons | #78 |
| pathogenesis rheumatoid arthritis | #78 |
| cartilage integrity | #78 |
| clinical arthritis | #78 |
| mononuclear lung | #79 |
| susceptibility disease | #79 |
| inflammatory autoimmune | #79 |
| 1ii | #79 |
| shared epitope | #79 |
| autoimmune experimental epitopes | #79 |
| chromosome study | #80 |
| oxidases | #80 |
| detection autoantibodies | #80 |
| erosive arthritis | #80 |
| hnrnpa2 | #81 |
| estrogen suppression | #81 |
| sex linkage | #81 |
| spleen study | #81 |
| mrl mp | #81 |
| mog mbp | #81 |
| dr1 antigen | #81 |
| induced leukocyte | #81 |
| type macrophages | #81 |
| class antigen expression | #81 |
| inflammatory phase | #81 |
| expression ll37 | #81 |
| aspartic acid position | #81 |
| mhcii expression | #81 |
| arthritis cells | #81 |
| nadphoxidase | #82 |
| pannus formation | #82 |
| 14weeks | #82 |
| mice igg | #83 |
| bcg infection | #83 |
| cell independent | #83 |
| expression mhc | #83 |
| drug encephalomyelitis | #83 |
| tlymphocyte genes | #83 |
| arthritis day | #84 |
| rat cardiac allografts | #84 |
| spontaneous development | #84 |
| strains animals | #84 |
| epidermal cells | #84 |
| reactive cells | #84 |
| multiple sclerosis evidence | #84 |
| naïve cells | #84 |
| class molecule | #85 |
| homopentamer | #85 |
| antiifngamma | #85 |
| inflammation joints | #85 |
| inflammation joint | #85 |
| knockout receptors | #85 |
| cells recognize | #85 |
| severe eae | #86 |
| phagocyte nadph | #86 |
| contribution genes | #86 |
| gfoger | #86 |
| monoclonal antibodies mab | #86 |
| anti cd4 | #86 |
| animal humans | #86 |
| mutant strains | #86 |
| preclinical stage | #86 |
| classical humans | #86 |
| smash | #87 |
| estrogen induced | #87 |
| inbred rat strains | #87 |
| mhc class gene | #87 |
| alpha1acid glycoprotein | #87 |
| fine specificities | #88 |
| narac | #88 |
| copy variation | #88 |
| inguinal lymph nodes | #88 |
| levels anti | #88 |
| thps | #88 |
| depletion cd8 cells | #89 |
| arthritic | #89 |
| mice antibodies | #89 |
| mabs mab | #89 |
| genetic quantitative | #89 |
| peptide immunization | #89 |
| experimental autoimmune | #89 |
| autoimmune inbred c57bl | #90 |
| susceptible | #90 |
| rheumatoid arthritis cells | #90 |
| arthritis compared | #90 |
| pineal hormone melatonin | #90 |
| genistein treatment | #90 |
| ilc2 activation | #90 |
| adjuvant arthritis | #90 |
| monkeys mice | #90 |
| mediated mechanisms | #90 |
| synovial fluid serum | #91 |
| histological sections | #91 |
| activation cd4 cells | #91 |
| backgroundan | #91 |
| protein induced | #91 |
| cattle collagen | #91 |
| cells apc | #91 |
| abdominal region | #92 |
| nod mhc | #92 |
| experimental mouse models | #92 |
| humans immunodominant | #92 |
| difco | #92 |
| anticitrullinated protein | #92 |
| knockout myelin | #93 |
| animals autoantibodies | #93 |
| xor | #93 |
| mice melatonin | #93 |
| cellspecific | #93 |
| natural polymorphisms | #93 |
| 290 patients | #93 |
| fcγrs | #94 |
| macrophages development | #94 |
| activated cells cells | #94 |
| autosomal genes | #94 |
| galactosylated | #94 |
| endosomal acidification | #94 |
| chronic phase disease | #95 |
| induced sarcoma | #95 |
| binding integrins | #95 |
| moderateintensity exercise | #95 |
| nonglycosylated | #96 |
| cell alpha | #96 |
| messenger tolllike receptor | #96 |
| macrophages stimulation | #96 |
| romani | #96 |
| data rats | #96 |
| ifnbeta | #96 |
| pregnancy disease | #96 |
| lung emphysema | #96 |
| fetal rejection | #96 |
| complex mice | #97 |
| il33r | #97 |
| citrullinated fibrinogen | #97 |
| cathelicidins | #97 |
| hydroxylysine | #97 |
| antiimmunoglobulin | #97 |
| genetic female genes | #97 |
| macrophages fibroblasts | #97 |
| rheumatoid lymphocytes | #97 |
| swr mice | #98 |
| acpa igg | #98 |
| autoimmune rats | #98 |
| autoimmune experimental | #98 |
| rheumatoid cartilage | #98 |
| ean | #98 |
| interleukin‐4 | #99 |
| collagen cytokines | #99 |
| alternative pathways | #99 |
| rat chromosomes | #99 |
| tlymphocyte immunity | #100 |
| invading pathogens | #100 |
| ccp anti | #100 |
| peptides cells | #100 |
| protein antibody | #100 |
| thy1 antigens | #100 |
| cultured crosses | #100 |
| inducer animals | #100 |
| rats monoclonal antibodies | #100 |
| tap2 | #100 |
| diarthrodial | #101 |
| singlenucleotide polymorphism | #101 |
| eira | #101 |
| susceptible strain | #101 |
| cell determinants | #101 |
| safety drugs | #101 |
| bone degradation | #101 |
| fprs | #101 |
| eae animal encephalomyelitis | #102 |
| mouse monoclonal antibodies | #102 |
| candidate autoantigen | #102 |
| brucei infection | #102 |
| findings treatment | #102 |
| pathogenesis emphysema | #103 |
| oxidative burst | #103 |
| hla dr1 | #103 |
| ros homeostasis | #103 |
| drb10401 | #103 |
| agalactosyl | #103 |
| thelper cells | #104 |
| arthritic disease | #104 |
| mutation mice | #104 |
| nonarthritic | #104 |
| haplotypes histocompatibility | #104 |
| f1 males | #104 |
| skg mice | #104 |
| mhcii | #104 |
| synchrotron infrared | #104 |
| male mice mice | #104 |
| vivo macrophages | #105 |
| type 22 | #105 |
| fcγr | #105 |
| development antibodies | #105 |
| autoreactivity | #105 |
| osteoclasts mice | #105 |
| hybridoma cell | #105 |
| dmaam | #105 |
| 273 | #106 |
| disease dose | #106 |
| arthritis hla | #106 |
| primed cells | #106 |
| proteoglycan loss | #106 |
| limited cross | #106 |
| tcell immunity | #106 |
| cells synovial | #107 |
| nzb mice | #107 |
| c3h mice | #107 |
| fpr | #108 |
| littermates | #108 |
| study tolerance | #108 |
| development autoimmune disease | #108 |
| reactive cell | #109 |
| presentation cells | #109 |
| structural polymorphism | #109 |
| enthesophytes | #109 |
| monoclonal igg | #109 |
| type hypersensitivity | #109 |
| autoantibodies autoantigens | #109 |
| citrullinated proteins | #109 |
| delayedtype hypersensitivity | #109 |
| autoimmune encephalomyelitis | #110 |
| carcinoma tumors | #110 |
| cartilage | #111 |
| streptococcal cell wall | #111 |
| experimental female | #111 |
| female hypersensitivity | #111 |
| inbred dba microscopy | #111 |
| toxic shock syndrome | #111 |
| backcross | #111 |
| dba 1j mice | #111 |
| mog eae | #111 |
| extensive literature search | #112 |
| humoral autoimmunity | #112 |
| alphabeta receptors antigen | #112 |
| amide bond | #112 |
| anti idiotypic antibodies | #112 |
| presymptomatic individuals | #112 |
| mice collageninduced arthritis | #113 |
| db1 | #113 |
| adjuvant properties | #113 |
| tcra | #113 |
| oligoclonality | #113 |
| autoimmune c57bl mice | #113 |
| trait loci | #113 |
| restricted cell | #113 |
| xid mice | #113 |
| ifngammaproducing cells | #114 |
| adjuvantinduced arthritis | #114 |
| proinflammatory cytokine | #115 |
| anti mcv | #115 |
| mice disease | #115 |
| drb10402 | #115 |
| rats collagen | #115 |
| autoantigens autoimmunity | #115 |
| experimental epitopes | #116 |
| lutz | #116 |
| pathogenesis autoimmune diseases | #116 |
| lymphocyte female | #116 |
| glycopeptides | #116 |
| susceptibility eae | #116 |
| ccp patients | #116 |
| glyco | #116 |
| immunosorbents | #116 |
| transgenic peptides receptors | #116 |
| encephalomyelitis autoimmune | #117 |
| tolerance induced | #117 |
| congenic lines | #117 |
| antibodies reactive | #117 |
| fluorescence nf | #117 |
| antiarthritic | #117 |
| mice type | #117 |
| psoriasiform dermatitis | #118 |
| class expression | #118 |
| α enolase | #118 |
| rats immunized | #118 |
| myelin oligodendrocyte | #118 |
| pineal hormone | #118 |
| samples individuals | #118 |
| alpha1acid | #118 |
| psa rheumatoid arthritis | #119 |
| cd4 tcells | #119 |
| radiological damage | #119 |
| rheumatoid arthritis review | #119 |
| response cells | #119 |
| 05m | #119 |
| neutrophils nets | #120 |
| protein mbp | #120 |
| experimental animal models | #121 |
| vivo animal models | #121 |
| chondrocyte cultures | #121 |
| pharmacological potential | #122 |
| acpa negative | #122 |
| transfer arthritis | #122 |
| patients acpa | #122 |
| t‐lymphocyte | #122 |
| immune complex deposition | #122 |
| treatment progesterone | #122 |
| genes age | #122 |
| transgenic neurons receptors | #122 |
| type cytokines | #123 |
| alphabeta cells | #123 |
| cell monoclonal | #123 |
| c5b | #123 |
| nox2 activation | #123 |
| symptoms associations | #123 |
| cartilage surface | #124 |
| tlr4 stimulation | #124 |
| inbred mouse | #124 |
| allelic variations | #125 |
| general mechanisms | #125 |
| disease mechanisms | #125 |
| preimmunized | #125 |
| helperinducer | #125 |
| genetic rats | #125 |
| cryogel | #125 |
| blocking antigens | #125 |
| oxidases neutrophils | #125 |
| immunodominant peptide | #125 |
| qtl genes | #125 |
| cyclic polymorphism | #126 |
| female immunization | #126 |
| nonobese diabetic | #126 |
| nzb nzw | #126 |
| pnipaam | #126 |
| atp8 | #127 |
| animal enzyme | #127 |
| microarray detection | #127 |
| knockout murine | #127 |
| absence cells | #127 |
| dominant epitope | #128 |
| chronic inflammatory disease | #128 |
| anticitrullinated peptide | #128 |
| lining layer | #128 |
| deiminases | #128 |
| rats patients | #129 |
| multiple epitopes | #129 |
| bxsb | #129 |
| spleen rats | #129 |
| cells eae | #130 |
| oestradiol testosterone | #130 |
| psd1 | #130 |
| disease induced | #130 |
| nos2 | #130 |
| vivo absence | #130 |
| epitope specific | #131 |
| onset arthritis | #131 |
| lipomannan | #131 |
| pronociceptive | #132 |
| disease cgd | #132 |
| induction regulatory cells | #132 |
| kgf | #132 |
| intercross | #132 |
| linomide | #132 |
| mineral oils | #132 |
| ggaa | #133 |
| reduced severity | #133 |
| leukosialin | #133 |
| rat chromosome | #133 |
| eae | #134 |
| patients cytokines | #134 |
| mice estrogen | #134 |
| myocellular | #134 |
| plasma synovial fluid | #134 |
| species animals | #134 |
| knockout receptors antigen | #134 |
| accentuate | #134 |
| interstitial collagens | #134 |
| spinal glial | #135 |
| igg immune complexes | #135 |
| peptides cyclic | #135 |
| immunizing | #136 |
| macrophages dendritic | #136 |
| intracellular reactive | #136 |
| chronic autoimmune disease | #136 |
| innate lymphocytes | #137 |
| stimulated muscle | #137 |
| immunopathological | #137 |
| receptor upregulation | #137 |
| ditiocarb | #138 |
| mice deficient | #138 |
| control development | #139 |
| dmannitol | #139 |
| immunomodulatory drug | #139 |
| autoimmune mice | #139 |
| tcrdelta | #140 |
| oligoclonal expansion | #141 |
| producing cell | #141 |
| thermoresponsive polymer | #141 |
| genetic factors development | #142 |
| single subcutaneous injection | #142 |
| interferon‐γ | #142 |
| gamma lymphocyte | #142 |
| rejection tolerance | #142 |
| phadia | #142 |
| smfish | #142 |
| or113 | #142 |
| tcell alphabeta receptors | #143 |
| cell hybridoma | #143 |
| class haplotypes | #143 |
| phosphate isomerase | #143 |
| mice beta | #143 |
| rheumatoid arthritis | #144 |
| synovial hyperplasia | #144 |
| rat strains | #144 |
| mhc haplotypes | #144 |
| tnf production | #145 |
| severe chronic | #145 |
| tcr gamma delta | #145 |
| lyme arthritis | #145 |
| inbred buf rats | #145 |
| treatment ici | #145 |
| syngenic | #145 |
| neonatal growth | #146 |
| rats induced | #146 |
| systemic challenge | #147 |
| cellular heterogeneity | #147 |
| ccp antibodies | #147 |
| pregnancy levels | #147 |
| function cells | #147 |
| gammainterferon | #147 |
| interestingly | #148 |
| autoimmune disease | #148 |
| α2i | #148 |
| cell surface antigen | #148 |
| phagocyte nadph oxidase | #148 |
| redox regulation | #148 |
| complex diseases | #149 |
| human autoimmune diseases | #149 |
| drb104 | #150 |
| mhc binding | #150 |
| larsen score | #150 |
| receptor rats | #151 |
| epicutaneously | #151 |
| differential gene expression | #151 |
| levels antibodies | #151 |
| mice animals | #151 |
| humans hybridomas | #151 |
| alphabeta receptors | #152 |
| arthritic animals | #153 |
| pepsin | #153 |
| mononuclear cells | #153 |
| key player | #153 |
| levels pregnancy | #153 |
| expression class | #154 |
| selfpeptides | #154 |
| fcgammar | #154 |
| critical event | #154 |
| c4bbinding protein | #154 |
| immune priming | #154 |
| daf1 | #154 |
| male rats rats | #154 |
| joint inflammation | #154 |
| infiltrating cells | #155 |
| f1 mice | #155 |
| autoantibodies autoimmune | #155 |
| serum synovial fluid | #155 |
| arthritis rheumatoid | #155 |
| padi4 | #155 |
| mace acs | #155 |
| specificities | #156 |
| suppressive role | #156 |
| stabilin1 | #156 |
| mhc region | #156 |
| downstream signals | #157 |
| adjuvanticity | #157 |
| murine keratinocytes | #157 |
| analysis structure | #158 |
| parentals | #158 |
| hypersensitivity reaction | #158 |
| genetic diabetes mellitus | #158 |
| animals autoimmunity | #159 |
| consensus motif | #159 |
| inbred c3h mice | #159 |
| systemic mice mice | #159 |
| arthritis infectious | #159 |
| meaib | #159 |
| specific autoimmunity | #161 |
| benzylated | #161 |
| gamma interferon | #161 |
| day onset | #161 |
| knockout severity | #161 |
| factors anti | #161 |
| nursed | #161 |
| arthritis inflammation | #162 |
| cd152 | #162 |
| epitope | #162 |
| binding collagen | #162 |
| βarrestin recruitment | #162 |
| rheumatoid autoantigens | #162 |
| anti ccp | #162 |
| psors1 | #162 |
| onset disease | #163 |
| mouse type | #163 |
| laboratory rats | #163 |
| chains humans | #163 |
| striking similarities | #164 |
| autoantibody responses | #164 |
| genes qtl | #164 |
| rats induction | #164 |
| mrl | #164 |
| endobetanacetylglucosaminidase | #164 |
| progesterone effects | #164 |
| agalactosyl igg | #164 |
| cells macrophages | #165 |
| animal humans immunity | #165 |
| tolerance induction | #166 |
| epitope alleles | #166 |
| pathogenic pathways | #166 |
| nonimmunized | #166 |
| melatonin mice mice | #166 |
| class mice | #167 |
| tlymphocyte humans | #167 |
| ag7 | #167 |
| human autoimmunity | #167 |
| nox2 | #167 |
| seronegative | #167 |
| phase disease | #168 |
| cd1 | #168 |
| genetic backgrounds | #168 |
| mice cd4 cells | #168 |
| oxazole | #169 |
| acpa levels | #169 |
| p12 | #169 |
| denoted | #169 |
| mirp | #170 |
| inherited disorder | #170 |
| joints male | #170 |
| cryogels | #170 |
| experimental animal | #170 |
| lymph node cells | #170 |
| pathogenesis arthritis | #170 |
| oxazolone | #171 |
| ros nitric oxide | #171 |
| encephalomyelitis eae | #171 |
| rheumatoid | #172 |
| autoimmune eae | #172 |
| rat placenta | #172 |
| single nucleotide polymorphism | #172 |
| autoimmunity cell | #172 |
| lst1 | #172 |
| peripheral lymphoid organs | #172 |
| monoclonal autoantibodies | #173 |
| inbred dba models | #173 |
| sod3 | #173 |
| presence autoantibodies | #174 |
| nasal cartilage | #174 |
| resistant rats | #174 |
| class gene | #174 |
| studies pain | #174 |
| ifn signature | #175 |
| maternal decidua | #175 |
| mice mutation | #175 |
| understanding pathogenesis | #175 |
| mammalian crosses | #176 |
| moab | #176 |
| skin disease | #176 |
| new mouse model | #176 |
| strains molecular | #176 |
| tryptophan catabolism | #176 |
| secondary challenge | #176 |
| lymphotoxinα | #177 |
| ctla‐4 | #178 |
| histocompatibility | #178 |
| hladrb1 alleles | #178 |
| mice role | #179 |
| protein anti | #179 |
| immunized | #179 |
| nod genes | #179 |
| alternative pathway complement | #179 |
| dextran sulphate sodium | #179 |
| epitopes female | #180 |
| complex disease | #180 |
| arthritis methods | #180 |
| cgd patients | #180 |
| alleles arthritis | #181 |
| molecular adaptations | #181 |
| genetic influence | #181 |
| autoimmunity disease | #181 |
| hormone melatonin | #182 |
| arginine deiminases | #182 |
| immunoglobulin mice mice | #185 |
| multistep process | #186 |
| rats reactive | #186 |
| antigen processing presentation | #186 |
| cells lymph nodes | #186 |
| b10 | #187 |
| tcell recognition | #187 |
| drb1 chains | #187 |
| dba | #187 |
| substrains | #188 |
| chondritis | #188 |
| molecular peptide | #188 |
| cells disease | #189 |
| mtec | #189 |
| synovial membranes | #190 |
| positionally | #190 |
| inflamed joint | #190 |
| hnrnpa2b1 | #190 |
| oligodendrocyte glycoprotein | #191 |
| cross‐reactivity | #192 |
| ly1 | #192 |
| autoantibody profiles | #192 |
| passive mice mice | #193 |
| fmlf | #193 |
| proteins myelin | #194 |
| glycoprotein peptide | #194 |
| cyclic predictive | #194 |
| mice mutant | #195 |
| chapter 16 | #195 |
| perpetuate | #195 |
| mhv | #195 |
| mhc class expression | #196 |
| oophorectomized | #196 |
| lewis rat | #196 |
| tcell response | #196 |
| myelin glycoprotein | #196 |
| acutephase response | #197 |
| pannus | #197 |
| multiplex assay | #197 |
| evidence development | #197 |
| igmrf | #198 |
| swedish patients | #198 |
| early appearance | #198 |
| genetic links | #198 |
| rat genome | #199 |
| dr4 antigen | #199 |
| interleukin17 | #199 |
| cell collagen | #200 |
| citrullinated peptide | #200 |
| hla association | #200 |
| pathogenesis autoimmune | #201 |
| myelin proteins myelin | #202 |
| myelin proteolipid protein | #202 |
| dendritic cells macrophages | #202 |
| instigation | #202 |
| acpa status | #202 |
| mice cells | #203 |
| complete elimination | #203 |
| 2 complex | #204 |
| class molecules | #204 |
| immunization immunoglobulin | #204 |
| spleen staining | #204 |
| nonparametric tlymphocytes | #205 |
| ides | #205 |
| macrophages mice | #205 |
| suppresses | #205 |
| native collagen | #205 |
| dth response | #205 |
| betaestradiol | #206 |
| wild rats | #206 |
| defb4 | #206 |
| insulitis diabetes | #207 |
| noxs | #207 |
| desmoglein 3 | #207 |
| alternative complement pathway | #207 |
| interleukin4 mice mice | #207 |
| parental strains | #207 |
| induced upregulation | #207 |
| mice peptide | #207 |
| intranasal challenge | #207 |
| severity disease | #208 |
| highest probability | #208 |
| immunization mice | #208 |
| naive mice | #208 |
| antigen presenting | #208 |
| vivo patients | #208 |
| immunoglobulin vh | #209 |
| cotwins | #209 |
| disease rheumatoid | #209 |
| highfatdiet | #210 |
| valuable tools | #210 |
| vav1 | #210 |
| specific antibodies | #210 |
| susceptible strains | #210 |
| citrullinated vimentin | #210 |
| natural antibodies | #211 |
| purified protein derivative | #211 |
| diseases genetic | #211 |
| hla dr4 | #211 |
| glucose6 phosphate | #211 |
| cells immobilized | #212 |
| association rheumatoid arthritis | #212 |
| large numbers | #212 |
| psoriasiform | #213 |
| mice injected | #213 |
| antibody binding | #213 |
| tsst1 | #214 |
| central tolerance | #215 |
| inbred rat | #215 |
| mhc class antigens | #215 |
| antigen induced | #215 |
| triethylsilane | #215 |
| cytofluorometric | #215 |
| training hiit | #216 |
| dissect | #216 |
| lower level | #216 |
| lentiviral vector | #217 |
| induced autoimmune | #217 |
| cd23 | #217 |
| resistant strain | #217 |
| rats immunization | #217 |
| inflammatory infiltrates | #217 |
| joints mice | #217 |
| treatment onset | #218 |
| antigen tcell | #218 |
| k8 | #219 |
| autoimmunity | #219 |
| fcrγ | #219 |
| granuloma formation | #219 |
| peptide antibodies | #219 |
| cells autoimmune | #220 |
| hyl | #220 |
| bone erosions | #220 |
| peptidylarginine deiminases | #220 |
| redox signaling | #221 |
| rheumatoid factor | #221 |
| pinealectomy | #221 |
| agouti rats | #221 |
| targeted deletion | #221 |
| fine specificity | #221 |
| cyclosporin treatment | #221 |
| cells dendritic | #221 |
| cartilage damage | #222 |
| cybb | #222 |
| thymectomized | #222 |
| wkymvm | #222 |
| monoclonal antigens differentiation | #222 |
| igg2a | #223 |
| carbamylated | #223 |
| multiplex | #223 |
| experimental autoimmune neuritis | #223 |
| inflammation vivo | #224 |
| expressing | #224 |
| clinical scoring | #225 |
| interleukin‐10 | #225 |
| lew | #225 |
| cells antigen | #225 |
| established disease | #225 |
| pathogenic antibodies | #226 |
| disease locus | #226 |
| macrophagelike cells | #227 |
| j1 | #227 |
| delayed type hypersensitivity | #228 |
| arthritis objective | #228 |
| presenting cells | #228 |
| cell selection | #229 |
| presence anti | #229 |
| eae rats | #230 |
| site inflammation | #230 |
| human rheumatoid | #231 |
| ls1 | #231 |
| monoclonal immunohistochemistry | #232 |
| reactive oxygen | #232 |
| synovial joints | #233 |
| role eosinophils | #233 |
| ameliorated | #233 |
| lack expression | #233 |
| production ros | #233 |
| centimorgan | #234 |
| lower numbers | #234 |
| mhc gene | #235 |
| staphylococcal infection | #235 |
| chronic psychosocial stress | #235 |
| chromosome 14 | #235 |
| immune complex | #236 |
| specificity animals | #236 |
| control strain | #237 |
| pathological mechanisms | #237 |
| progression arthritis | #238 |
| autoimmune chronic | #238 |
| trait locus | #239 |
| c5 | #239 |
| inbred dba tlymphocytes | #240 |
| study plasma | #241 |
| strong influence | #242 |
| joint pain | #242 |
| monoclonal antigen | #243 |
| class genetic | #243 |
| multicomponent | #243 |
| positive anti | #243 |
| hla drb1 | #243 |
| protected | #243 |
| cutaneous infection | #244 |
| treatment autoimmune | #244 |
| common denominator | #244 |
| inflammation cartilage | #244 |
| estrus cycle | #244 |
| crosses | #244 |
| binding antibodies | #245 |
| rt1l | #246 |
| allelic differences | #246 |
| development emphysema | #246 |
| new model | #247 |
| inbred strain | #247 |
| antibodies anti | #247 |
| antibody response | #247 |
| florescence | #247 |
| normal cartilage | #247 |
| activity assays | #248 |
| efficient expression | #248 |
| oxygen species | #249 |
| induced chronic | #249 |
| node cells | #250 |
| fragments rats | #250 |
| arthritic joints | #250 |
| inflammation score | #250 |
| picryl | #250 |
| mouse rat | #250 |
| treatment rats | #251 |
| hyperinflammation | #251 |
| conditional knockout mice | #251 |
| develops | #251 |
| nadph oxidase | #251 |
| mice lymphocytes | #252 |
| dark agouti | #252 |
| response disease | #252 |
| role model | #252 |
| mice lack | #252 |
| cartilage matrix | #254 |
| dinitrofluorobenzene | #254 |
| class mhc | #254 |
| onset clinical | #254 |
| proteins glycoproteins | #254 |
| lpr mice | #254 |
| lacking | #254 |
| autoimmune response | #255 |
| inbred c3h | #255 |
| inflammatory disorder | #256 |
| postmenopausal bone | #256 |
| anti arthritic | #256 |
| specific neutralizing | #256 |
| specific subgroups | #256 |
| disease cell | #257 |
| additive interaction | #258 |
| class mhc molecules | #259 |
| relationship immunologic | #260 |
| mir144 | #260 |
| chronic granulomatous | #260 |
| lymphocytes helper | #261 |
| autoimmune neuritis | #261 |
| secondary osteoporosis | #261 |
| mediated suppression | #261 |
| denatured | #261 |
| mice expressing | #261 |
| immunologic animals | #262 |
| selfantigen | #263 |
| tolerance mice | #265 |
| pregnancy mice | #265 |
| mouse strain | #265 |
| primary immunization | #265 |
| crossreactive | #265 |
| genetic techniques | #265 |
| cysteine proteases | #267 |
| vim2 | #267 |
| rats animals | #267 |
| antigen specific | #267 |
| posttranslational modifications | #268 |
| lentiviral gene | #268 |
| xid | #268 |
| mann whitney | #269 |
| pathogenic roles | #269 |
| oxpl | #270 |
| complement c5 | #270 |
| selfantigens | #271 |
| monosodium urate crystals | #271 |
| melatonin effects | #271 |
| castrated | #271 |
| experimental model | #273 |
| amino acid transporters | #273 |
| lewis rats | #274 |
| nasally | #275 |
| inhibitory peptide | #275 |
| hdac1 | #275 |
| tcells | #275 |
| synovial lining | #275 |
| fcgr3b | #276 |
| macrophages dendritic cells | #276 |
| rheumatoid arthritis association | #277 |
| deiminase type | #277 |
| producing cells | #277 |
| viral female hepatitis | #277 |
| metabolic properties | #278 |
| recognize | #278 |
| interferongamma | #279 |
| gp70 | #279 |
| colon length | #279 |
| induced tolerance | #280 |
| dinucleotide phosphate | #280 |
| neonatal mice | #281 |
| immunological receptors antigen | #281 |
| passive transfer | #281 |
| inflammatory conditions | #281 |
| recipient mice | #281 |
| hemiacetal | #282 |
| inbred nod | #283 |
| factor production | #283 |
| isoflavone genistein | #283 |
| igg2b | #283 |
| disease susceptibility | #283 |
| helper inducer | #284 |
| increased serum levels | #284 |
| aire | #284 |
| severe colitis | #284 |
| theilovirus | #285 |
| endophilin | #285 |
| publication animals antibodies | #285 |
| aureus strain | #285 |
| idiotope | #285 |
| complete protection | #285 |
| maintained | #285 |
| emulsified | #286 |
| hla dr2 | #287 |
| melatonin mice | #288 |
| melatonin release | #288 |
| tlr9 mice | #288 |
| myelin basic protein | #288 |
| antibody production | #288 |
| cells autoimmunity | #289 |
| mice immunized | #289 |
| synovial cells | #291 |
| disease cells | #291 |
| ctla4 expression | #291 |
| autoimmune mechanisms | #292 |
| rheumatic conditions | #292 |
| induced ros | #293 |
| cytokines disease | #293 |
| increased copy | #293 |
| collagen receptors | #293 |
| unique model | #294 |
| mouse genes | #294 |
| c57bl 6 mice | #295 |
| antigen processing | #295 |
| gastric parietal | #295 |
| c3h | #295 |
| immunological receptors | #296 |
| nerve conduction | #296 |
| tissue‐specific | #296 |
| 6week | #296 |
| dnfb | #297 |
| phosphopyruvate | #297 |
| murine dendritic cells | #297 |
| helical peptides | #297 |
| gene selection | #298 |
| cd19 cells | #298 |
| vivo imaging | #298 |
| ppad | #298 |
| citrullination | #299 |
| solidphase synthesis | #299 |
| transplantation antigens | #299 |
| tcr beta | #300 |
| neutrophil extracellular traps | #301 |
| posttranslational rats | #301 |
| peptide antibody | #302 |
| extraembryonic tissues | #302 |
| alphabeta | #302 |
| draining lymph | #302 |
| 1 interferon | #303 |
| pathogeneses | #303 |
| animals antibodies | #303 |
| strains mice | #303 |
| epidemiological investigation | #303 |
| igg glycosylation | #304 |
| cgd | #304 |
| conditioned disease models | #304 |
| autoimmune diseases | #304 |
| immunological function | #305 |
| cartilage development | #305 |
| cells tcr | #305 |
| mutant strains mice | #305 |
| murine colitis | #306 |
| hcdr3 | #306 |
| αgalcer | #306 |
| immunological studies | #306 |
| gammaifn | #306 |
| class histocompatibility | #307 |
| inpp4b | #307 |
| immunisation | #307 |
| basal metabolic rate | #308 |
| chromosome 10 | #309 |
| basal metabolic | #309 |
| articular cattle cells | #310 |
| arthritis study | #310 |
| perpetuation | #311 |
| multiple sclerosis eae | #311 |
| alleles animals | #312 |
| synthetic peptide | #312 |
| inflamed joints | #312 |
| disease symptoms | #312 |
| c3bi | #313 |
| exuberant | #313 |
| epitopes | #313 |
| activatory | #314 |
| induced colitis | #314 |
| intradermally | #315 |
| mice genes | #315 |
| r620w | #315 |
| trypanosoma brucei brucei | #316 |
| onset rheumatoid | #318 |
| classical risk factors | #318 |
| genetic interactions | #319 |
| galactosyl | #319 |
| tubule cells | #319 |
| deiminase | #320 |
| spleen bone marrow | #320 |
| mice subjected | #320 |
| genomewide linkage analysis | #320 |
| cells specific | #323 |
| il21r | #323 |
| expressing human | #324 |
| ccp1 | #324 |
| daf2 | #324 |
| impact disease | #324 |
| expression cells | #325 |
| rat gene | #325 |
| specific cell | #325 |
| surprisingly | #326 |
| mgps | #327 |
| resembles | #327 |
| allelic variant | #328 |
| c57bl mice | #328 |
| publication adjuvants | #329 |
| constant light | #329 |
| immunoenzyme | #329 |
| complex genes | #330 |
| early arthritis | #331 |
| rheumatoid synovial | #332 |
| glycoprotein mog | #332 |
| fcgammariia | #332 |
| nucleotide polymorphism | #332 |
| mouse hepatitis virus | #333 |
| anticcp | #333 |
| 35ssulfate | #334 |
| joint tissues | #335 |
| susceptibility genes | #335 |
| mrl lpr mice | #335 |
| autoimmune inflammation | #336 |
| cell response | #338 |
| epitope specificity | #340 |
| delayed onset | #340 |
| cells spleen | #340 |
| adjuvants immunologic | #341 |
| erosive | #341 |
| ros oxygen species | #341 |
| activation macrophages | #341 |
| rat | #341 |
| specific autoimmune | #342 |
| 6weeks | #342 |
| incident cardiovascular events | #342 |
| animal enzyme inhibitors | #342 |
| rapid spread | #343 |
| sequence animals | #343 |
| drb1 alleles | #343 |
| rats injection | #343 |
| diabetic mouse | #343 |
| monoclonals | #344 |
| 182780 | #344 |
| favor | #345 |
| acpa positivity | #345 |
| energetic costs | #346 |
| intraperitoneal injection | #347 |
| pemphigus vulgaris pv | #348 |
| complement activity | #349 |
| reduced capacity | #349 |
| neuritis | #349 |
| igg autoantibodies | #350 |
| phenotype rats | #351 |
| thymic selection | #352 |
| methylcholanthrene | #352 |
| anti cyclic | #353 |
| c3h hej | #353 |
| mice induction | #353 |
| immunoregulation | #353 |
| mice cd4 | #354 |
| autoantigens autoimmune | #354 |
| arthritis synovial | #354 |
| splenic macrophages | #355 |
| dsg3 | #357 |
| adjuvant activity | #358 |
| cells autoantibodies | #358 |
| tbetarii | #358 |
| injected | #359 |
| enos | #359 |
| neuritogenic | #359 |
| tcrbeta | #360 |
| pvg | #361 |
| tlr3 | #361 |
| freund | #361 |
| murine lupus | #362 |
| hla transgenic | #362 |
| identification genes | #363 |
| determines | #363 |
| allergic encephalomyelitis | #363 |
| mouse chromosome | #363 |
| generation ros | #363 |
| hladr4 | #364 |
| recognized | #364 |
| cells anti | #364 |
| sex chromosomes | #366 |
| european journal | #366 |
| immune deviation | #366 |
| glycoproteins mice | #366 |
| psychosocial stress | #367 |
| antiidiotypic antibodies | #367 |
| autoimmune responses | #368 |
| loci | #368 |
| ncf2 | #368 |
| toxic shock | #368 |
| 100 micrograms | #368 |
| affinity ligand | #368 |
| nasal administration | #369 |
| histocompatibility antigens | #369 |
| pentameric | #369 |
| increased production | #370 |
| immune pathogenesis | #370 |
| serum transfer | #371 |
| regulate | #371 |
| clinical onset | #371 |
| role mif | #372 |
| newborn antibodies | #372 |
| alternative activation | #373 |
| rheumatoid cell | #375 |
| autoantigens | #375 |
| acutephase proteins | #376 |
| undifferentiated arthritis | #376 |
| glucose6 | #377 |
| gia | #379 |
| reparixin | #380 |
| mouse monoclonal antibody | #381 |
| induced lupus | #381 |
| oxidase deficiency | #381 |
| fia | #382 |
| fragments immunoglobulin | #382 |
| granulomatous | #383 |
| granulomatous disease | #384 |
| c1a | #384 |
| naive rats | #384 |
| specific loci | #384 |
| postmenopausal bone loss | #385 |
| shock syndrome | #385 |
| cell specificity | #386 |
| pc4 | #386 |
| filaggrin | #387 |
| backcrosses | #387 |
| ptpn22 gene | #387 |
| antioxid | #387 |
| inbred nod receptors | #388 |
| phase response | #388 |
| downregulating | #389 |
| deficient | #390 |
| ovulation rate | #390 |
| greater 50 | #390 |
| peptidylarginine | #391 |
| anaphylatoxin c5a | #391 |
| radiological progression | #391 |
| finetune | #392 |
| rf1 | #394 |
| il4 il10 | #394 |
| ameliorating | #395 |
| induced metabolic | #397 |
| autoantibody levels | #397 |
| draining | #397 |
| juvenile chronic arthritis | #398 |
| regulation animals | #399 |
| protein myelin | #399 |
| immunized mice | #399 |
| inflammatory reactions | #400 |
| reactive oxygen species | #400 |
| antibody formation | #401 |
| genes cells | #401 |
| inflammation demyelination | #403 |
| immunopeptidome | #403 |
| biacore | #403 |
| beta chain | #404 |
| fcγriib | #404 |
| basic protein | #405 |
| experimental | #405 |
| n31 | #407 |
| rheumatoid case | #407 |
| effects models | #407 |
| pam3csk4 | #408 |
| major locus | #409 |
| immunogenetics | #409 |
| 3hproline | #410 |
| diabetes loci | #410 |
| intracellular processing | #410 |
| cell phenotypes | #412 |
| hladrb1 | #412 |
| cd43 | #412 |
| susceptibility loci | #413 |
| titres | #413 |
| reproductive performance | #414 |
| characteristic feature | #414 |
| cultured collagen | #415 |
| igk | #415 |
| female mice | #416 |
| levels autoantibodies | #416 |
| spontaneous mutation | #417 |
| lupus mice | #417 |
| synovial inflammation | #417 |
| genetically modified mice | #418 |
| class hdacs | #419 |
| molecular interactions | #419 |
| wtccc | #419 |
| induced pain | #419 |
| hiit | #420 |
| ameliorate | #420 |
| tcell | #421 |
| dr4 | #422 |
| lower affinity | #422 |
| lipidomic | #423 |
| restricted | #424 |
| subsets animals | #424 |
| hyaline cartilage | #425 |
| congenic strain | #426 |
| regulatory animals | #426 |
| inflammatory cells | #426 |
| carbohydrate moiety | #429 |
| epitopes humans | #430 |
| nonimmunogenic | #430 |
| postimmunization | #430 |
| nod mouse | #430 |
| immunoregulatory | #431 |
| il10 mice | #433 |
| patients healthy individuals | #433 |
| cells antibodies | #434 |
| spontaneous autoimmune | #435 |
| factor 5 | #435 |
| cells beta | #436 |
| reactivities | #436 |
| crystallizable | #437 |
| chromosomes chromosome | #437 |
| decalcified | #437 |
| mass spectrometric analysis | #437 |
| helperinducer tlymphocytes | #438 |
| mice effects | #438 |
| immunised | #438 |
| specific antigens | #438 |
| joint swelling | #439 |
| cells | #439 |
| nod | #440 |
| wildtype mice | #440 |
| vitro techniques leukocytes | #441 |
| normal rats rats | #441 |
| effector functions | #441 |
| female immunoglobulin | #441 |
| mice activation | #442 |
| complete adjuvant | #442 |
| patients population | #442 |
| mhc class molecules | #443 |
| methylβcyclodextrin | #443 |
| tlr2 expression | #444 |
| myelin basic | #444 |
| systemic mice | #445 |
| mouse models | #445 |
| genomewide scan | #445 |
| mice humans | #445 |
| skeletal muscle function | #445 |
| ros production | #447 |
| inbred strains receptors | #448 |
| induced mice | #448 |
| pain model | #448 |
| control mice | #448 |
| synovial tissue | #449 |
| tcell responses | #449 |
| complement factor | #449 |
| innate adaptive | #450 |
| igg anti | #451 |
| apcs | #451 |
| hybridoma cells | #452 |
| reduced production | #452 |
| heterologous | #452 |
| differs | #454 |
| cells chronic | #456 |
| lglutamine | #456 |
| inbred c57bl tlymphocytes | #457 |
| raloxifene | #457 |
| rheumatoid cells | #459 |
| eae cns | #459 |
| resembling | #459 |
| lung macrophages | #459 |
| priming | #459 |
| antibodies monoclonal | #460 |
| 256 | #462 |
| neutrophil functions | #462 |
| autoantigen | #462 |
| gilt | #463 |
| fab fragments | #464 |
| autoantibody production | #465 |
| salivary glands | #466 |
| receptor tcr | #466 |
| cells lymph | #467 |
| titers | #469 |
| earlier onset | #469 |
| antibody mediated | #474 |
| anticyclic citrullinated peptide | #474 |
| disease mice | #474 |
| arthritic rats | #474 |
| cartilage cells | #475 |
| human autoimmune | #476 |
| mice exhibited | #477 |
| cluster genes | #477 |
| therapeutic vaccination | #478 |
| mediated inflammation | #478 |
| female hla | #479 |
| apoptosis arthritis | #479 |
| laboratory rat | #479 |
| quantitative trait loci | #480 |
| aggravated | #480 |
| deacetylase 1 | #480 |
| anti idiotypic | #482 |
| polymorphonuclear cells | #482 |
| immune reactions | #484 |
| immunologists | #485 |
| immunoglobulin male | #486 |
| controlling | #487 |
| tcralpha | #487 |
| jca | #487 |
| oxyntic | #487 |
| invariant natural | #488 |
| specific immune | #488 |
| insulitis | #488 |
| gland animals | #489 |
| normal mice | #490 |
| cytoplasmic calcium | #494 |
| nacetylglucosaminidase | #495 |
| conclude | #496 |
| early rheumatoid | #496 |
| reactive nitrogen | #496 |
| h2b | #496 |
| gammadelta cells | #496 |
| small effects | #498 |
| mbp | #498 |
| receptor 9 | #499 |
| biologicals | #500 |
| immunoenzyme techniques | #503 |
| autoreactive cd4 | #503 |
| nadph | #503 |
| pathogenic | #506 |
| immunofluorescence analysis | #507 |
| chondrocytes collagen | #507 |
| persistent pain | #508 |
| mineral oil | #508 |
| isopropyl | #508 |
| mab mabs | #508 |
| gingipain | #509 |
| immunization passive | #509 |
| orosomucoid | #509 |
| mice knockout mice | #510 |
| mhc class | #510 |
| c3h hej mice | #511 |
| systemic spread | #511 |
| deficient mice | #511 |
| differential gene | #511 |
| 812 | #511 |
| blymphocytes | #512 |
| mrp8 | #515 |
| hydroxyquinolines | #517 |
| behavioral alterations | #517 |
| u1 | #518 |
| antibody complex | #518 |
| chronic granulomatous disease | #519 |
| suggestive linkage | #519 |
| inflammation | #519 |
| tcr recognition | #520 |
| modified form | #521 |
| dextran sulfate sodium | #522 |
| pcorr | #522 |
| ttg | #522 |
| data peptide | #523 |
| inflammation role | #523 |
| litter size | #524 |
| encephalitogenic | #524 |
| p47phox | #524 |
| neutrophil granulocytes | #525 |
| mechanical hypersensitivity | #526 |
| tconv | #526 |
| mnc | #526 |
| disease acute | #527 |
| maternal antibodies | #527 |
| spleen cells | #527 |
| larsen | #528 |
| tolonium | #528 |
| primed | #528 |
| vaccinates | #528 |
| displayed | #529 |
| tolllike receptor tlr4 | #529 |
| ifa | #529 |
| rat rats | #529 |
| cell antibodies | #530 |
| isac | #530 |
| pathogenesis sle | #530 |
| antigen presentation | #530 |
| autoantibody | #530 |
| ratg | #531 |
| epistatic | #532 |
| bred | #532 |
| complex role | #533 |
| lyt2 | #533 |
| posttranslational receptors | #534 |
| resorptions | #536 |
| spleen lymphocytes | #536 |
| translational modification | #536 |
| urokinase | #537 |
| synovial | #537 |
| cells inflammatory | #538 |
| experimental rats | #538 |
| animals | #538 |
| suppressive | #540 |
| joints | #540 |
| antigen recognition | #540 |
| fibroblast synoviocytes | #540 |
| membrane attack complex | #541 |
| rheumatoid humans | #543 |
| specific autoantibodies | #544 |
| protein tyrosine phosphatase | #545 |
| regulating | #545 |
| hypomorphic | #546 |
| shortcut | #547 |
| animal gene | #547 |
| tlymphocytes | #547 |
| immunohistochemical methods | #548 |
| formyl peptide receptors | #548 |
| entheses | #548 |
| mog | #550 |
| immunoglobulin fab | #552 |
| mixed lymphocyte reaction | #553 |
| nox activity | #554 |
| breeder | #555 |
| beta animals | #557 |
| cell epitopes | #557 |
| stronger association | #557 |
| cells control | #558 |
| early onset | #559 |
| healthy mice | #560 |
| elispot assay | #561 |
| transgenic molecular | #562 |
| ptdins3p | #563 |
| inbred strains | #563 |
| negative selection | #563 |
| neutrophil depletion | #564 |
| therapeutic treatment | #565 |
| deeper layers | #565 |
| immunoglobulin heavy chains | #566 |
| darkness | #566 |
| earlier | #566 |
| target tissue | #566 |
| crucial | #567 |
| outbred | #568 |
| disease loci | #568 |
| interferon signature | #568 |
| cells pathogenesis | #569 |
| mycobacteria | #569 |
| neutrophilia | #569 |
| concomitantly | #570 |
| mice compared | #571 |
| transgenic mouse models | #572 |
| btla | #572 |
| keratin8 | #573 |
| col2 | #574 |
| pepstatins | #576 |
| presenting | #576 |
| estrogen treatment | #577 |
| terpenes | #577 |
| keratinocyte growth factor | #578 |
| prolactin prl | #578 |
| ptm | #579 |
| sera patients | #579 |
| triple helix | #580 |
| methotrexate mice | #581 |
| f1 hybrids | #581 |
| hybridoma | #583 |
| inflammatory joint | #583 |
| production ifngamma | #583 |
| lymphocyte antigens | #584 |
| exaggerated | #584 |
| time onset | #584 |
| antibody reactions | #585 |
| traps nets | #590 |
| environmental triggers | #591 |
| antigen antibody | #591 |
| immunological tolerance | #592 |
| lxrα | #592 |
| oligoclonal | #592 |
| transgenic models | #593 |
| noncollagenous | #593 |
| macrophages | #594 |
| adaptive immunity | #594 |
| autoimmune disorders | #594 |
| multiplexing | #595 |
| th1 cytokines | #595 |
| clonal expansion | #595 |
| xanthine oxidoreductase | #596 |
| cells study | #599 |
| tcell activation | #599 |
| develop | #600 |
| augmented | #602 |
| n85 | #602 |
| spite | #602 |
| th2 cytokines | #602 |
| common diseases | #603 |
| mouse monoclonal | #603 |
| pemphigus vulgaris | #603 |
| phagosomal | #604 |
| cells male | #604 |
| cells involved | #604 |
| mice inbred | #606 |
| animal rats | #606 |
| oxa | #606 |
| class humans | #607 |
| frozen sections | #608 |
| genotype hla | #608 |
| spleen animals | #609 |
| inefficiently | #610 |
| regulatory role | #610 |
| naive | #611 |
| production ifn | #611 |
| positive individuals | #612 |
| quantitative trait locus | #615 |
| mutant strains receptors | #616 |
| acetophenones | #616 |
| alpha chains | #616 |
| autoantibodies | #616 |
| exponential phase | #616 |
| class antigens | #616 |
| idiotypic | #616 |
| th1 type | #616 |
| oral immunization | #617 |
| nonobese | #617 |
| beta type | #618 |
| day mice | #619 |
| wistar restraint | #620 |
| promiscuous | #620 |
| receptor 3 | #621 |
| consequent | #621 |
| inflammatory role | #621 |
| nicotinamide adenine | #622 |
| fluorine18 | #624 |
| receptors antigen | #624 |
| loci identified | #625 |
| chronic stage | #625 |
| cytoplasmic ca2 | #628 |
| animal mice | #628 |
| local injection | #629 |
| cross reactions | #630 |
| inflammatory disease | #630 |
| reactive antibodies | #632 |
| healthy rats | #632 |
| development eae | #633 |
| fibromodulin | #634 |
| highintensity interval training | #634 |
| vivo binding | #635 |
| langerhans cells | #635 |
| nabs | #637 |
| ifn beta | #637 |
| class genes | #638 |
| cells inhibition | #638 |
| estrogens female | #640 |
| inflammation autoimmunity | #640 |
| biotinylated | #643 |
| mouse lung | #644 |
| cell binding | #645 |
| immune serum | #646 |
| haplotype | #649 |
| patients sera | #650 |
| antigen specificity | #650 |
| genetic disease | #652 |
| hexadecane | #654 |
| idiotypic antibodies | #654 |
| antibody titres | #655 |
| interphalangeal | #655 |
| genetic linkage | #658 |
| new pathway | #658 |
| axotomized | #659 |
| cyba | #660 |
| sialoprotein | #660 |
| inbred cba mice | #661 |
| acute inflammation | #661 |
| peptide binding | #661 |
| mutated | #662 |
| cartilage destruction | #663 |
| ifng | #664 |
| animal ear | #665 |
| delayed hypersensitivity | #665 |
| superantigens | #666 |
| lymphoid organs | #666 |
| receptors igg | #666 |
| 264 | #666 |
| reactive | #666 |
| activation mice | #669 |
| apeced | #670 |
| drb1 | #670 |
| disease autoimmune | #671 |
| purified proteins | #673 |
| cells induce | #674 |
| treatment protocol | #674 |
| genetic epistasis | #675 |
| pyramidal neurons | #675 |
| desmoglein | #675 |
| strikingly | #676 |
| idiotypes | #677 |
| germinal center | #677 |
| adherent cells | #677 |
| china cohort | #678 |
| il12p70 | #679 |
| igg response | #679 |
| major genes | #679 |
| thelper | #680 |
| lymphocytes mice | #682 |
| cells role | #682 |
| puzzle | #683 |
| normal animals | #683 |
| inbred c57bl mice | #683 |
| helper cell | #684 |
| specific antibody | #684 |
| intradermal injection | #686 |
| transgenic receptors | #687 |
| βarrestin | #688 |
| subsets | #689 |
| foot joints | #689 |
| delayed | #689 |
| rendered | #690 |
| early rheumatoid arthritis | #690 |
| production autoantibodies | #691 |
| disease genes | #692 |
| knockout polymorphism | #695 |
| muscle glucose | #695 |
| igg antibodies | #696 |
| paam | #696 |
| luminex | #697 |
| anas | #697 |
| disease hla | #698 |
| mice model | #698 |
| uterus | #700 |
| heavy chain genes | #701 |
| microspectroscopy | #703 |
| quantitative trait | #704 |
| inbred | #704 |
| complete freund | #706 |
| fibroblastlike synoviocytes | #707 |
| histopathological analysis | #707 |
| extracellular trap | #708 |
| estradiol female | #710 |
| specific cells | #710 |
| igl | #712 |
| posttranslational | #713 |
| spleens | #716 |
| predetermined | #716 |
| mice lacking | #717 |
| antibodies patients | #718 |
| acute bout | #718 |
| lymphocyte depletion | #719 |
| regulatory function | #720 |
| proliferative response | #720 |
| deficiency syndromes | #721 |
| buf | #721 |
| surrounding tissues | #722 |
| th1 th17 | #723 |
| human hand | #725 |
| macrophages mice mice | #725 |
| dmaema | #728 |
| cd1d | #728 |
| mhc molecules | #729 |
| th2 cytokine | #729 |
| ccps | #729 |
| cdk6 | #730 |
| administrated | #732 |
| animals antigens antigens | #732 |
| cholesterol metabolism | #732 |
| cns inflammation | #732 |
| excessive inflammation | #734 |
| finding | #735 |
| rats treatment | #736 |
| net formation | #736 |
| locus | #737 |
| cheeks | #739 |
| operates | #740 |
| c57bl | #740 |
| species specificity | #741 |
| cd5 cells | #741 |
| tissue destruction | #742 |
| nkt | #742 |
| immunologic deficiency | #743 |
| cell responses | #743 |
| vivo mice | #743 |
| treatment anti | #744 |
| role disease | #746 |
| mycobacterial infections | #747 |
| nonobese diabetic mice | #749 |
| keratinocyte | #749 |
| intensity interval | #749 |
| autoantibodies autoimmunity | #749 |
| transferred | #751 |
| preclinical phase | #751 |
| control disease | #753 |
| metabolomic | #755 |
| tlr activation | #755 |
| hapten | #755 |
| ere | #755 |
| mice anti | #757 |
| autoantibodies type | #758 |
| disease protection | #758 |
| phenotypic differences | #758 |
| hyperinflammatory | #759 |
| reacted | #759 |
| linkage region | #760 |
| knockout tlymphocytes | #760 |
| ccp | #761 |
| ifngamma production | #761 |
| polycytidylic | #762 |
| immunocap | #763 |
| gamma ifn | #765 |
| glut4 translocation | #767 |
| periarticular | #772 |
| cells apcs | #773 |
| hkexchanging | #773 |
| redox signal | #773 |
| peripheral tolerance | #774 |
| afflicted | #777 |
| diseases cell | #778 |
| fab fragment | #778 |
| interacted | #779 |
| inbred nzb | #780 |
| acid transporters | #781 |
| nox1 | #782 |
| arthritis osteoarthritis | #782 |
| development autoimmunity | #782 |
| pathogenic role | #782 |
| arthritis psa | #783 |
| chronic colitis | #784 |
| clinical scores | #786 |
| transgenic mutation | #789 |
| peptide fragments | #790 |
| reduced incidence | #790 |
| transgenic receptors antigen | #790 |
| inflammatory lesions | #790 |
| pineal gland | #791 |
| polyarthritis | #792 |
| cell gamma | #793 |
| antibodies directed | #794 |
| cell humans | #794 |
| neutrophil function | #796 |
| neutrophil extracellular | #796 |
| interval training | #796 |
| pathogen free | #797 |
| lymphocyte proliferation | #798 |
| genes immunoglobulin | #798 |
| carbohydrate moieties | #800 |
| matrix proteins | #801 |
| polyi | #801 |
| blymphocyte chain genes | #802 |
| innate adaptive immunity | #802 |
| monoclonal binding | #802 |
| thy1 | #802 |
| helper cells | #805 |
| induces | #805 |
| count male | #805 |
| redox control | #805 |
| multinucleated giant cells | #808 |
| backcrossing | #809 |
| bone erosion | #810 |
| catabolism | #811 |
| function mutation | #811 |
| strains receptors | #812 |
| acc1 | #812 |
| resident cells | #812 |
| febuxostat | #813 |
| nonreceptor type | #815 |
| arginines | #817 |
| ctb | #817 |
| leads | #820 |
| auricle | #820 |
| cd8 antigens | #821 |
| collagen cross | #821 |
| leukocyte infiltration | #822 |
| piece | #823 |
| colocalizes | #824 |
| humoral immune response | #824 |
| electroporated | #824 |
| psoriasis psoriatic arthritis | #825 |
| prominently | #825 |
| genetic environmental | #825 |
| muscle training | #826 |
| response animals | #826 |
| chondroid | #827 |
| class antigen | #829 |
| growth factor beta | #829 |
| producing | #830 |
| effects immune | #830 |
| cross reactivity | #834 |
| lpr | #841 |
| inbred c57bl | #841 |
| immunoglobulin mice | #842 |
| peyers patches | #842 |
| diabetic nod | #844 |
| therapeutic approaches | #844 |
| il25 | #845 |
| chronic active | #845 |
| mice transgenic | #846 |
| inflammatory arthritis | #846 |
| induce | #848 |
| intermingled | #850 |
| macroscopically | #851 |
| antigen cell | #852 |
| lymphocyte | #852 |
| leukocyte migration | #854 |
| new possibilities | #854 |
| ms275 | #855 |
| tcell receptors antigen | #855 |
| importantly | #856 |
| strongest association | #856 |
| alveolar mice mice | #856 |
| mcv | #858 |
| post translational | #861 |
| immune defence | #862 |
| treatment reduced | #865 |
| lyme | #866 |
| mice reduced | #867 |
| factor anti | #867 |
| mediated inflammatory | #867 |
| knockin mice | #867 |
| strongest | #868 |
| cross reactive | #868 |
| parietal cells | #869 |
| hinge region | #869 |
| lentiviral | #869 |
| lnc | #872 |
| dextran sulfate | #873 |
| immune tolerance | #873 |
| lower expression | #874 |
| parasitemia | #874 |
| elisas | #875 |
| cells expressing | #876 |
| granulomas | #877 |
| fcγri | #878 |
| synovial fluid patients | #878 |
| arthritis inflammatory | #879 |
| adoptive | #881 |
| antigen4 | #881 |
| pregnancy animal | #882 |
| systemic autoimmune diseases | #882 |
| testosterone treatment | #883 |
| fluid synovial | #884 |
| cartilaginous | #888 |
| standard therapies | #890 |
| psoriasis vulgaris | #891 |
| genetic dissection | #891 |
| basic | #893 |
| regulator | #895 |
| completely | #896 |
| intranasal administration | #897 |
| inflammation mediators | #897 |
| ctla4 antigen | #898 |
| interleukin1alpha | #898 |
| phosphatase receptor | #902 |
| granulocytes | #904 |
| partly | #904 |
| inception cohort | #905 |
| γδ cells | #906 |
| infiltrations | #906 |
| rats inbred | #907 |
| lipocalins | #908 |
| extracellular traps | #909 |
| immunohistochemical analyses | #910 |
| immunoglobulin levels | #911 |
| single injection | #911 |
| liu | #911 |
| chromosome 16 | #912 |
| lectin pathway | #913 |
| mitochondrial ros | #913 |
| pneumonitis | #914 |
| ciita | #914 |
| allelic variation | #915 |
| proliferate | #915 |
| enolase | #915 |
| immunemediated diseases | #916 |
| cytokine response | #923 |
| neutrophil chemotaxis | #924 |
| psoriatic arthritis psa | #924 |
| antibodies antibody | #924 |
| chromosome mapping | #925 |
| cd200 | #925 |
| fluorobenzene | #925 |
| phenotypic analysis | #926 |
| nkt cells | #926 |
| repertoires | #929 |
| burst | #930 |
| tissue transglutaminase | #931 |
| data role | #932 |
| hydratase | #933 |
| citrulline | #933 |
| alpha animals | #935 |
| macropinocytosis | #936 |
| alters | #937 |
| arthritides | #938 |
| lymphocyte activation | #938 |
| 1040 | #939 |
| synovia | #939 |
| immune reactivity | #940 |
| analysed | #940 |
| rns | #940 |
| vitro stimulation | #941 |
| genetic analysis | #941 |
| disease model | #941 |
| collagen structure | #941 |
| mediated autoimmune | #944 |
| association hla | #945 |
| sciatic nerves | #945 |
| mice mice | #947 |
| clinical observations | #948 |
| fluid patients | #948 |
| inflammatory pathways | #948 |
| humanized mice | #949 |
| riii | #950 |
| vivo | #950 |
| l3t4 | #954 |
| environmental determinants | #955 |
| nos1 | #957 |
| carrying | #958 |
| differentiation tlymphocyte antigens | #959 |
| mhc peptide | #962 |
| levels ros | #962 |
| chronic disease | #963 |
| cellular immunization | #965 |
| animals cytokines | #967 |
| cells lymphocytes | #967 |
| monoclonal antigens | #967 |
| cytotoxic tlymphocytes | #967 |
| cell transfer | #969 |
| lower frequency | #969 |
| chromosome 15 | #971 |
| draining lymph nodes | #972 |
| secreting cells | #973 |
| susceptibility locus | #978 |
| cartilage articular | #979 |
| synovial membrane | #981 |
| genes chromosome | #982 |
| lymphocytes | #982 |
| w5 | #982 |
| binding peptides | #983 |
| pain behavior | #984 |
| tbb | #987 |
| tallele | #988 |
| microspectrophotometry | #990 |
| knockout models | #991 |
| macrophages cells | #991 |
| allergic contact dermatitis | #992 |
| immunodominance | #992 |
| cells reactive | #993 |
| patients rp | #994 |
| 510 | #994 |
| transgenic expression | #994 |
| cartilage bone | #995 |
| hej | #995 |
| knee joints | #997 |
| spontaneously | #997 |
| formyl peptide | #997 |
| laminin fibronectin | #998 |
| antigen expression | #999 |
| immunoglobulin fragments | #1000 |
| lymphocyte subpopulations | #1002 |
| multiple loci | #1003 |
| processing presentation | #1004 |
| expands | #1004 |
| aggravate | #1004 |
| protective role | #1007 |
| igg subclasses | #1011 |
| nrc | #1012 |
| cyclic peptides | #1012 |
| interleukin21 | #1013 |
| 95 stroke | #1013 |
| direct comparison | #1015 |
| model multiple | #1015 |
| igg | #1015 |
| cells mast | #1016 |
| cellular composition | #1016 |
| nerve roots | #1016 |
| aged arthritis | #1017 |
| patients early | #1019 |
| melatonin levels | #1019 |
| cd4 antigens | #1020 |
| immunoglobulin variable | #1022 |
| cysteine protease | #1025 |
| diseases animals | #1026 |
| genetic humans | #1027 |
| innate killer cells | #1028 |
| il4 | #1029 |
| dr1 | #1031 |
| baseline 24 months | #1031 |
| mice treated | #1032 |
| oxidase | #1034 |
| major regulator | #1036 |
| species production | #1039 |
| tramp | #1040 |
| arthritis psoriatic | #1041 |
| expression mrna | #1042 |
| complementary genes | #1043 |
| das28 | #1045 |
| parental strain | #1050 |
| myelin proteins | #1050 |
| patients rheumatoid | #1051 |
| chromosome 5 | #1052 |
| inflammatory macrophages | #1055 |
| gamma delta | #1055 |
| immune defense | #1056 |
| antigens differentiation | #1056 |
| mannans | #1057 |
| rat cells | #1060 |
| lymphocytes cells | #1062 |
| morula | #1062 |
| sterile inflammation | #1062 |
| transgenic | #1063 |
| tarsus | #1066 |
| decidua | #1069 |
| oxazoles | #1069 |
| disease humans polymorphism | #1069 |
| role immune | #1069 |
| synovial fluids | #1071 |
| transgenic cells | #1075 |
| fcγ | #1076 |
| radiological | #1077 |
| peptidylarginine deiminase | #1078 |
| epistasis | #1079 |
| adjuvant cfa | #1080 |
| key steps | #1080 |
| lymphoid cells | #1082 |
| reestablishment | #1082 |
| irf1 | #1086 |
| dependent regulation | #1087 |
| al2 | #1088 |
| uppsala | #1089 |
| haplotypes | #1089 |
| enlarged | #1091 |
| inflamed | #1092 |
| osteoclast formation | #1093 |
| 7 weeks | #1096 |
| oligodendrocyte | #1098 |
| inkt cells | #1102 |
| igs | #1103 |
| effector mechanisms | #1104 |
| cells increased | #1105 |
| arginine deiminase | #1114 |
| subdominant | #1115 |
| molecular mimicry | #1115 |
| fibril | #1115 |
| clinical disease | #1116 |
| sclerosis myelin | #1116 |
| animal immunity | #1117 |
| antitoxin | #1117 |
| disulfide | #1117 |
| genetic factors | #1117 |
| deamidation | #1117 |
| cd5 | #1117 |
| antigenic peptides | #1118 |
| pil | #1121 |
| lymphocytes regulatory | #1123 |
| recognizing | #1126 |
| primary immunodeficiency | #1127 |
| foreign antigens | #1128 |
| predisposing | #1128 |
| humans lymphocyte | #1128 |
| cells ifn | #1128 |
| isomerase | #1128 |
| dissected | #1130 |
| skeletal muscle fibers | #1132 |
| treatment day | #1132 |
| superantigen | #1134 |
| cryosections | #1135 |
| immune response | #1135 |
| glucosyl | #1136 |
| overlapped | #1136 |
| vivo administration | #1136 |
| c57 | #1137 |
| underline | #1138 |
| peptide sequence | #1138 |
| editorial | #1139 |
| anticardiolipin antibodies | #1139 |
| cd4foxp3 | #1142 |
| mice rats | #1146 |
| syntenic | #1147 |
| treatment animals | #1149 |
| helpers | #1149 |
| agonist | #1150 |
| cd4 cells | #1151 |
| subcloned | #1155 |
| disease onset | #1157 |
| antibody affinity | #1160 |
| lxr | #1161 |
| inactivating | #1161 |
| respiratory burst | #1163 |
| prolactin rats | #1164 |
| demonstrating | #1168 |
| stainings | #1168 |
| increased severity | #1170 |
| activated cells | #1171 |
| transduction toll | #1174 |
| gp91phox | #1175 |
| nadph oxidoreductases | #1176 |
| models disease | #1178 |
| inflamed tissues | #1178 |
| 10b | #1179 |
| recombinant interferon | #1180 |
| preponderance | #1180 |
| genetic background | #1181 |
| chemiluminescent | #1182 |
| destructive | #1182 |
| arginine residues | #1184 |
| objective investigate | #1186 |
| disease haplotypes humans | #1186 |
| synovial fibroblasts | #1188 |
| lymphocytes cell | #1188 |
| human type | #1190 |
| ileitis | #1191 |
| splenic cells | #1192 |
| rat human | #1192 |
| antiphospholipid | #1193 |
| infiltrates | #1195 |
| primary sjögrens syndrome | #1195 |
| cells rheumatoid | #1199 |
| basic mechanisms | #1200 |
| antibodies mabs | #1200 |
| antibody | #1200 |
| susceptibility | #1200 |
| somatically | #1201 |
| lung mice mice | #1204 |
| protein arginine | #1208 |
| identified loci | #1210 |
| h2k | #1211 |
| predisposition disease | #1212 |
| onset progression | #1212 |
| c5a | #1213 |
| rationales | #1214 |
| singlecell | #1214 |
| hdacs | #1217 |
| chronic inflammation | #1218 |
| critical issues | #1218 |
| igg subclass | #1220 |
| ilc2 | #1221 |
| adaptive immune response | #1223 |
| mononuclear | #1223 |
| compared wt | #1223 |
| subcellular fractionation | #1224 |
| adaptive immune responses | #1225 |
| tlymphocyte antigens | #1226 |
| chromosome 4 | #1227 |
| linkage analysis | #1229 |
| antimicrobial peptides amps | #1229 |
| analyse | #1230 |
| experimental models | #1231 |
| therapeutically | #1232 |
| subsets lymphocytes | #1233 |
| aps | #1233 |
| host defense | #1238 |
| immunological mechanisms | #1240 |
| human cd4 | #1241 |
| cell lymphocytes | #1244 |
| indel | #1247 |
| mouse | #1250 |
| immune inflammatory | #1251 |
| lining | #1252 |
| ltb | #1253 |
| animal | #1253 |
| dead cells | #1254 |
| animal doseresponse relationship | #1259 |
| mesenteric lymph nodes | #1263 |
| differentiation lymphocyte | #1263 |
| antigen presenting cells | #1264 |
| synovium | #1265 |
| pathogenic mechanisms | #1266 |
| suppress | #1269 |
| adenine dinucleotide | #1269 |
| suppressive function | #1270 |
| rheumatoid arthritis patients | #1270 |
| molecular pathogenesis | #1270 |
| synovial fluid | #1271 |
| rat mouse | #1273 |
| claudin4 | #1274 |
| eae model | #1274 |
| rats mice | #1275 |
| chromosomal regions | #1275 |
| inducer | #1279 |
| rattus norvegicus | #1282 |
| becn1 | #1282 |
| hla molecules | #1283 |
| c4a | #1283 |
| staphylococcal | #1283 |
| rodent models | #1284 |
| spreading | #1286 |
| joint destruction | #1287 |
| attacked | #1288 |
| disease response | #1290 |
| pathological processes | #1294 |
| immunochip | #1295 |
| suppressor cells | #1296 |
| day pregnancy | #1297 |
| peripheral cells | #1297 |
| serm | #1297 |
| nadph oxidase activity | #1299 |
| production anti | #1299 |
| data protein | #1300 |
| publication animals antigens | #1300 |
| restimulation | #1305 |
| model experimental | #1307 |
| hdac3 | #1307 |
| peptide library | #1309 |
| ali | #1310 |
| social isolation | #1310 |
| fab2 | #1312 |
| phagocytic cells | #1313 |
| generated | #1313 |
| introgressed | #1314 |
| lymphoproliferation | #1315 |
| permissive | #1315 |
| detailed characterization | #1316 |
| increased susceptibility | #1316 |
| immune | #1316 |
| protects | #1319 |
| estradiol treatment | #1320 |
| immunoglobulin isotypes | #1321 |
| hydrolyzes | #1321 |
| phagocytes | #1322 |
| healthy human subjects | #1322 |
| intrathymic | #1322 |
| collagen types | #1323 |
| submandibular | #1323 |
| aureus infections | #1325 |
| acute phase proteins | #1327 |
| valuable tool | #1327 |
| therapeutic antibodies | #1328 |
| dietary nitrate | #1329 |
| human igg | #1330 |
| receptor 2 | #1330 |
| immunological memory | #1332 |
| pockets | #1333 |
| identically | #1335 |
| thymectomy | #1335 |
| new therapies | #1336 |
| rats rats | #1336 |
| acute phase response | #1338 |
| induction phase | #1341 |
| cells mice | #1341 |
| adjuvants | #1344 |
| increasing evidence | #1348 |
| knockout mutation | #1349 |
| promiscuity | #1350 |
| galactosylceramides | #1356 |
| allergic contact | #1359 |
| alp | #1361 |
| position | #1361 |
| elimination | #1361 |
| regulatory genes | #1362 |
| disease activity score | #1364 |
| believed | #1364 |
| n44 | #1366 |
| hypersensitivity | #1367 |
| 590 | #1368 |
| bacterial arthritis | #1372 |
| ameliorates | #1374 |
| shared | #1375 |
| trait | #1375 |
| betad | #1375 |
| membrane glycoproteins | #1375 |
| rat spinal cord | #1379 |
| il1r | #1381 |
| abrogates | #1383 |
| immunogen | #1383 |
| surface cells | #1384 |
| rats humans | #1388 |
| exacerbation | #1388 |
| suffer | #1389 |
| variable region | #1389 |
| cd2 | #1390 |
| regulatory treg | #1390 |
| clinical signs | #1390 |
| squalene | #1392 |
| human patients | #1392 |
| feto | #1393 |
| phage display | #1393 |
| cd4cd8 | #1394 |
| effects rats | #1396 |
| inbred mice | #1397 |
| disease outcomes | #1397 |
| positional | #1399 |
| submandibular glands | #1400 |
| early patients | #1403 |
| joint disease | #1403 |
| mononuclear phagocytes | #1406 |
| linkage genetic | #1409 |
| disease phenotypes | #1412 |
| animals disease | #1413 |
| antigens humans | #1415 |
| enzymelinked immunosorbent | #1416 |
| activation neutrophils | #1417 |
| humans immune | #1417 |
| cytokine profile | #1424 |
| class switching | #1425 |
| bacterial infections | #1431 |
| genetic heterogeneity | #1436 |
| gene usage | #1438 |
| stages disease | #1439 |
| cells type | #1440 |
| peptide | #1441 |
| guillainbarré syndrome | #1451 |
| arthritis systemic | #1453 |
| inbred strains mice | #1454 |
| alpha1 | #1458 |
| cell activation | #1458 |
| monoclonal | #1460 |
| knockout rats | #1461 |
| proinflammatory responses | #1461 |
| expression genetic | #1462 |
| lupus | #1464 |
| salt concentrations | #1465 |
| pfp | #1467 |
| opens | #1467 |
| ccr6 | #1467 |
| cell origin | #1468 |
| inflammatory properties | #1469 |
| cells pregnancy | #1472 |
| activation status | #1473 |
| cartilage cell | #1474 |
| immune deficiency | #1474 |
| muscle muscle | #1476 |
| cells activated | #1478 |
| allelic variants | #1479 |
| allotype | #1480 |
| specific gene | #1482 |
| responses animals | #1482 |
| markers genetic | #1483 |
| blisters | #1483 |
| cells lung | #1486 |
| initiate | #1486 |
| inflammatory diseases | #1486 |
| genetic regulation | #1486 |
| stroke 95 | #1487 |
| hormone release | #1489 |
| host defence | #1489 |
| donated | #1490 |
| mice day | #1491 |
| human cartilage | #1491 |
| inbred rats | #1491 |
| humoral immune | #1497 |
| myelin | #1499 |
| emphysematous | #1499 |
| regulatory effects | #1504 |
| treatment inflammatory | #1504 |
| monocytes neutrophils | #1504 |
| vivo vitro | #1505 |
| specific monoclonal | #1505 |
| eluate | #1507 |
| mimicking | #1507 |
| joint arthritis | #1507 |
| fls | #1508 |
| mapped | #1509 |
| inflammatory cell | #1510 |
| hindlimbs | #1511 |
| chromosome 6 | #1512 |
| stimulates | #1515 |
| egfp | #1516 |
| induced ali | #1520 |
| human leukocyte antigen | #1524 |
| earlier studies | #1525 |
| lia | #1525 |
| genes dominant | #1528 |
| knockout mitochondria | #1530 |
| sex steroids | #1531 |
| streptococcus pyogenes | #1533 |
| glutamic acid | #1535 |
| malaise | #1536 |
| lysines | #1537 |
| downregulate | #1540 |
| net release | #1545 |
| protein rna | #1546 |
| production macrophages | #1547 |
| unexpectedly | #1547 |
| increased numbers | #1548 |
| acetylglucosaminidase | #1549 |
| chronic phase | #1554 |
| higher level | #1555 |
| mediated diseases | #1559 |
| intraperitoneally | #1560 |
| neuroimmunomodulation | #1563 |
| 4 humans | #1563 |
| copy variations | #1563 |
| activate | #1564 |
| intradermal | #1565 |
| vsg | #1566 |
| guerin | #1567 |
| matrix components | #1567 |
| immunoglobulin humans | #1568 |
| mammalian embryo | #1568 |
| formyl | #1569 |
| sufficient | #1573 |
| pineal | #1574 |
| cytotoxic lymphocyte | #1574 |
| independent | #1577 |
| cochran | #1577 |
| cathelicidin | #1578 |
| glycolipid | #1580 |
| collagens | #1585 |
| fab | #1592 |
| mac1 | #1593 |
| factor beta | #1597 |
| conserved | #1597 |
| directed | #1597 |
| defines | #1598 |
| adoptive transfer | #1600 |
| cell mediated | #1600 |
| f1 | #1600 |
| twins | #1600 |
| reactive nitrogen species | #1603 |
| autoantibodies biomarkers | #1604 |
| cell receptor | #1605 |
| estriol | #1607 |
| cells th17 | #1607 |
| helical | #1611 |
| stromal cells | #1615 |
| chondrocyte | #1616 |
| chronic inflammatory diseases | #1617 |
| immunity animals | #1617 |
| isosteric | #1619 |
| autoimmune diabetes | #1621 |
| anaphylatoxin | #1622 |
| c57bl 6 | #1622 |
| humans immunoglobulin | #1622 |
| differently | #1625 |
| antigen | #1626 |
| unreactive | #1626 |
| rat spinal | #1629 |
| iggs | #1630 |
| complement component | #1632 |
| c3b | #1635 |
| immunohistology | #1635 |
| lund | #1639 |
| collagen fibers | #1639 |
| type interferon | #1641 |
| mice increased | #1642 |
| p6 | #1644 |
| abrogated | #1644 |
| c4b | #1645 |
| aspartic acid | #1647 |
| intracellular ros | #1651 |
| sjl | #1652 |
| opsonization | #1653 |
| complement activation | #1657 |
| linked | #1658 |
| defence | #1658 |
| commonly | #1660 |
| complement receptors | #1660 |
| immune complexes | #1661 |
| staphylococcal enterotoxin | #1661 |
| transporter type | #1661 |
| enterotoxins | #1662 |
| mice knockout | #1664 |
| tcell receptors | #1665 |
| salt intake | #1668 |
| tumor vasculature | #1669 |
| coincided | #1670 |
| primary sjögren | #1671 |
| isopropylacrylamide | #1672 |
| immunologic epitopes | #1673 |
| pathogenic cells | #1673 |
| gamma production | #1678 |
| single nucleotide | #1683 |
| cd206 | #1686 |
| complement c5a | #1686 |
| cocktail | #1689 |
| auto | #1689 |
| igm antibodies | #1691 |
| method analysis | #1693 |
| agouti | #1694 |
| ido1 | #1694 |
| transgenic mice | #1696 |
| classical pathway | #1696 |
| severity | #1701 |
| precede | #1704 |
| triple | #1704 |
| animals autoantigens | #1704 |
| 5 months | #1704 |
| suppressors | #1706 |
| encoded | #1707 |
| treg cells | #1711 |
| disulfiram | #1711 |
| beta chains | #1712 |
| erosions | #1712 |
| mice neutrophils | #1714 |
| ankylosis | #1719 |
| sjögrens syndrome | #1719 |
| evoke | #1720 |
| pulmonary aspergillosis | #1721 |
| tolerance | #1721 |
| skewing | #1725 |
| oophorectomy | #1727 |
| showing | #1728 |
| myelin proteolipid | #1729 |
| mutant mice | #1729 |
| drug targets | #1732 |
| analysis protein | #1734 |
| immune responses | #1734 |
| 369 | #1734 |
| staphylococcal infections | #1736 |
| sicca | #1737 |
| phagocytic | #1737 |
| fmoc | #1739 |
| intranasally | #1740 |
| arthritis patients | #1742 |
| affinity binding | #1743 |
| 626 | #1744 |
| prophylactic treatment | #1744 |
| cd11 | #1745 |
| osteoclasts | #1746 |
| zap70 | #1748 |
| strain mice | #1748 |
| alternative pathway | #1748 |
| new loci | #1749 |
| responded | #1750 |
| neoplastic disease models | #1753 |
| peroxide | #1758 |
| infiltrating | #1762 |
| endoglycosidase | #1764 |
| dr2 | #1766 |
| inhibitory receptors | #1766 |
| triggering | #1770 |
| higher frequency | #1770 |
| multiple genes | #1770 |
| glycosylation | #1774 |
| peptide antigens | #1775 |
| operate | #1776 |
| blocking | #1781 |
| adoptively | #1782 |
| cnbr | #1783 |
| articular cell | #1784 |
| ll37 | #1784 |
| local administration | #1788 |
| immunohistological | #1789 |
| compartmentalized | #1791 |
| carbohydrates | #1792 |
| pathogenesis | #1793 |
| dogma | #1794 |
| render | #1794 |
| competed | #1797 |
| immune recognition | #1800 |
| polymorphism genetic | #1801 |
| disease pathogenesis | #1801 |
| rat models | #1802 |
| rechallenge | #1803 |
| cd19 antigens | #1803 |
| peyer | #1804 |
| obese diabetic | #1805 |
| aureus infection | #1808 |
| immunogenic | #1810 |
| predisposed | #1810 |
| elucidation | #1811 |
| complement pathway | #1811 |
| activated lymphocytes | #1811 |
| psoriatic | #1813 |
| recovery phase | #1814 |
| nonfunctional | #1817 |
| pregnancy rats | #1817 |
| il2r | #1818 |
| ossification | #1818 |
| promoting | #1818 |
| intravenously | #1819 |
| blymphocyte | #1819 |
| crossed | #1823 |
| katpase | #1824 |
| myelin sheath | #1825 |
| hydroxylated | #1825 |
| neurodegenerative diseases | #1827 |
| deplete | #1830 |
| female sex | #1833 |
| genetic susceptibility | #1836 |
| new treatments | #1839 |
| pathogenesis disease | #1841 |
| trif | #1843 |
| resolution inflammation | #1844 |
| clinical score | #1846 |
| subsequently | #1846 |
| inflammation macrophages | #1847 |
| estrogen | #1848 |
| cultured disease | #1849 |
| pyogenes | #1852 |
| specific immunity | #1854 |
| genetic variance | #1854 |
| macrophages neutrophils | #1856 |
| cd8 lymphocytes | #1856 |
| humoral | #1857 |
| barre | #1858 |
| rac2 | #1858 |
| cocktails | #1860 |
| haenszel | #1862 |
| secreting | #1863 |
| structural basis | #1864 |
| aggravation | #1864 |
| lacrimal apparatus | #1865 |
| silastic | #1871 |
| rats groups | #1871 |
| immunoadsorption | #1873 |
| inkt | #1874 |
| carries | #1875 |
| major | #1876 |
| cartilages | #1879 |
| subsequent development | #1879 |
| candidate | #1883 |
| antigen humans | #1890 |
| inflammation lung | #1892 |
| polyclonal | #1893 |
| bacterial clearance | #1894 |
| ovalbumin | #1897 |
| cyanogen | #1900 |
| striking | #1902 |
| tcr repertoire | #1903 |
| lymphatics | #1903 |
| complexity | #1905 |
| indicating | #1905 |
| proteins rats | #1907 |
| model rats | #1908 |
| mediated | #1910 |
| gammadelta | #1910 |
| enzyme linked | #1911 |
| cell maturation | #1912 |
| cells neutrophils | #1912 |
| interferon gamma | #1914 |
| erythematosus sle | #1916 |
| chromosome | #1916 |
| totally | #1918 |
| 6 hours | #1920 |
| cartilage tissue | #1923 |
| anti | #1924 |
| 721 | #1924 |
| gαq | #1926 |
| pronounced | #1927 |
| ears | #1929 |
| isoantigens | #1931 |
| bcell receptors | #1933 |
| expression cytokines | #1934 |
| trypanosoma brucei | #1937 |
| animals lymphocytes | #1937 |
| sialyltransferases | #1939 |
| mice receptors | #1940 |
| antigen tcell receptors | #1944 |
| type plasminogen | #1945 |
| predisposition | #1949 |
| prevented | #1950 |
| subclasses | #1950 |
| constituting | #1955 |
| cardiac allografts | #1956 |
| perforin | #1957 |
| snakes | #1957 |
| agp | #1959 |
| mmc | #1962 |
| levels serum | #1967 |
| pinocytosis | #1967 |
| edition | #1967 |
| iga igg | #1967 |
| fcγ receptor | #1969 |
| possibilities | #1969 |
| strong | #1971 |
| intravenous injection | #1972 |
| react | #1975 |
| mip | #1977 |
| stimulations | #1978 |
| carp | #1979 |
| synovial tissues | #1979 |
| inbred cba | #1980 |
| ova | #1980 |
| cd154 | #1982 |
| pregnant rats | #1983 |
| cell clone | #1985 |
| disease pathology | #1985 |
| milder | #1988 |
| spans | #1997 |
| mast cell | #1999 |
| cd18 | #2000 |
| transgenic rats | #2001 |
| microglia activation | #2002 |
| presenting cell | #2006 |
| heteroplasmy | #2007 |
| reverted | #2008 |
| contact dermatitis | #2008 |
| rats effects | #2008 |
| prototypic | #2011 |
| response infection | #2016 |
| abca1 | #2016 |
| barré syndrome | #2018 |
| knockout | #2020 |
| tissue inflammation | #2021 |
| immunoglobulin | #2023 |
| genes | #2025 |
| cell | #2027 |
| mabs | #2028 |
| cytokine secretion | #2028 |
| demyelination | #2030 |
| chord | #2031 |
| tetramers | #2032 |
| c5ar | #2033 |
| beta gene | #2035 |
| conformational epitopes | #2035 |
| mesenteric lymph | #2035 |
| 4 tlr4 | #2041 |
| factor mif | #2041 |
| mab | #2042 |
| diethyldithiocarbamate | #2043 |
| immunomodulatory properties | #2044 |
| sex chromosome | #2045 |
| cell immunity | #2047 |
| oestrogens | #2050 |
| hypergammaglobulinemia | #2050 |
| cell function | #2053 |
| species signal | #2053 |
| castration | #2053 |
| coinciding | #2055 |
| emphysema | #2056 |
| glycosylation humans | #2057 |
| innate inflammation | #2058 |
| increased frequency | #2058 |
| dramatically | #2059 |
| activation complement | #2061 |
| vitro vivo | #2061 |
| accompanied | #2067 |
| genetic differences | #2068 |
| dominant | #2070 |
| contributors | #2071 |
| proteomics analysis | #2072 |
| hyaluronoglucosaminidase | #2072 |
| mdsc | #2076 |
| polyradiculoneuropathy | #2077 |
| mature cells | #2077 |
| respiratory tract | #2079 |
| lysine residues | #2080 |
| antiphospholipid syndrome | #2081 |
| cell depletion | #2082 |
| mice pregnancy | #2083 |
| complement | #2094 |
| methotrexate mtx | #2094 |
| conditional deletion | #2095 |
| lysine | #2096 |
| addressed | #2097 |
| bioreactor | #2100 |
| αβ | #2100 |
| suggested | #2102 |
| led | #2103 |
| evokes | #2103 |
| antigens hla | #2104 |
| patients rheumatoid arthritis | #2105 |
| human chondrocytes | #2110 |
| nose | #2117 |
| lentiviral vectors | #2120 |
| glycan | #2122 |
| pulmonary inflammation | #2122 |
| immune functions | #2126 |
| pad4 | #2127 |
| oxidants | #2129 |
| total igg | #2130 |
| secondary receptors | #2133 |
| inducing | #2136 |
| occurring | #2139 |
| histopathological | #2140 |
| selective estrogen | #2141 |
| target tissues | #2141 |
| dissection | #2142 |
| plasminogen | #2143 |
| transduction lymphocytes | #2145 |
| extracellular calcium | #2146 |
| subphenotypes | #2146 |
| h2d | #2147 |
| bound | #2147 |
| circulating monocytes | #2149 |
| 129 strain mice | #2151 |
| immunohistochemical analysis | #2151 |
| reality | #2153 |
| clinical aspects | #2157 |
| periphery | #2161 |
| major histocompatibility complex | #2162 |
| rheumatoid biomarkers | #2165 |
| late stages | #2165 |
| moabs | #2165 |
| prone | #2169 |
| entire | #2174 |
| syringes | #2176 |
| mimics | #2177 |
| animal model | #2179 |
| immune regulation | #2180 |
| human leukocytes | #2181 |
| psoriatic arthritis | #2184 |
| dynorphins | #2184 |
| dnp | #2185 |
| native | #2188 |
| injury ali | #2200 |
| dss | #2203 |
| lps stimulation | #2204 |
| structural requirements | #2211 |
| molecular pathways | #2213 |
| confirming | #2214 |
| 12th | #2215 |
| interleukin2 | #2216 |
| therapeutic effects | #2216 |
| activation cells | #2217 |
| animal mice mice | #2217 |
| naïve | #2219 |
| regulates | #2220 |
| galactose | #2220 |
| suggesting | #2221 |
| wt mice | #2224 |
| immunoreactivity | #2225 |
| shrna | #2232 |
| mammalian | #2232 |
| neutralized | #2233 |
| governs | #2233 |
| presentation | #2234 |
| accelerates | #2236 |
| autoimmune conditions | #2239 |
| reduced susceptibility | #2239 |
| ctla4 | #2239 |
| lacked | #2240 |
| graft rejection | #2244 |
| inflammatory phenotype | #2248 |
| cholera toxin | #2248 |
| cell priming | #2252 |
| exacerbated | #2253 |
| monoclonal antibodies | #2254 |
| cell receptors | #2256 |
| tcell proliferation | #2261 |
| sjögren | #2263 |
| regulation immune | #2265 |
| involved pathogenesis | #2267 |
| hla | #2269 |
| mph | #2274 |
| progeny | #2274 |
| immunospot | #2278 |
| antigenic | #2279 |
| murine | #2279 |
| mice treatment | #2280 |
| neutrophil apoptosis | #2280 |
| lymph nodes | #2281 |
| dependent | #2284 |
| inflammatory | #2288 |
| immunizations | #2289 |
| homologous | #2292 |
| plasmatic | #2293 |
| histological evaluation | #2296 |
| modified proteins | #2296 |
| determining | #2296 |
| cba mice | #2297 |
| regulatory mechanisms | #2299 |
| knockout mice | #2300 |
| apocynin | #2302 |
| segregating | #2308 |
| infiltrating macrophages | #2309 |
| presentation antigens | #2310 |
| wounding | #2312 |
| drastically | #2315 |
| genetic basis | #2315 |
| il10 | #2317 |
| healthy donors | #2318 |
| hydroxylation | #2320 |
| barré | #2320 |
| inflammatory mechanisms | #2321 |
| sera | #2325 |
| throughput nucleotide | #2325 |
| p00002 | #2326 |
| antigens histocompatibility | #2328 |
| wild | #2329 |
| cells induced | #2331 |
| demyelinating disease | #2336 |
| n24 | #2338 |
| lewis | #2345 |
| gk | #2347 |
| receptor α | #2353 |
| reciprocal | #2353 |
| ethylenes | #2358 |
| specific igg | #2358 |
| illness stress | #2361 |
| monosaccharide | #2363 |
| hyaline | #2364 |
| biological agents | #2365 |
| acrylamides | #2366 |
| sex hormone | #2366 |
| lectins type | #2366 |
| degradative | #2367 |
| phosphoproteins | #2369 |
| wf | #2374 |
| eliminated | #2374 |
| lymphotoxin | #2375 |
| immunogens | #2375 |
| peptides derived | #2375 |
| treatment rheumatoid arthritis | #2376 |
| genetic selection | #2376 |
| cxcl1 | #2382 |
| amps | #2382 |
| antinociceptive | #2383 |
| nonalcoholic steatohepatitis | #2384 |
| mouse model | #2386 |
| contaminating | #2386 |
| sidechain | #2391 |
| phenotypes | #2391 |
| receptor transforming | #2392 |
| syngeneic | #2394 |
| knock | #2394 |
| septic arthritis | #2396 |
| systemic lupus erythematosus | #2397 |
| hla genes | #2398 |
| p38 mapk | #2400 |
| inflammatory reaction | #2400 |
| serum autoantibodies | #2408 |
| increased incidence | #2409 |
| mice models | #2411 |
| equina | #2413 |
| intraperitoneal injections | #2418 |
| genetic receptors | #2420 |
| genetic studies | #2420 |
| structure analysis | #2423 |
| realtime pcr | #2424 |
| mice expression | #2426 |
| tlr2 tlr4 | #2429 |
| lentivirus | #2430 |
| suggestive evidence | #2430 |
| acute phase | #2430 |
| unmodified | #2431 |
| cytokines chemokines | #2432 |
| cko | #2432 |
| collagen fibrils | #2432 |
| lymphocytes cd4 | #2432 |
| cells antigens | #2434 |
| agents arthritis | #2440 |
| early phases | #2440 |
| inflammatory activity | #2442 |
| mice multiple | #2446 |
| genetic predisposition | #2449 |
| b6 | #2450 |
| receptors complement | #2450 |
| 551 | #2451 |
| lipoxin | #2458 |
| inflammatory demyelinating | #2459 |
| animal disease models | #2463 |
| exemplified | #2466 |
| idiotype | #2468 |
| antibody responses | #2469 |
| strains | #2471 |
| administration intranasal | #2473 |
| animals cd4 | #2473 |
| additively | #2477 |
| translational modifications | #2477 |
| axotomy | #2477 |
| class | #2480 |
| quantitative | #2480 |
| regulatory | #2487 |
| animal experiments | #2492 |
| specific | #2493 |
| organ specific | #2497 |
| transforming growth factor | #2498 |
| negative feedback | #2501 |
| albeit | #2502 |
| alleviated | #2502 |
| cystatin | #2504 |
| mhc class genes | #2505 |
| multiparous | #2511 |
| transgenic microscopy | #2512 |
| bystander | #2515 |
| il17a | #2516 |
| ppd | #2518 |
| dichotomous | #2519 |
| chemokines cytokines | #2519 |
| contribute | #2522 |
| naturally | #2523 |
| treatment rheumatoid | #2524 |
| hyperostosis | #2525 |
| amiloride | #2526 |
| nod mice | #2527 |
| microsatellite markers | #2534 |
| pathogenicity | #2534 |
| infiltration | #2541 |
| resemblance | #2542 |
| undertaken | #2545 |
| postmenopausal osteoporosis | #2546 |
| proteolipid | #2552 |
| dapsone | #2560 |
| similarities | #2561 |
| igm iga | #2562 |
| kynurenine | #2563 |
| plp | #2563 |
| deprotection | #2564 |
| nox | #2566 |
| succeeded | #2567 |
| transferring | #2573 |
| fine | #2573 |
| passive | #2574 |
| rp patients | #2575 |
| dying cells | #2575 |
| tumor models | #2576 |
| incomplete | #2577 |
| quantitative traits | #2577 |
| complementarity | #2580 |
| peptides | #2585 |
| chick | #2589 |
| calgranulin | #2590 |
| peritoneal macrophages | #2591 |
| antibody levels | #2591 |
| misinterpretation | #2593 |
| interferon type | #2595 |
| sex hormones | #2597 |
| fibrinolysin | #2598 |
| antiinflammatory properties | #2603 |
| onset | #2603 |
| unlinked | #2605 |
| zymosan | #2610 |
| induction | #2611 |
| postulated | #2614 |
| exert | #2615 |
| antimicrobial peptides | #2618 |
| surprising | #2621 |
| interferon beta | #2623 |
| proteolipid protein | #2632 |
| ifn α | #2634 |
| single chain | #2639 |
| sialoglycoproteins | #2643 |
| plasmin | #2647 |
| unable | #2649 |
| asparagine | #2651 |
| tlr9 | #2653 |
| antigens | #2656 |
| disease genotype | #2658 |
| hla antigens | #2659 |
| submandibular gland | #2663 |
| functional impact | #2663 |
| antinuclear | #2663 |
| eluted | #2666 |
| osteonectin | #2667 |
| invading | #2670 |
| n22 | #2670 |
| brucei | #2670 |
| microliters | #2671 |
| biological pathways | #2673 |
| bordetella | #2680 |
| new therapeutic strategies | #2683 |
| ease | #2683 |
| leukocyte antigen | #2688 |
| th1 | #2690 |
| acd | #2696 |
| day treatment | #2697 |
| allelic | #2697 |
| igg3 | #2698 |
| genetic variations | #2698 |
| animal encephalomyelitis | #2702 |
| neutrophils macrophages | #2703 |
| gamma mice | #2711 |
| peptides protein | #2714 |
| γδ | #2716 |
| treatment mice | #2717 |
| rat model | #2718 |
| human complement | #2725 |
| patients anti | #2727 |
| polymorphic | #2729 |
| lymphocyte subsets | #2730 |
| ifngamma | #2730 |
| biased | #2730 |
| post partum | #2731 |
| lamina propria | #2735 |
| fumigatus | #2735 |
| serum anti | #2738 |
| vav | #2743 |
| fragment | #2743 |
| mice exposed | #2750 |
| leucocyte | #2754 |
| resemble | #2762 |
| bromocriptine | #2768 |
| transgenic mouse | #2772 |
| depleting | #2773 |
| human leukocyte | #2774 |
| tyrosine phosphatase | #2774 |
| qtls | #2777 |
| strong evidence | #2777 |
| cytolysis | #2777 |
| enigmatic | #2780 |
| detectable | #2780 |
| iga igm | #2780 |
| genetically | #2782 |
| explanation | #2785 |
| finemapping | #2785 |
| alcoholic steatohepatitis | #2786 |
| treated rats | #2786 |
| intraperitoneal | #2787 |
| tolerogenic | #2789 |
| bone cartilage | #2790 |
| sjogren syndrome | #2791 |
| inbred mrl | #2798 |
| current review | #2798 |
| animal encephalomyelitis autoimmune | #2799 |
| hk | #2801 |
| callithrix | #2804 |
| spleen | #2812 |
| 261 | #2813 |
| neuropathology | #2817 |
| genistein | #2819 |
| alpha | #2821 |
| lack | #2822 |
| activated macrophages | #2825 |
| hyaluronidase | #2830 |
| conventionally | #2831 |
| narrowed | #2832 |
| prl | #2835 |
| olive oil | #2838 |
| demyelinating diseases | #2841 |
| resistant | #2842 |
| hallmark | #2843 |
| glucose uptake | #2846 |
| beta receptor | #2847 |
| beta tgf | #2848 |
| bind | #2848 |
| th1 response | #2852 |
| demyelinating | #2852 |
| polymorphonuclear leukocytes | #2856 |
| phases | #2858 |
| dependent cell | #2859 |
| treg cell | #2859 |
| antibodies antinuclear | #2864 |
| polymorphonuclear | #2864 |
| interleukin receptors | #2864 |
| splenocytes | #2865 |
| characterising | #2865 |
| rats inbred strains | #2869 |
| interleukin33 | #2869 |
| cyanogen bromide | #2874 |
| disease characterized | #2875 |
| guillain | #2875 |
| cells cd8 | #2881 |
| periodontitis | #2882 |
| parvalbumin | #2884 |
| reveals | #2885 |
| clone cells | #2885 |
| exacerbate | #2888 |
| igg iga | #2891 |
| migration inhibitory | #2892 |
| costimulatory molecules | #2895 |
| tgfbeta | #2895 |
| innate immune responses | #2896 |
| dce | #2896 |
| antigens class humans | #2898 |
| dq | #2905 |
| antigen hla | #2907 |
| atp synthase | #2909 |
| enhancement | #2911 |
| linked immunosorbent | #2911 |
| studying | #2918 |
| diseases disease | #2920 |
| shortly | #2920 |
| ergometry | #2921 |
| allogenic | #2921 |
| steadily | #2925 |
| vaccine development | #2925 |
| type lectin | #2926 |
| obvious | #2927 |
| ifn γ | #2931 |
| autoimmune disorder | #2935 |
| dextran | #2939 |
| female flow | #2943 |
| injections | #2944 |
| expression macrophages | #2944 |
| ifn gamma | #2945 |
| proteins peptides | #2946 |
| cd68 | #2947 |
| patients antibodies | #2949 |
| interleukin4 | #2950 |
| cells immune | #2955 |
| eventually | #2956 |
| toll receptor | #2961 |
| cell infiltration | #2962 |
| expressions | #2963 |
| calcium ions | #2964 |
| qtl | #2965 |
| histocytochemistry | #2967 |
| suppressed | #2967 |
| hnrnp | #2980 |
| genetics | #2982 |
| ifn response | #2985 |
| cepacia | #2988 |
| antirheumatic agents | #2993 |
| elusive | #2994 |
| hdac | #2995 |
| thymus gland | #2997 |
| swedish | #2998 |
| respective | #3000 |
| lineage commitment | #3003 |
| indoleamine | #3009 |
| time points | #3009 |
| cells female | #3010 |
| therapeutic strategies | #3014 |
| innate | #3014 |
| illustrating | #3017 |
| anthrax | #3019 |
| interferon ifn | #3020 |
| wild type mice | #3026 |
| defensins | #3027 |
| vdr | #3031 |
| accelerating | #3033 |
| lung inflammation | #3033 |
| macrophage migration | #3036 |
| endo | #3039 |
| t‐cell | #3039 |
| synthetic peptides | #3040 |
| appearance | #3045 |
| quinoxalines | #3047 |
| cd8 | #3048 |
| immunomodulator | #3050 |
| model mice | #3051 |
| longterm treatment | #3052 |
| twin studies | #3053 |
| complex traits | #3055 |
| ppt | #3058 |
| interleukin23 | #3061 |
| profound | #3067 |
| sjögren syndrome | #3069 |
| prevailing | #3073 |
| salivary | #3076 |
| mediated immune | #3077 |
| role cell | #3078 |
| beta | #3080 |
| destruction | #3082 |
| model human | #3083 |
| irrespective | #3083 |
| gene expression profiling | #3086 |
| impairing | #3087 |
| nodes | #3091 |
| glutamic | #3092 |
| inhibitory factors | #3092 |
| parvalbumins | #3093 |
| inbred balb mice | #3098 |
| receptor 4 | #3098 |
| genetic deletion | #3100 |
| detailed description | #3101 |
| postpartum period | #3107 |
| germinal | #3108 |
| antirheumatic | #3109 |
| staphylococcus | #3114 |
| type wt | #3120 |
| neuronal cell | #3123 |
| effects treatment | #3124 |
| suspect | #3127 |
| igm igg | #3130 |
| specificity | #3131 |
| glycans | #3136 |
| monoclonal antibody | #3137 |
| receptors tlrs | #3142 |
| psoriasis | #3142 |
| logarithm | #3146 |
| cd4 cd8 | #3147 |
| preformed | #3151 |
| immune systems | #3152 |
| possibility | #3153 |
| cell activity | #3154 |
| molecule | #3155 |
| propria | #3155 |
| cba | #3164 |
| posttranslational modification | #3167 |
| sjogren | #3171 |
| massively | #3172 |
| accumulated | #3180 |
| cell specific | #3185 |
| precedes | #3185 |
| blockage | #3187 |
| tissue specific | #3191 |
| dynorphin | #3191 |
| pertussis toxin | #3192 |
| cells rats | #3193 |
| adult mice | #3193 |
| keratinocytes | #3194 |
| unravel | #3199 |
| reactivity | #3202 |
| helper | #3204 |
| modified | #3205 |
| ovx | #3208 |
| serum levels | #3210 |
| erbeta | #3211 |
| antiinflammatory | #3211 |
| phagosomes | #3212 |
| nitroarginine | #3212 |
| abs | #3216 |
| cells animals | #3224 |
| publication arthritis | #3224 |
| gpi | #3226 |
| chromosome 1 | #3237 |
| class iii | #3239 |
| clarified | #3242 |
| permitting | #3246 |
| collagenous | #3247 |
| macrophage | #3247 |
| lod score | #3252 |
| bacterial antibodies | #3254 |
| backbone | #3257 |
| nonalcoholic steatohepatitis nash | #3260 |
| female gonadal | #3263 |
| treated animals | #3264 |
| acrylic | #3265 |
| chronic inflammatory | #3267 |
| meps | #3270 |
| immunosorbent assay | #3272 |
| implicate | #3274 |
| inflammation interferon | #3278 |
| proteoglycans | #3278 |
| sch | #3280 |
| arthralgia | #3283 |
| nephritis | #3283 |
| gonadal steroid | #3284 |
| normal rats | #3287 |
| abundantly | #3289 |
| igg1 | #3298 |
| models genetic | #3298 |
| immunoglobulin heavy | #3303 |
| erythematosus | #3305 |
| adaptations | #3309 |
| proteins mice | #3309 |
| characterise | #3314 |
| elicits | #3314 |
| blastocyst | #3315 |
| nociception | #3316 |
| absence | #3318 |
| diseases autoimmune | #3321 |
| publication animals | #3325 |
| beta receptors | #3325 |
| mice protein | #3327 |
| anticardiolipin | #3328 |
| confirmed | #3329 |
| gc cells | #3331 |
| serologically | #3332 |
| suppression | #3338 |
| regional lymph nodes | #3341 |
| macromolecular | #3343 |
| clinical phenotypes | #3345 |
| cd62l | #3353 |
| influenced | #3355 |
| trypanosoma | #3358 |
| akr | #3371 |
| vitamin d3 | #3373 |
| editor | #3377 |
| antinuclear antibodies | #3382 |
| sle | #3384 |
| genetic polymorphisms | #3385 |
| ovariectomy | #3386 |
| levels inflammatory | #3395 |
| macroporous | #3395 |
| mechanistic studies | #3395 |
| explains | #3396 |
| mount | #3397 |
| tubercle | #3402 |
| somatic mutations | #3406 |
| receptors transforming | #3410 |
| early phase | #3413 |
| haptens | #3413 |
| positions | #3418 |
| nk cells | #3419 |
| erythematosus systemic | #3419 |
| reacts | #3421 |
| neutrophil activation | #3421 |
| penetrant | #3425 |
| reply | #3432 |
| proving | #3434 |
| receptor type | #3434 |
| dendritic cells | #3436 |
| serum igg | #3437 |
| alleles | #3440 |
| permitted | #3441 |
| cauda | #3443 |
| 4 months | #3444 |
| injection | #3445 |
| superoxide production | #3446 |
| protein tyrosine | #3447 |
| obscure | #3448 |
| humans immunization | #3448 |
| increased sensitivity | #3449 |
| antimicrobial peptide | #3451 |
| diffusely | #3459 |
| characterised | #3469 |
| patients sle | #3470 |
| h5n1 | #3470 |
| flow cytometry | #3476 |
| modifying | #3477 |
| multimers | #3491 |
| inflammatory mediators | #3491 |
| proteoglycan | #3496 |
| successes | #3497 |
| il21 | #3500 |
| ly | #3501 |
| elucidate | #3503 |
| developed | #3505 |
| classical | #3505 |
| protein processing | #3506 |
| salivary gland | #3507 |
| publication animals animals | #3509 |
| neutrophilic | #3510 |
| pathobiology | #3511 |
| pathological features | #3517 |
| specific cd4 | #3519 |
| globulins | #3526 |
| 267 | #3528 |
| deoxyguanosine | #3528 |
| germline | #3529 |
| phenotypically | #3529 |
| predispose | #3532 |
| lacrimal | #3534 |
| micrometer | #3534 |
| transglutaminases | #3535 |
| radiolabelled | #3539 |
| regulatory cells tregs | #3540 |
| cyclosporins | #3540 |
| mbq | #3541 |
| dominantly | #3548 |
| histological examination | #3554 |
| investigate | #3559 |
| infections staphylococcus | #3561 |
| mast cells | #3563 |
| cultured disease models | #3568 |
| socs1 | #3570 |
| humans interferon | #3571 |
| histological | #3574 |
| homogenate | #3576 |
| interesting | #3580 |
| gamma | #3580 |
| negative patients | #3583 |
| artificially | #3584 |
| role development | #3585 |
| cytolytic | #3589 |
| hindlimb | #3590 |
| il33 | #3593 |
| compared wild | #3597 |
| triggered | #3597 |
| usage | #3601 |
| immunohistochemical staining | #3608 |
| upregulation | #3612 |
| previous findings | #3617 |
| intranasal | #3619 |
| tcr | #3622 |
| cleave | #3624 |
| potential roles | #3624 |
| genetic association | #3629 |
| rp | #3633 |
| attenuate | #3633 |
| mapping chromosomes | #3634 |
| genetic | #3637 |
| valuable | #3637 |
| adhere | #3638 |
| today | #3645 |
| cultured culture media | #3651 |
| allele | #3655 |
| gene deletion | #3657 |
| enhances | #3657 |
| cd4 positive | #3659 |
| exerts | #3663 |
| tolllike receptor | #3665 |
| clinical severity | #3665 |
| luminol | #3667 |
| 95 association | #3671 |
| cd44 | #3678 |
| il23 | #3690 |
| tgf beta | #3691 |
| female genes | #3694 |
| fibronectins | #3697 |
| toll receptors | #3700 |
| igg igm | #3702 |
| heavy chain | #3705 |
| synovitis | #3708 |
| publication animals humans | #3708 |
| cyclohexanecarboxylic | #3709 |
| aggregated | #3717 |
| inbred nod mice | #3730 |
| systemic male | #3735 |
| sequence deletion | #3740 |
| dh | #3742 |
| 378 | #3746 |
| cells produce | #3750 |
| therapeutic benefit | #3752 |
| macrophage cell | #3753 |
| mediate | #3754 |
| contributing | #3754 |
| complement c4 | #3758 |
| immunochemistry | #3759 |
| type 4 | #3763 |
| biomedicine | #3763 |
| lymphocytes tumor | #3766 |
| epitope mapping | #3767 |
| identification | #3771 |
| partum | #3772 |
| mtdna | #3773 |
| d3 | #3775 |
| th17 | #3786 |
| jakob | #3786 |
| reduced expression | #3787 |
| diphtheria | #3803 |
| immunohistochemical | #3805 |
| hind | #3808 |
| skewed | #3820 |
| integrins | #3822 |
| superoxide | #3822 |
| ribonucleoprotein | #3823 |
| new opportunities | #3831 |
| models immunological | #3834 |
| encompassing | #3838 |
| puerperal | #3839 |
| mmp9 expression | #3839 |
| noncoding rna | #3840 |
| unclear | #3847 |
| amelioration | #3854 |
| postulate | #3858 |
| il17 | #3858 |
| identical | #3859 |
| housed | #3861 |
| genetic dna | #3867 |
| cells treg | #3873 |
| genetic promoter regions | #3880 |
| kinase2 | #3887 |
| glycoside | #3887 |
| prominent | #3887 |
| reacting | #3888 |
| dinucleotide | #3894 |
| decreased levels | #3896 |
| synoviocytes | #3900 |
| microsatellite repeats | #3903 |
| superoxides | #3904 |
| dominate | #3907 |
| recognition | #3912 |
| endogenous | #3918 |
| established | #3919 |
| animal studies | #3926 |
| rats messenger | #3931 |
| hladr | #3934 |
| immunophenotyping | #3941 |
| manifestations | #3942 |
| nerves | #3944 |
| toes | #3946 |
| neutrophils | #3947 |
| affect | #3947 |
| polymorphism | #3949 |
| gingivalis | #3957 |
| nets | #3958 |
| mechanisms involved | #3961 |
| involvement | #3973 |
| disrupted | #3975 |
| associate | #3975 |
| 297 | #3982 |
| adult arthritis | #3988 |
| stimulate | #3992 |
| heavy chains | #3992 |
| ifn β | #3999 |
| question | #3999 |
| broader | #4001 |
| patients osteoarthritis | #4009 |
| elevated levels | #4012 |
| sinuses | #4016 |
| chondrocytes | #4018 |
| superoxide dismutase | #4018 |
| individual patients | #4028 |
| ags | #4029 |
| inflammatory processes | #4033 |
| influences | #4034 |
| higher expression | #4034 |
| efficiently | #4050 |
| glycoproteins | #4054 |
| hla alleles | #4059 |
| expression cell | #4063 |
| conferred | #4065 |
| c1q | #4069 |
| produce | #4072 |
| fragments | #4072 |
| hinge | #4074 |
| eliciting | #4075 |
| stat4 | #4076 |
| requirement | #4076 |
| plethora | #4077 |
| glycoprotein | #4077 |
| contrast | #4085 |
| llc | #4089 |
| upregulated | #4090 |
| systemic lupus | #4092 |
| expression type | #4098 |
| fine mapping | #4102 |
| atpases | #4103 |
| leukocyte | #4105 |
| glands | #4107 |
| conferring | #4108 |
| neutrophil | #4113 |
| creutzfeldt | #4115 |
| current concepts | #4116 |
| gelatin | #4120 |
| absent | #4121 |
| therapy genetic | #4122 |
| sclerosis animals | #4124 |
| regulatory cells | #4126 |
| drives | #4126 |
| protect | #4131 |
| mycobacterial | #4133 |
| promoter polymorphism | #4137 |
| stat1 | #4144 |
| functionally | #4147 |
| articular cartilage | #4161 |
| lupus erythematosus | #4162 |
| hla dq | #4165 |
| motor neurons | #4166 |
| polygenic | #4169 |
| placenta pregnancy | #4173 |
| tumour necrosis factor | #4177 |
| stimulatory | #4178 |
| early pregnancy | #4180 |
| immunology | #4183 |
| effector | #4184 |
| systemic disease | #4187 |
| superoxide anion | #4191 |
| infiltrating lymphocytes | #4192 |
| spe | #4193 |
| monocyte | #4201 |
| breeders | #4203 |
| enterotoxin | #4206 |
| porphyromonas gingivalis | #4207 |
| ici | #4207 |
| beads | #4213 |
| antigens cd8 | #4214 |
| animal drug | #4222 |
| depletion | #4223 |
| cytometric analysis | #4224 |
| parathyroid | #4225 |
| long noncoding | #4227 |
| mutant | #4232 |
| inbred balb | #4239 |
| treated mice | #4242 |
| macrophage infiltration | #4244 |
| kidneys | #4244 |
| granulocytic | #4249 |
| chondrosarcoma | #4250 |
| continuously | #4250 |
| witnessed | #4252 |
| conjunction | #4256 |
| immunological | #4257 |
| immunity innate | #4258 |
| bout | #4260 |
| igh | #4262 |
| lymphoid | #4264 |
| cell repertoire | #4268 |
| day1 | #4270 |
| denominator | #4270 |
| complex | #4272 |
| suggestive | #4276 |
| dermatitis | #4285 |
| experimental mice | #4285 |
| clues | #4286 |
| gene targeting | #4290 |
| cd4 | #4291 |
| balb | #4292 |
| disease genetic | #4294 |
| repertoire | #4302 |
| provocation | #4303 |
| molecular modeling | #4303 |
| sciatic | #4307 |
| shares | #4307 |
| tuberculin | #4308 |
| positive cells | #4309 |
| functional role | #4310 |
| cell populations | #4317 |
| receptors interleukin2 | #4317 |
| suppressive effects | #4320 |
| hydroxy2deoxyguanosine | #4331 |
| pparγ | #4350 |
| new insight | #4353 |
| trypanosomiasis | #4358 |
| glutamine | #4364 |
| fungal infection | #4364 |
| peritonitis | #4365 |
| wildtype | #4370 |
| immunoassays | #4373 |
| swelling | #4375 |
| caused | #4381 |
| penetrance | #4381 |
| cell clones | #4396 |
| disease chronic | #4402 |
| mucous | #4402 |
| prevents | #4414 |
| restored | #4417 |
| joint | #4420 |
| modulating | #4426 |
| receptor beta | #4434 |
| closer | #4434 |
| disturbed | #4434 |
| buprenorphine | #4435 |
| model systems | #4443 |
| early | #4453 |
| acute chronic | #4454 |
| aspartic | #4458 |
| parathyroid glands | #4470 |
| confers | #4473 |
| inflammatory pain | #4477 |
| disease duration | #4480 |
| thymocytes | #4481 |
| calmette | #4488 |
| strains rats | #4489 |
| synthase type | #4490 |
| treg | #4493 |
| neutralizing antibodies | #4503 |
| thickened | #4503 |
| human cell | #4505 |
| genetic loci | #4510 |
| extensively | #4516 |
| colitis | #4526 |
| derived cells | #4532 |
| therapeutic implications | #4534 |
| immunotoxins | #4535 |
| beta cells | #4539 |
| cells th2 | #4541 |
| challenged | #4542 |
| lymphocytes cd8 | #4545 |
| 101 | #4546 |
| cytotoxic lymphocytes | #4547 |
| articular chondrocytes | #4553 |
| interleukin5 | #4558 |
| messenger rats rats | #4564 |
| beta cell | #4566 |
| extracellular ca2 | #4576 |
| homing | #4576 |
| hydrolases | #4577 |
| fasl | #4578 |
| cell separation | #4580 |
| proliferative | #4581 |
| neurosecretory | #4585 |
| immunologic | #4592 |
| production inflammatory | #4593 |
| suggests | #4596 |
| inbred shr rats | #4607 |
| modulatory | #4608 |
| interact | #4613 |
| igg antibody | #4613 |
| ros levels | #4613 |
| confer | #4616 |
| depleted | #4639 |
| conditioned medium | #4642 |
| environmental factors | #4643 |
| fashion | #4658 |
| positive selection | #4658 |
| porphyromonas | #4666 |
| visualized | #4667 |
| endorphins | #4669 |
| implicated | #4670 |
| determinant | #4675 |
| causing | #4678 |
| chains | #4681 |
| langerhans | #4681 |
| monocytes macrophages | #4683 |
| animals antigens | #4693 |
| 259 | #4696 |
| female rats | #4699 |
| protecting | #4707 |
| lymph | #4707 |
| inherited | #4709 |
| defined | #4710 |
| destabilization | #4716 |
| facs | #4718 |
| human studies | #4720 |
| orthomyxoviridae infections | #4725 |
| humans inflammation | #4729 |
| cell population | #4734 |
| positive patients | #4736 |
| α1 | #4739 |
| clone | #4741 |
| mediating | #4744 |
| factor 88 | #4750 |
| panel | #4753 |
| gout | #4757 |
| new drugs | #4764 |
| histopathology | #4767 |
| orchiectomy | #4773 |
| cellular localization | #4775 |
| alveolar macrophages | #4776 |
| e4 | #4776 |
| purified | #4778 |
| differing | #4793 |
| eralpha | #4798 |
| male membrane | #4800 |
| rodents | #4801 |
| osteoclastogenesis | #4809 |
| displaying | #4809 |
| hydrolyzed | #4815 |
| tumor antigens | #4816 |
| effector cells | #4819 |
| cd4 cd8 cells | #4821 |
| paw | #4821 |
| cytokines | #4821 |
| cholera | #4822 |
| distinct | #4831 |
| coincides | #4833 |
| litters | #4843 |
| stress rats | #4846 |
| tissue injury | #4847 |
| rats receptors | #4850 |
| matrix ecm | #4852 |
| interferon γ | #4852 |
| stemness | #4860 |
| articular | #4861 |
| venules | #4863 |
| infiltrate | #4868 |
| th17 cells | #4872 |
| tlr2 | #4880 |
| hpa axis | #4882 |
| ifn | #4885 |
| exocrine | #4888 |
| multifactorial | #4889 |
| 116 | #4891 |
| lod | #4892 |
| specific binding | #4893 |
| ige | #4896 |
| humoral immunity | #4897 |
| induced lung | #4899 |
| preimplantation | #4905 |
| essential roles | #4915 |
| discuss | #4916 |
| immunosorbent | #4917 |
| correlating | #4923 |
| interleukins | #4927 |
| deacetylases | #4928 |
| closely | #4932 |
| timepoints | #4940 |
| humans multiple | #4945 |
| deficiency | #4946 |
| disease process | #4962 |
| naturally occurring | #4962 |
| monitored | #4964 |
| elicit | #4966 |
| forelimb | #4967 |
| contradictory | #4975 |
| point mutation | #4976 |
| cell antigen | #4990 |
| understand | #4995 |
| male rats | #4998 |
| kupffer cells | #5001 |
| thymic | #5003 |
| innate immune | #5004 |
| eosinophilia | #5004 |
| modulates | #5011 |
| isotype | #5012 |
| wt | #5012 |
| upa | #5014 |
| opened | #5018 |
| sh3 | #5019 |
| granuloma | #5021 |
| gland | #5024 |
| enhancing | #5026 |
| expand | #5026 |
| vimentin | #5026 |
| poliomyelitis | #5041 |
| explaining | #5042 |
| il5 | #5044 |
| diamines | #5048 |
| heterozygous | #5049 |
| coculture techniques | #5051 |
| cd8 cells | #5055 |
| caveolin | #5065 |
| th1 cells | #5067 |
| linkage | #5067 |
| phospholipid | #5071 |
| arthritis juvenile | #5072 |
| sitedirected mutagenesis | #5076 |
| molecular basis | #5084 |
| cells blood | #5085 |
| bcg | #5086 |
| alum | #5087 |
| autologous | #5087 |
| olive | #5088 |
| new treatment | #5089 |
| multiple sclerosis | #5098 |
| master regulator | #5100 |
| osteopontin | #5109 |
| aged anti | #5110 |
| elispot | #5112 |
| occurs | #5112 |
| sulfasalazine | #5115 |
| isoantibodies | #5120 |
| dq antigens | #5134 |
| contributes | #5139 |
| lesser | #5145 |
| traditionally | #5148 |
| cytosolic | #5152 |
| epidermis | #5158 |
| connection | #5165 |
| cytokines female | #5170 |
| titrated | #5171 |
| preceded | #5175 |
| antigen receptor | #5178 |
| lymphocytes cytotoxic | #5179 |
| binding | #5185 |
| sex characteristics | #5186 |
| transfer | #5187 |
| polymorphism single | #5188 |
| phenotypic | #5191 |
| complement proteins | #5192 |
| molecular level | #5196 |
| ovariectomized | #5210 |
| popliteal | #5224 |
| ers | #5235 |
| beta2 | #5238 |
| serves | #5238 |
| chimeric | #5241 |
| immunosuppressive | #5246 |
| epidermal | #5250 |
| cognate | #5258 |
| mucus | #5258 |
| cd86 | #5261 |
| tested | #5262 |
| deleterious effects | #5266 |
| progenitors | #5270 |
| costimulation | #5275 |
| osteoclast | #5277 |
| detects | #5277 |
| erosion | #5278 |
| therapeutic intervention | #5280 |
| prolactin | #5280 |
| maternally | #5289 |
| gels | #5292 |
| leu | #5294 |
| plasmapheresis | #5298 |
| clinical findings | #5299 |
| drug humans | #5301 |
| neutralization | #5301 |
| key component | #5301 |
| amino | #5310 |
| staphylococcus aureus | #5312 |
| suggestion | #5312 |
| anhydrases | #5315 |
| manner | #5320 |
| c57bl 6j | #5320 |
| spontaneous | #5321 |
| lipopolysaccharides macrophages | #5345 |
| genetic mapping | #5348 |
| ketoglutarate | #5350 |
| opposing | #5352 |
| proinflammatory | #5365 |
| clathrin | #5369 |
| multiplexed | #5371 |
| glomerulonephritis | #5377 |
| modifies | #5379 |
| cultured human | #5386 |
| expansion | #5387 |
| il1α | #5391 |
| tolllike receptors | #5397 |
| oxidation reduction | #5398 |
| new strategies | #5401 |
| mice molecular | #5402 |
| positive lymphocytes | #5402 |
| tnf α | #5411 |
| epigenetic mechanisms | #5417 |
| antiinflammatory agents | #5417 |
| adversely | #5418 |
| activation | #5420 |
| fulvestrant | #5420 |
| dendritic | #5428 |
| antigens surface | #5429 |
| compartments | #5429 |
| signaling molecules | #5432 |
| mif | #5457 |
| cell culture | #5458 |
| wide spectrum | #5473 |
| sideeffects | #5478 |
| multitude | #5482 |
| located | #5499 |
| immunoglobulins | #5500 |
| reproduced | #5507 |
| histological analysis | #5507 |
| lactating | #5515 |
| cytotoxic | #5519 |
| cytokines humans | #5525 |
| balb mice | #5542 |
| therapeutic | #5547 |
| thymus | #5551 |
| immunosuppressive agents | #5559 |
| sexual dimorphism | #5560 |
| pv | #5560 |
| nociceptive | #5565 |
| redox | #5572 |
| cell expansion | #5578 |
| acute lung | #5583 |
| t1d | #5585 |
| percentage | #5588 |
| allergic reactions | #5592 |
| typed | #5596 |
| lipopolysaccharide lps | #5598 |
| potently | #5600 |
| acute lung injury | #5603 |
| oxidase activity | #5613 |
| control animals | #5614 |
| structural homology | #5616 |
| sequence amino | #5621 |
| synthases | #5633 |
| biotinylation | #5642 |
| bead | #5645 |
| pemphigus | #5649 |
| urgent | #5650 |
| type ifn | #5655 |
| proliferative responses | #5658 |
| abolished | #5660 |
| explants | #5660 |
| regarded | #5663 |
| 198 | #5671 |
| directing | #5676 |
| lung mice | #5677 |
| heterotrimeric | #5684 |
| numbers | #5685 |
| antioxidant defense | #5685 |
| aetiology | #5687 |
| triggers | #5689 |
| keratins | #5695 |
| progression disease | #5697 |
| cytokine expression | #5697 |
| skeletal muscle | #5698 |
| experimental animals | #5700 |
| immune mediated | #5710 |
| avenues | #5715 |
| effective treatments | #5735 |
| altogether | #5737 |
| variable | #5759 |
| integrases | #5760 |
| hfd | #5762 |
| ecm | #5776 |
| mechanisms | #5794 |
| mast | #5802 |
| frozen | #5808 |
| b16 | #5808 |
| linking | #5808 |
| inflammatory disorders | #5809 |
| diabetes t1d | #5814 |
| allergic | #5820 |
| splenic | #5829 |
| bal | #5830 |
| hampered | #5832 |
| toxoid | #5835 |
| earliest | #5837 |
| key regulators | #5844 |
| gabapentin | #5847 |
| type receptors | #5850 |
| large proportion | #5851 |
| proteinases | #5862 |
| cfa | #5868 |
| stronger | #5871 |
| disease genotype humans | #5872 |
| hyaluronan receptors | #5875 |
| deleted | #5875 |
| vitro experiments | #5880 |
| microtomography | #5882 |
| single cells | #5896 |
| evidence role | #5898 |
| modulation | #5900 |
| ace2 | #5917 |
| standardization | #5918 |
| abp | #5919 |
| synthetic | #5920 |
| bronchoalveolar lavage fluid | #5925 |
| low doses | #5925 |
| ics | #5932 |
| subclass | #5941 |
| identifying | #5941 |
| depend | #5947 |
| genomic regions | #5947 |
| explain | #5951 |
| interfere | #5953 |
| biobank | #5960 |
| cytokine production | #5962 |
| expression humans | #5965 |
| nerve regeneration | #5966 |
| factor 1 | #5968 |
| avidin | #5970 |
| foxp3 | #5975 |
| costimulatory | #5977 |
| clarify | #5980 |
| symptom onset | #5983 |
| denaturation | #5986 |
| inability | #5988 |
| knee joint | #5990 |
| eosinophils | #5991 |
| cell subset | #6000 |
| immunity | #6010 |
| glyburide | #6010 |
| 88 | #6014 |
| tetanus | #6019 |
| stress induced | #6022 |
| consisting | #6023 |
| fluorescent dyes | #6044 |
| cnvs | #6045 |
| stimulated | #6056 |
| nih | #6065 |
| igm | #6073 |
| cleared | #6074 |
| tumor infiltrating | #6074 |
| laminin | #6075 |
| genetic therapy | #6077 |
| relapsing remitting | #6083 |
| sle patients | #6089 |
| responsible | #6091 |
| undertook | #6097 |
| messengers | #6100 |
| cages | #6103 |
| stat6 | #6105 |
| ligated | #6107 |
| bone diseases | #6115 |
| uncoupling | #6115 |
| telomeric | #6122 |
| infection mice | #6127 |
| unique | #6140 |
| replacing | #6149 |
| plasma cells | #6150 |
| lowers | #6156 |
| inguinal | #6166 |
| responses | #6171 |
| susceptibility gene | #6171 |
| prophylactic | #6183 |
| genomewide association studies | #6193 |
| instances | #6210 |
| cell functions | #6210 |
| models human | #6217 |
| interferon | #6220 |
| translation | #6222 |
| humans lupus | #6235 |
| characterized | #6236 |
| progesterone | #6253 |
| introduction | #6260 |
| cell type | #6265 |
| exclusively | #6269 |
| protective | #6270 |
| microarray | #6272 |
| serum concentration | #6278 |
| sexes | #6280 |
| immune cell | #6285 |
| myelomonocytic | #6286 |
| histone | #6287 |
| biological evaluation | #6290 |
| difficult | #6298 |
| dermis | #6313 |
| sheath | #6316 |
| monolithic | #6318 |
| allowed | #6320 |
| minor | #6320 |
| tracheal | #6322 |
| estrus | #6336 |
| immunomodulatory | #6337 |
| lymphocyte count | #6339 |
| localize | #6347 |
| tumor immune | #6348 |
| cell biology | #6355 |
| remitting | #6355 |
| borrelia burgdorferi | #6355 |
| microsatellite | #6356 |
| virgin | #6356 |
| signs | #6360 |
| tears | #6363 |
| tryptic | #6370 |
| pertussis | #6372 |
| unresolved | #6378 |
| ros generation | #6379 |
| cells cell | #6381 |
| metalloproteinase | #6392 |
| human subjects | #6394 |
| nicotinamide | #6408 |
| registers | #6410 |
| prodromal | #6450 |
| gonadal | #6451 |
| neuropathological | #6454 |
| models molecular | #6455 |
| peritoneum | #6460 |
| express | #6470 |
| biologic | #6473 |
| transgenes | #6474 |
| c4 | #6475 |
| immunity mucosal | #6476 |
| inoculation | #6477 |
| genetic variants | #6477 |
| severe | #6501 |
| gene function | #6502 |
| demonstrates | #6508 |
| organ specificity | #6511 |
| cell numbers | #6513 |
| stages | #6515 |
| synergy | #6523 |
| nitrite | #6523 |
| chronic | #6523 |
| share | #6539 |
| played | #6540 |
| apc | #6559 |
| proteins animals | #6559 |
| antibody titers | #6572 |
| cytotoxicity immunologic | #6575 |
| pace | #6583 |
| rheumatic | #6588 |
| proteases | #6588 |
| expression genes | #6603 |
| toll | #6603 |
| stain | #6604 |
| major source | #6614 |
| translocating | #6615 |
| parturition | #6635 |
| hpa | #6636 |
| whitney | #6639 |
| solid phase | #6644 |
| affinity | #6645 |
| parenchyma | #6650 |
| regulation | #6650 |
| presently | #6651 |
| sclerosis | #6655 |
| memory cell | #6657 |
| cystine | #6658 |
| cells cd4 | #6665 |
| subfamily | #6672 |
| melatonin | #6683 |
| animals antioxidants | #6683 |
| current understanding | #6687 |
| burgdorferi | #6696 |
| macrophages alveolar | #6701 |
| long noncoding rnas | #6715 |
| histone deacetylases | #6742 |
| pups | #6747 |
| normal levels | #6747 |
| estrogens | #6749 |
| demonstration | #6755 |
| relevant | #6761 |
| comparative genomics | #6768 |
| elastase | #6774 |
| cd8 positive | #6776 |
| interleukin18 | #6782 |
| helpful | #6782 |
| cytometric | #6804 |
| demonstrate | #6812 |
| study role | #6813 |
| glucose transport | #6814 |
| crystal structure | #6819 |
| induced acute | #6825 |
| intra articular | #6825 |
| cterminal | #6829 |
| eosinophil | #6829 |
| cd19 | #6829 |
| conflicting | #6830 |
| lname | #6833 |
| antilymphocyte | #6836 |
| molecules | #6840 |
| case control | #6852 |
| aspergillosis | #6852 |
| lymphoid tissues | #6854 |
| periodontal disease | #6855 |
| participates | #6855 |
| vascular endothelium | #6862 |
| sciatic nerve | #6863 |
| alter | #6865 |
| bioreactors | #6867 |
| activating | #6871 |
| facial nerve | #6873 |
| cell communication | #6882 |
| tool | #6883 |
| cytokine release | #6887 |
| lethality | #6889 |
| inflammatory responses | #6893 |
| lung injury | #6900 |
| ankle joint | #6907 |
| harboring | #6908 |
| gastritis | #6915 |
| tumour necrosis | #6921 |
| recessive | #6922 |
| acetaldehyde | #6925 |
| induced pulmonary | #6931 |
| alternative | #6934 |
| microarray analysis | #6937 |
| cyclic | #6951 |
| inflammatory response | #6953 |
| sulfones | #6960 |
| player | #6974 |
| likewise | #6976 |
| exacerbations | #6984 |
| cdr | #6993 |
| equally | #7001 |
| rac1 | #7013 |
| biological function | #7014 |
| mapping | #7016 |
| degrade | #7020 |
| translational | #7020 |
| mimic | #7025 |
| fewer | #7033 |
| assay elisa | #7033 |
| suppressing | #7047 |
| th1 th2 | #7048 |
| histology | #7056 |
| nucleotide | #7060 |
| target cells | #7063 |
| genome wide | #7063 |
| heterogeneous | #7071 |
| aureus | #7072 |
| subjected | #7072 |
| immune cells | #7075 |
| serine proteases | #7082 |
| proportion | #7083 |
| reduced | #7086 |
| glomeruli | #7088 |
| finally | #7092 |
| atherosclerotic lesions | #7094 |
| orthomyxoviridae | #7108 |
| lyme disease | #7115 |
| thp1 cells | #7121 |
| apoptotic cells | #7124 |
| dividing | #7134 |
| mounted | #7137 |
| autophagy | #7144 |
| extracellular | #7153 |
| immunity cellular | #7161 |
| genetic markers | #7162 |
| messenger rats | #7166 |
| cascades | #7175 |
| synteny | #7188 |
| moiety | #7194 |
| promoted | #7198 |
| higher incidence | #7202 |
| lymphoid tissue | #7205 |
| bovine serum albumin | #7219 |
| dependency | #7223 |
| amino acid | #7225 |
| relevance | #7233 |
| mtx | #7237 |
| recognised | #7238 |
| polysaccharides | #7242 |
| sirt1 | #7251 |
| participate | #7253 |
| prevalent | #7262 |
| immuno | #7265 |
| role pathogenesis | #7272 |
| breeding | #7286 |
| inheritance | #7292 |
| rolling | #7300 |
| prime | #7313 |
| dissecting | #7326 |
| avidity | #7332 |
| expressed genes | #7334 |
| adhesins | #7335 |
| inflammasome | #7342 |
| potential targets | #7343 |
| secreted | #7347 |
| disease specific | #7350 |
| uncontrolled | #7353 |
| metalloendopeptidases | #7355 |
| microglobulin | #7363 |
| adulthood | #7369 |
| transduction animals | #7370 |
| oxide nitric | #7377 |
| array | #7387 |
| analyses | #7391 |
| nervous | #7406 |
| transglutaminase | #7410 |
| chemokines | #7411 |
| interleukin6 | #7411 |
| proven | #7418 |
| supernatants | #7428 |
| genotyping | #7446 |
| immunocytochemistry | #7453 |
| fusion protein | #7456 |
| cells peripheral | #7461 |
| β2 | #7467 |
| airways | #7489 |
| adjuvant | #7493 |
| inhibitory factor | #7500 |
| cytotoxic cells | #7518 |
| disease incidence | #7535 |
| anchor | #7536 |
| eliminate | #7540 |
| early disease | #7541 |
| il1 beta | #7545 |
| lesser extent | #7547 |
| interleukin1beta | #7549 |
| necrotic | #7550 |
| activity relationship | #7553 |
| responder | #7562 |
| elevations | #7589 |
| interacting | #7594 |
| micrograms | #7596 |
| hydrocarbon | #7610 |
| appeared | #7610 |
| arginine | #7621 |
| evident | #7628 |
| cytometry | #7630 |
| unexplained | #7632 |
| allogeneic | #7640 |
| peripheral nervous | #7645 |
| sustain | #7654 |
| receptors immunologic | #7659 |
| component | #7661 |
| graft survival | #7661 |
| murine model | #7665 |
| considerable | #7704 |
| histone deacetylase | #7707 |
| placental | #7712 |
| differentially expressed | #7721 |
| chromosomes | #7722 |
| activators | #7728 |
| motifs | #7730 |
| critical roles | #7731 |
| bacterial toxins | #7735 |
| diagnostics | #7735 |
| initiation | #7745 |
| 325 | #7749 |
| rodent | #7751 |
| chain | #7753 |
| granulocyte | #7754 |
| leukocytes mononuclear | #7766 |
| candidate genes | #7769 |
| activates | #7772 |
| mer | #7772 |
| 37°c | #7773 |
| manuscript | #7780 |
| resolving | #7797 |
| carbonic | #7798 |
| cells tregs | #7800 |
| cell surface receptors | #7807 |
| diet fat | #7810 |
| tgf beta1 | #7831 |
| lipopolysaccharides | #7836 |
| patients levels | #7843 |
| strain | #7844 |
| cells pbmcs | #7853 |
| sirtuin | #7854 |
| retinoid | #7862 |
| interleukin1 | #7866 |
| ifnγ | #7872 |
| gene therapy | #7878 |
| amenable | #7895 |
| analyze | #7897 |
| illness | #7901 |
| lymphopenia | #7909 |
| 2nd | #7917 |
| th2 | #7918 |
| fact | #7925 |
| mann | #7929 |
| myocarditis | #7932 |
| discoveries | #7955 |
| cellular immune | #7957 |
| immunodiffusion | #7959 |
| transform infrared | #7960 |
| positive | #7982 |
| nitrites | #7983 |
| candidate gene | #7987 |
| scoring | #7989 |
| tregs | #7991 |
| direct effects | #7991 |
| unknown | #7993 |
| immune function | #7994 |
| oxidative | #7996 |
| fertilized | #8002 |
| identifies | #8007 |
| haplotypes humans | #8011 |
| polymorphisms | #8012 |
| psa | #8015 |
| essential | #8017 |
| hydroxy | #8030 |
| capacity | #8031 |
| raised | #8040 |
| lncrna | #8047 |
| macroscopic | #8049 |
| myeloid differentiation | #8054 |
| respiratory distress | #8063 |
| address | #8064 |
| drive | #8066 |
| evaluation preclinical | #8067 |
| factor signal | #8077 |
| ascertained | #8077 |
| spanning | #8085 |
| hypophyseal | #8087 |
| tetramer | #8088 |
| appearing | #8088 |
| clinical evaluation | #8089 |
| suboptimal | #8101 |
| physiological | #8105 |
| prolongation | #8108 |
| homozygosity | #8108 |
| considerably | #8109 |
| intronic | #8113 |
| prerequisite | #8120 |
| reasons | #8130 |
| nash | #8133 |
| bovine | #8133 |
| latest | #8134 |
| definition | #8141 |
| macrophages peritoneal | #8141 |
| dying | #8148 |
| trachea | #8156 |
| peripheral nerve | #8160 |
| relapses | #8166 |
| elevated | #8167 |
| conditioned | #8167 |
| characterize | #8170 |
| harbor | #8170 |
| bacterial infection | #8176 |
| expression | #8180 |
| member | #8181 |
| induced inflammation | #8186 |
| rescue | #8192 |
| sacrificed | #8197 |
| cassette | #8198 |
| analysing | #8209 |
| underlying | #8214 |
| preferential | #8216 |
| genetic associations | #8225 |
| sulphate | #8225 |
| defective | #8238 |
| ors | #8241 |
| marginal zone | #8244 |
| foster | #8245 |
| wide | #8261 |
| cultured cytokines | #8268 |
| ppar | #8274 |
| fibrinogen | #8275 |
| bone resorption | #8290 |
| clinical manifestations | #8294 |
| differ | #8295 |
| disease genome | #8295 |
| subcutaneous injection | #8300 |
| streptococcal | #8302 |
| oxygen | #8304 |
| combined treatment | #8309 |
| monoester | #8310 |
| remodeling | #8311 |
| peptide1 | #8316 |
| 11 | #8316 |
| aspergillus fumigatus | #8316 |
| genetically modified | #8320 |
| tlr | #8339 |
| cov2 infection | #8349 |
| boronic | #8363 |
| vh | #8363 |
| frequency | #8364 |
| parietal | #8367 |
| firstly | #8379 |
| fibrils | #8388 |
| migrate | #8391 |
| expressed | #8400 |
| residue | #8401 |
| poly | #8401 |
| p001 | #8404 |
| cd11b | #8408 |
| unaffected | #8411 |
| hydrophilicity | #8420 |
| advancement | #8424 |
| notion | #8424 |
| macrophage activation | #8429 |
| highlights | #8433 |
| defense | #8436 |
| viable | #8460 |
| 14 | #8468 |
| lamina | #8472 |
| manifestation | #8482 |
| protein conformation | #8485 |
| damaging | #8500 |
| promotes | #8502 |
| booster | #8512 |
| inflammatory process | #8516 |
| involves | #8520 |
| cells express | #8525 |
| mildly | #8527 |
| phenotype | #8539 |
| drug development | #8539 |
| burkholderia | #8540 |
| forkhead transcription | #8544 |
| human neutrophils | #8545 |
| estradiol | #8546 |
| copy | #8554 |
| tubule | #8558 |
| adaptive | #8568 |
| inflammatory cytokines | #8576 |
| responsive | #8580 |
| cellular functions | #8582 |
| marginal | #8600 |
| productive | #8609 |
| region | #8618 |
| stress reactive | #8622 |
| chickens | #8638 |
| xanthine | #8641 |
| positivity | #8659 |
| uncovered | #8689 |
| inducers | #8705 |
| outline | #8708 |
| experimental mice mice | #8716 |
| vigorous | #8717 |
| constitutive expression | #8717 |
| ccaat | #8720 |
| staphylococci | #8725 |
| regulatory cell | #8734 |
| cytokine | #8750 |
| recovered | #8751 |
| resorption | #8757 |
| rejection | #8759 |
| larynx | #8761 |
| subset | #8775 |
| chemokine receptor | #8777 |
| impaired | #8781 |
| highlight | #8782 |
| promoter | #8789 |
| cells human | #8790 |
| 4 weeks | #8792 |
| homozygous | #8792 |
| generate | #8799 |
| fungal infections | #8807 |
| occasionally | #8808 |
| human serum | #8808 |
| chemically | #8809 |
| parotid | #8809 |
| generates | #8811 |
| female male | #8812 |
| cytokine levels | #8825 |
| correlated | #8830 |
| kupffer | #8836 |
| cell phenotype | #8866 |
| pathway | #8867 |
| precisely | #8877 |
| bovis | #8882 |
| pathways | #8883 |
| unidentified | #8885 |
| frequencies | #8890 |
| deletion | #8893 |
| key regulator | #8903 |
| endopeptidases | #8922 |
| flow cytometric | #8932 |
| hypothalamo | #8941 |
| strengthen | #8941 |
| and or | #8942 |
| staining | #8944 |
| chemiluminescence | #8945 |
| modulate | #8948 |
| pge2 | #8966 |
| pitfalls | #8967 |
| subpopulation | #8967 |
| attack | #8975 |
| neonatal | #8981 |
| gene | #8983 |
| endosomal | #8987 |
| 129 | #8990 |
| vasculature | #9008 |
| rna long | #9017 |
| chemoattractant | #9019 |
| adrenocorticotropic | #9019 |
| discriminate | #9043 |
| thp1 | #9068 |
| leading | #9074 |
| positioned | #9075 |
| specific role | #9081 |
| glut4 | #9084 |
| hl60 | #9115 |
| cd4 cell | #9129 |
| human | #9131 |
| differentially | #9131 |
| cell surface | #9135 |
| pad | #9136 |
| ongoing | #9160 |
| reconstitution | #9166 |
| negative | #9175 |
| causative | #9182 |
| preincubation | #9186 |
| secrete | #9196 |
| tnf | #9198 |
| lethal | #9205 |
| serologic | #9213 |
| respiratory syndrome | #9222 |
| innate immunity | #9233 |
| started | #9233 |
| sequence | #9238 |
| cells isolated | #9241 |
| glomerulus | #9242 |
| immortalized | #9244 |
| severely | #9250 |
| offer | #9255 |
| orphan | #9255 |
| millions | #9268 |
| ubiquitous | #9272 |
| matrix | #9273 |
| killer | #9278 |
| crystal structures | #9313 |
| clear | #9315 |
| smoking status | #9329 |
| sdspage | #9335 |
| copolymers | #9346 |
| carbohydrate | #9368 |
| neutralizing | #9381 |
| immunoblot | #9395 |
| sweden | #9420 |
| functionality | #9425 |
| cysteine | #9458 |
| ifnα | #9459 |
| lacks | #9460 |
| treatment strategies | #9463 |
| immunomodulation | #9473 |
| luminescent | #9474 |
| molecular | #9484 |
| endotoxins | #9487 |
| tlr4 | #9501 |
| immobilized | #9505 |
| immunofluorescence | #9519 |
| hormonal | #9519 |
| cyclosporin | #9519 |
| sensitized | #9523 |
| detrimental | #9524 |
| heritable | #9530 |
| preexisting | #9543 |
| neuroinflammation | #9558 |
| factor beta1 | #9560 |
| interferon regulatory | #9572 |
| regulated | #9576 |
| culture techniques | #9577 |
| analogous | #9593 |
| entering | #9608 |
| affinities | #9614 |
| steroid hormones | #9615 |
| pretreated | #9624 |
| vaccinated | #9638 |
| gestation | #9639 |
| mammalian cells | #9643 |
| attached | #9647 |
| genetic models | #9655 |
| basement membrane | #9657 |
| key | #9658 |
| vehicle | #9670 |
| cell adhesion | #9678 |
| dramatic | #9694 |
| slight | #9694 |
| accessible | #9708 |
| snp | #9709 |
| azathioprine | #9721 |
| ear | #9723 |
| environment interaction | #9730 |
| humanized | #9753 |
| livers | #9753 |
| maintenance | #9756 |
| metabolic syndrome mets | #9758 |
| functional analysis | #9772 |
| blocked | #9776 |
| cleavage | #9781 |
| microscopic | #9784 |
| adhesion cell | #9784 |
| nasal | #9786 |
| plasminogen activator | #9788 |
| structure activity | #9789 |
| lowered | #9804 |
| infectious | #9804 |
| sterile | #9810 |
| driven | #9836 |
| fibronectin | #9846 |
| delineation | #9856 |
| rheumatology | #9870 |
| phage | #9872 |
| memory cells | #9874 |
| nonhuman primates | #9876 |
| pathogens | #9902 |
| serological | #9907 |
| coculture | #9927 |
| interleukin8 | #9936 |
| healthy control | #9938 |
| reactions | #9953 |
| monkeys | #9973 |
| anticipated | #9993 |
| nucleic acids | #10007 |
| flare | #10014 |
| inflammatory cytokine | #10023 |
| genotype | #10053 |
| serum | #10061 |
| leukocytes | #10067 |
| administered | #10070 |
| differentiation factor | #10076 |
| inflammation male | #10091 |
| generating | #10093 |
| surface receptors | #10102 |
| fibrin | #10105 |
| virulence factors | #10110 |
| cells patients | #10110 |
| activated | #10122 |
| ccl4 | #10125 |
| il1beta | #10131 |
| edge | #10132 |
| new strategy | #10136 |
| host cells | #10139 |
| mitogens | #10140 |
| kappa | #10143 |
| cell signaling | #10143 |
| th2 cells | #10147 |
| retroviridae | #10157 |
| postmenopausal | #10172 |
| traps | #10177 |
| hydrogen peroxide | #10184 |
| placenta | #10185 |
| named | #10188 |
| tlrs | #10207 |
| delta | #10218 |
| summarize | #10236 |
| day | #10244 |
| molecular biology | #10259 |
| rats spraguedawley receptors | #10277 |
| arg | #10279 |
| reproducible | #10283 |
| animals anti | #10304 |
| germ | #10305 |
| gene environment | #10307 |
| tendency | #10317 |
| scid | #10324 |
| lectins | #10329 |
| dismutase | #10332 |
| avian influenza | #10343 |
| reductive | #10347 |
| complete | #10365 |
| mediators | #10378 |
| nterminal | #10392 |
| partially | #10400 |
| lasting | #10406 |
| promote | #10424 |
| determine | #10429 |
| cterminus | #10432 |
| refined | #10437 |
| kill | #10441 |
| cattle | #10446 |
| assays | #10447 |
| indirectly | #10460 |
| mediates | #10474 |
| thioredoxin | #10475 |
| occur | #10477 |
| motif | #10479 |
| redundant | #10502 |
| receptor binding | #10504 |
| developing | #10513 |
| behavior animal | #10515 |
| promoter regions | #10545 |
| phosphate | #10548 |
| produced | #10552 |
| exception | #10554 |
| dysregulated | #10557 |
| critical | #10564 |
| influence | #10568 |
| understood | #10572 |
| converting enzyme | #10584 |
| progressive | #10597 |
| rise | #10608 |
| female | #10609 |
| shortened | #10612 |
| small molecule | #10616 |
| nf kappa | #10617 |
| extracellular matrix | #10620 |
| paralysis | #10632 |
| primers | #10636 |
| collectively | #10637 |
| underlie | #10642 |
| testosterone | #10659 |
| macrophage colony | #10664 |
| selective inhibitor | #10667 |
| aged osteoarthritis | #10675 |
| summary | #10684 |
| repeats | #10685 |
| pbs | #10702 |
| respond | #10705 |
| cerebrospinal fluid | #10708 |
| 17 | #10713 |
| disruption | #10729 |
| issue | #10762 |
| conformation | #10767 |
| il18 | #10770 |
| generation | #10781 |
| cleaved | #10800 |
| 103 | #10811 |
| conditional | #10821 |
| capture | #10822 |
| operated | #10824 |
| seropositive | #10826 |
| cellular mechanisms | #10838 |
| belonging | #10857 |
| saline | #10857 |
| restraint | #10864 |
| phosphatase | #10866 |
| immunoblotting | #10872 |
| factor1 | #10880 |
| base | #10885 |
| connective tissue | #10896 |
| multifunctional | #10904 |
| phagocytosis | #10904 |
| avoid | #10909 |
| ineffective | #10909 |
| luciferase | #10915 |
| bronchoalveolar | #10916 |
| promise | #10920 |
| pivotal | #10926 |
| secondary | #10926 |
| mulatta | #10929 |
| mannose | #10934 |
| persisted | #10939 |
| concluded | #10955 |
| methotrexate | #10967 |
| myeloid cells | #10978 |
| airway inflammation | #10982 |
| degrading | #10983 |
| subcutaneously | #10984 |
| immunoassay | #10984 |
| characterization | #10986 |
| governing | #10998 |
| septic | #11000 |
| ethanol | #11000 |
| tnfα | #11003 |
| mpo | #11010 |
| cell subsets | #11012 |
| originally | #11016 |
| 263 | #11027 |
| immunohistochemistry | #11028 |
| occurrence | #11030 |
| scid mice | #11030 |
| messenger | #11037 |
| hyper | #11040 |
| optical imaging | #11045 |
| skin | #11056 |
| establish | #11066 |
| calcitriol | #11067 |
| tumor progression | #11088 |
| paternal | #11094 |
| add | #11096 |
| freezing | #11102 |
| systemic | #11112 |
| infection animals | #11117 |
| focusing | #11144 |
| genetic polymorphism | #11161 |
| innate immune response | #11167 |
| male | #11167 |
| osteoarthritis | #11176 |
| influx | #11177 |
| receptors | #11177 |
| subsequent | #11177 |
| affinity chromatography | #11186 |
| genes involved | #11187 |
| ankylosing spondylitis | #11197 |
| article | #11201 |
| directly | #11208 |
| bsa | #11210 |
| limited | #11223 |
| sorting | #11229 |
| elicited | #11230 |
| interleukin10 | #11232 |
| disulfides | #11233 |
| contributed | #11248 |
| peptidase | #11251 |
| human blood | #11281 |
| ability | #11284 |
| extensive | #11297 |
| humans influenza | #11314 |
| genotyped | #11318 |
| compared controls | #11322 |
| depends | #11323 |
| oxidant | #11344 |
| caution | #11347 |
| addressing | #11351 |
| tissue damage | #11352 |
| correlate | #11354 |
| extra | #11356 |
| histopathologic | #11376 |
| neuroglia | #11384 |
| modifications | #11385 |
| experimental evidence | #11409 |
| increased expression | #11410 |
| pharmacology | #11413 |
| oxidative phosphorylation | #11428 |
| eosinophilic | #11432 |
| interleukin12 | #11437 |
| quantified | #11438 |
| receptor | #11445 |
| hla class | #11447 |
| cell death | #11460 |
| enhance | #11461 |
| reduces | #11466 |
| governed | #11476 |
| initiating | #11479 |
| contrasting | #11480 |
| melanoma cells | #11488 |
| compared healthy | #11489 |
| cd8 cell | #11498 |
| ankle | #11508 |
| serine | #11525 |
| cytosol | #11542 |
| recipient | #11546 |
| ca2 | #11559 |
| therapeutic interventions | #11561 |
| mets | #11566 |
| jurkat | #11569 |
| backgrounds | #11570 |
| inflammatory effects | #11595 |
| culture medium | #11599 |
| differential expression | #11606 |
| frequently | #11627 |
| alteration | #11627 |
| chicken | #11649 |
| swiss | #11652 |
| enhanced | #11661 |
| exerted | #11663 |
| immunologic memory | #11672 |
| transforming growth | #11678 |
| relief | #11691 |
| synergism | #11703 |
| controls | #11730 |
| psychotic | #11730 |
| toxin | #11735 |
| aiming | #11737 |
| innovative | #11751 |
| amyotrophic | #11769 |
| cell lineage | #11773 |
| constitutes | #11774 |
| inoculated | #11781 |
| commentary | #11785 |
| multiple | #11805 |
| selective | #11814 |
| display | #11817 |
| moderately | #11819 |
| altered | #11829 |
| insufficient | #11830 |
| sequence homology | #11840 |
| 9 | #11857 |
| graft | #11866 |
| analogues | #11871 |
| forkhead | #11888 |
| stained | #11890 |
| enzyme | #11942 |
| augmentation | #11943 |
| classic | #11944 |
| supplied | #11946 |
| gastrointestinal tract | #11958 |
| animals bone | #11966 |
| reveal | #11966 |
| maternal fetal | #11968 |
| adherent | #11980 |
| stress response | #11991 |
| contribution | #11998 |
| tgf | #12005 |
| biomarker | #12016 |
| antiserum | #12017 |
| cricetulus | #12021 |
| deacetylase | #12050 |
| encoding | #12051 |
| plasma cell | #12059 |
| aethiops | #12067 |
| propose | #12072 |
| fat diet | #12104 |
| immunologic factors | #12106 |
| protection | #12107 |
| downstream | #12107 |
| il2 | #12111 |
| tyrosine | #12113 |
| lung | #12116 |
| effectively | #12118 |
| replaced | #12144 |
| induced cell | #12147 |
| bromide | #12152 |
| humans | #12155 |
| quiescent | #12181 |
| switched | #12181 |
| genetic vectors | #12203 |
| oligodeoxyribonucleotides | #12204 |
| myd88 | #12222 |
| histologic | #12222 |
| lectin | #12223 |
| therapeutics | #12230 |
| toxic | #12231 |
| mesenteric | #12231 |
| represents | #12233 |
| receptors estrogen | #12236 |
| corticosterone | #12242 |
| noncoding | #12244 |
| diabetic mice | #12257 |
| fibroblasts humans | #12268 |
| recombinant | #12270 |
| splice | #12271 |
| involving | #12273 |
| fluorescent antibody | #12276 |
| mineral | #12297 |
| tnf alpha | #12300 |
| streptococcus | #12310 |
| harmful | #12319 |
| depending | #12361 |
| acid | #12363 |
| leukocyte count | #12369 |
| syndromes | #12371 |
| tradeoff | #12389 |
| interplay | #12412 |
| origin | #12416 |
| clonal | #12420 |
| microfilament | #12423 |
| reversed | #12439 |
| publication adaptor proteins | #12462 |
| weaker | #12464 |
| protein expression | #12503 |
| pain | #12532 |
| hydrochloride | #12535 |
| drug design | #12567 |
| functional | #12573 |
| suppressor | #12596 |
| rats treated | #12596 |
| binding site | #12597 |
| monomeric | #12605 |
| cells natural | #12637 |
| medullary | #12637 |
| explained | #12643 |
| macaca | #12645 |
| notably | #12664 |
| fetuses | #12665 |
| chronic diseases | #12665 |
| cdnas | #12679 |
| adenine | #12679 |
| 6 weeks | #12681 |
| p38 mitogen | #12681 |
| investigation | #12697 |
| instance | #12709 |
| alveolar | #12729 |
| persistent | #12729 |
| receptor alpha | #12743 |
| modulators | #12770 |
| interactions | #12785 |
| aimed | #12791 |
| nature | #12795 |
| influencing | #12800 |
| diminished | #12804 |
| initiated | #12813 |
| tibia | #12813 |
| sole | #12814 |
| metalloproteinases | #12819 |
| thought | #12823 |
| twin | #12854 |
| isolated | #12871 |
| solely | #12882 |
| disadvantages | #12886 |
| sulfhydryl | #12921 |
| sustained | #12922 |
| assay | #12926 |
| breakdown | #12984 |
| cell division | #13004 |
| embryonic development | #13020 |
| damage | #13056 |
| removing | #13067 |
| tryptophan | #13079 |
| tightly | #13087 |
| crystallography | #13101 |
| hyaluronic | #13102 |
| enabling | #13133 |
| time pcr | #13141 |
| publications | #13143 |
| receptors cell | #13145 |
| stereoisomerism | #13158 |
| distress syndrome | #13175 |
| ancestral | #13179 |
| retained | #13203 |
| valine | #13205 |
| division | #13213 |
| suffering | #13215 |
| single nucleotide polymorphisms | #13234 |
| opportunity | #13243 |
| opportunities | #13258 |
| 1 protein | #13270 |
| chemotaxis | #13279 |
| modulator | #13283 |
| lavage fluid | #13293 |
| transgene | #13297 |
| ascending | #13302 |
| regulators | #13320 |
| elucidated | #13323 |
| purity | #13330 |
| bronchoalveolar lavage | #13334 |
| nk | #13353 |
| fisher | #13357 |
| inhibitory effects | #13362 |
| lymphoproliferative | #13372 |
| amyotrophic lateral | #13377 |
| facilitating | #13380 |
| overexpressed | #13383 |
| scattered | #13389 |
| borrelia | #13393 |
| intact | #13410 |
| independently | #13433 |
| thiol | #13434 |
| fibroblast | #13447 |
| oocytes | #13463 |
| embryos | #13465 |
| marrow derived | #13484 |
| spraguedawley receptors | #13488 |
| overcome | #13489 |
| endopeptidase | #13500 |
| aspect | #13523 |
| lateral sclerosis | #13577 |
| tail | #13589 |
| selectively | #13591 |
| lipopolysaccharide | #13598 |
| elisa | #13612 |
| heritability | #13616 |
| vertebrates | #13627 |
| renal disease | #13634 |
| cure | #13674 |
| peripheral | #13689 |
| reproductive | #13755 |
| clones | #13757 |
| requires | #13783 |
| profiling gene | #13808 |
| lavage | #13811 |
| exon | #13822 |
| arising | #13831 |
| secretory | #13835 |
| techniques | #13873 |
| 6 | #13879 |
| killer cells | #13891 |
| exposed | #13917 |
| cloned | #13927 |
| iga | #13936 |
| hepatocytes | #13938 |
| tolerant | #13992 |
| lncrnas | #14002 |
| anti inflammatory | #14010 |
| killed | #14033 |
| selectin | #14034 |
| sensitization | #14035 |
| environmental | #14057 |
| insertion | #14063 |
| recombinant proteins | #14070 |
| neighboring | #14098 |
| reflects | #14102 |
| great | #14120 |
| preclinical | #14123 |
| highlighting | #14145 |
| preventing | #14148 |
| healthy individuals | #14159 |
| administration | #14164 |
| vaccination | #14176 |
| potent | #14183 |
| retroviral | #14208 |
| multigene | #14246 |
| advances | #14275 |
| amino acids | #14298 |
| ester | #14310 |
| oxidative stress | #14315 |
| cord | #14319 |
| incidence | #14322 |
| impairs | #14323 |
| domain | #14325 |
| psychosis | #14326 |
| bovine serum | #14329 |
| p38 | #14329 |
| isolation | #14334 |
| differentiation | #14342 |
| multiprotein | #14366 |
| mineral density | #14406 |
| differentiation cells | #14414 |
| #14414 | |
| resolve | #14420 |
| colony stimulating | #14421 |
| consistently | #14448 |
| kinases animals | #14452 |
| paracrine | #14452 |
| adenoviridae | #14472 |
| chlorocebus | #14481 |
| marrow transplantation | #14485 |
| targeted | #14490 |
| pathology | #14492 |
| il1 | #14500 |
| integrative | #14510 |
| cells vitro | #14537 |
| monocytes | #14540 |
| bone density | #14589 |
| infectious diseases | #14593 |
| biomedical | #14605 |
| nitrate | #14616 |
| nf kappab | #14627 |
| recombinant human | #14632 |
| divergent | #14638 |
| pathological | #14640 |
| enzyme activation | #14658 |
| lupus nephritis | #14661 |
| smoking | #14673 |
| transforming | #14675 |
| gfp | #14681 |
| inborn | #14696 |
| hand | #14698 |
| green fluorescent | #14703 |
| scarce | #14718 |
| risk developing | #14724 |
| substances | #14724 |
| nitrates | #14728 |
| oxide synthase | #14731 |
| p005 | #14732 |
| particulate | #14751 |
| oxidoreductases | #14753 |
| protein binding | #14757 |
| blood vessels | #14759 |
| human cells | #14768 |
| interferon alpha | #14780 |
| il1β | #14800 |
| degenerative | #14815 |
| proteinase | #14817 |
| originating | #14824 |
| vitro | #14829 |
| overlapping | #14835 |
| biocompatible | #14851 |
| prostaglandins | #14881 |
| controlled | #14895 |
| interaction | #14916 |
| chronically | #14923 |
| genomic dna | #14929 |
| potential therapeutic | #14939 |
| colleagues | #14950 |
| plays | #15011 |
| cross | #15041 |
| implications | #15063 |
| escape | #15078 |
| granule | #15079 |
| receptor gene | #15089 |
| phosphoric | #15090 |
| converting | #15126 |
| acute respiratory | #15173 |
| spinal cord | #15185 |
| seroepidemiologic | #15205 |
| bmd | #15213 |
| proliferation cells | #15219 |
| covalently | #15234 |
| preferentially | #15252 |
| adhesion | #15299 |
| fetus | #15300 |
| processed | #15329 |
| allografts | #15337 |
| synthase | #15339 |
| bone mineral density | #15340 |
| accelerate | #15346 |
| neurodegenerative | #15377 |
| pretreatment | #15379 |
| blood mononuclear | #15414 |
| interleukin6 il6 | #15440 |
| comparative | #15474 |
| selected | #15486 |
| antigens bacterial | #15511 |
| cells dcs | #15513 |
| locally | #15521 |
| transcriptase polymerase | #15530 |
| influenza human | #15537 |
| basis | #15540 |
| hormone | #15542 |
| central nervous | #15566 |
| estrogen receptor | #15572 |
| transduction | #15579 |
| vaccines | #15623 |
| responsiveness | #15647 |
| rna interference | #15649 |
| binds | #15651 |
| accelerator | #15673 |
| limitation | #15675 |
| pyruvate | #15682 |
| sequenced | #15696 |
| conformational | #15701 |
| cd28 | #15708 |
| connective | #15748 |
| gastric | #15775 |
| single | #15789 |
| fluorescent | #15793 |
| bone loss | #15832 |
| induced expression | #15835 |
| protein structure | #15849 |
| spinal | #15861 |
| vasculitis | #15884 |
| treating | #15887 |
| kappab | #15894 |
| gcsf | #15908 |
| competitive | #15910 |
| positron emission | #15913 |
| downregulation | #15914 |
| systemic inflammation | #15944 |
| methylated | #15945 |
| neurodegeneration | #15945 |
| involve | #15980 |
| ap1 | #15985 |
| plasmon resonance | #15986 |
| reflected | #15993 |
| chromatographic | #16019 |
| cnv | #16065 |
| oligonucleotide array | #16092 |
| 106 | #16097 |
| responding | #16105 |
| pluripotent | #16135 |
| bone mineral | #16141 |
| undetectable | #16148 |
| skeletal | #16151 |
| neurons | #16154 |
| tissue distribution | #16155 |
| disequilibrium | #16156 |
| beta1 | #16172 |
| exhibited | #16189 |
| response treatment | #16236 |
| grafted | #16238 |
| array sequence | #16239 |
| glandular | #16252 |
| functional studies | #16273 |
| responders | #16278 |
| new class | #16282 |
| subunit | #16293 |
| required | #16309 |
| animals base | #16310 |
| subclinical | #16311 |
| linkage disequilibrium | #16342 |
| receptor signaling | #16351 |
| difference | #16367 |
| remarkably | #16382 |
| molecular structure | #16391 |
| form | #16409 |
| signalling | #16414 |
| molecular mechanism | #16419 |
| publication antibodies | #16433 |
| cd40 | #16468 |
| shr | #16471 |
| capable | #16496 |
| grouped | #16512 |
| subcutaneous | #16522 |
| fibroblasts | #16525 |
| revealing | #16544 |
| targeting | #16552 |
| node | #16585 |
| respiratory | #16585 |
| organs | #16586 |
| tumor cells | #16600 |
| antibodies bacterial | #16603 |
| subunits | #16626 |
| profiling | #16651 |
| necrosis | #16655 |
| establishing | #16709 |
| negatively | #16709 |
| uric | #16743 |
| irradiated | #16757 |
| nick | #16765 |
| intramolecular | #16795 |
| deeper | #16801 |
| instrumental | #16812 |
| detected | #16851 |
| clinically | #16859 |
| immunoreactive | #16859 |
| serve | #16878 |
| inhibitory | #16881 |
| documented | #16904 |
| greatly | #16907 |
| colony | #16928 |
| turn | #16941 |
| immunosuppression | #16942 |
| mmps | #16957 |
| inhibition | #16959 |
| receptor 1 | #16964 |
| additionally | #16970 |
| humans hydrogen | #16982 |
| structurally | #16985 |
| prior | #16994 |
| additional | #17005 |
| binding protein | #17006 |
| recombinant fusion | #17013 |
| sulfate | #17069 |
| b7 | #17077 |
| count | #17083 |
| il12 | #17096 |
| sex factors | #17111 |
| consist | #17113 |
| minimal | #17116 |
| alpha subunit | #17119 |
| lysosomal | #17126 |
| unexpected | #17137 |
| tissue | #17148 |
| pluripotent stem | #17151 |
| receptors tumor | #17172 |
| csf | #17185 |
| activator | #17202 |
| lymph node | #17208 |
| underlying mechanisms | #17217 |
| stimulation | #17249 |
| starting | #17298 |
| peritoneal | #17299 |
| cell proliferation | #17318 |
| fluid | #17330 |
| propensity | #17345 |
| generations | #17377 |
| humans immunity | #17410 |
| constitute | #17425 |
| demonstrated | #17444 |
| membrane | #17466 |
| muscle skeletal | #17479 |
| allowing | #17505 |
| types | #17505 |
| transcriptase | #17515 |
| fibrous | #17515 |
| type iii | #17546 |
| localization | #17547 |
| constitutive | #17559 |
| cytometry humans | #17570 |
| discovery | #17583 |
| treatments | #17596 |
| peripheral blood | #17615 |
| variation | #17616 |
| packed | #17678 |
| differed | #17683 |
| expanded | #17687 |
| proved | #17691 |
| plasmon | #17698 |
| longitudinally | #17713 |
| pbmcs | #17728 |
| stimulating factor | #17743 |
| somatic | #17805 |
| inflammatory bowel disease | #17815 |
| dcs | #17827 |
| relating | #17861 |
| alpha tnf | #17880 |
| neuroendocrine | #17920 |
| oligonucleotide | #17954 |
| homology | #17962 |
| surface plasmon | #17971 |
| pregnancy | #17985 |
| chromosomal | #17994 |
| post | #17998 |
| inhibit | #18002 |
| labelled | #18004 |
| damaged | #18064 |
| osmolar | #18107 |
| 2 4 | #18130 |
| creating | #18142 |
| cytoplasm | #18155 |
| released | #18157 |
| trigger | #18161 |
| corticosteroids | #18164 |
| species | #18168 |
| endocrine | #18192 |
| vertebrate | #18206 |
| labeled | #18208 |
| subcellular | #18231 |
| rna messenger | #18235 |
| protein serine | #18279 |
| limiting | #18281 |
| reverse transcriptase | #18325 |
| evidenced | #18329 |
| truncated | #18336 |
| net | #18345 |
| avian | #18345 |
| males | #18375 |
| critically | #18389 |
| assumed | #18433 |
| modulated | #18444 |
| rats wistar | #18448 |
| pathogen | #18464 |
| immunogenicity | #18486 |
| acids | #18490 |
| reaching | #18494 |
| nonparametric | #18512 |
| constitutively | #18518 |
| processing | #18609 |
| hyaluronan | #18609 |
| sulfonamides | #18643 |
| investigating | #18651 |
| 15 | #18656 |
| 22 | #18658 |
| verify | #18669 |
| signal transduction | #18682 |
| agents steroidal | #18685 |
| remaining | #18721 |
| aim | #18788 |
| cerebrospinal | #18788 |
| created | #18803 |
| balanced | #18823 |
| cultured | #18823 |
| carry | #18829 |
| pathophysiological | #18830 |
| production | #18927 |
| nerve | #18943 |
| nested | #18957 |
| nfκb | #18987 |
| failed | #18988 |
| sequence analysis | #19002 |
| specific antigen | #19050 |
| observations | #19062 |
| provided | #19067 |
| bone marrow | #19084 |
| lungs | #19111 |
| stimulating | #19136 |
| protein | #19164 |
| bearing | #19167 |
| publication administration | #19185 |
| gained | #19200 |
| mitochondrial | #19260 |
| symptoms | #19288 |
| lost | #19298 |
| majority | #19304 |
| intra | #19311 |
| interacts | #19344 |
| hormones | #19441 |
| fatal | #19464 |
| interferons | #19489 |
| analyzing | #19515 |
| exogenous | #19526 |
| adrenal | #19553 |
| cytoskeletal | #19553 |
| rapidly | #19574 |
| inducible | #19616 |
| etiology | #19652 |
| environment | #19668 |
| implanted | #19680 |
| lps | #19681 |
| mice scid | #19683 |
| vesicular | #19701 |
| lineage | #19719 |
| markers | #19789 |
| histologically | #19817 |
| offers | #19826 |
| cutaneous | #19834 |
| precise | #19836 |
| pharmacological | #19854 |
| fetal | #19862 |
| shifted | #19875 |
| newly | #19892 |
| supporting | #19915 |
| vitro techniques | #19945 |
| yielded | #19948 |
| 8 | #19978 |
| 28 | #19979 |
| cns | #19979 |
| response relationship | #20014 |
| transient | #20038 |
| modify | #20055 |
| designated | #20056 |
| reverse | #20057 |
| casecontrol study | #20088 |
| mutagenesis | #20118 |
| illustrated | #20126 |
| downregulated | #20133 |
| ultimately | #20202 |
| κb | #20256 |
| 1 diabetes | #20263 |
| hypothalamic | #20285 |
| primary | #20303 |
| entered | #20310 |
| nitric | #20316 |
| gene expression | #20364 |
| markedly | #20453 |
| genotype humans | #20460 |
| mature | #20491 |
| microglia | #20561 |
| circulating | #20574 |
| overexpressing | #20593 |
| human pair | #20604 |
| polyacrylamide | #20612 |
| marrow | #20651 |
| defining | #20660 |
| pregnant | #20665 |
| equal | #20678 |
| resting | #20729 |
| injured | #20739 |
| mild | #20819 |
| local | #20825 |
| discovered | #20835 |
| cricetinae | #20839 |
| reduction | #20847 |
| illustrate | #20874 |
| lactic | #20908 |
| hypothesized | #20913 |
| tended | #20919 |
| 10 | #20952 |
| successful | #20952 |
| cell derived | #20955 |
| aberrant | #20961 |
| animals biomarkers | #21033 |
| 2 | #21085 |
| attractive | #21228 |
| acute | #21279 |
| produces | #21297 |
| transfected | #21316 |
| marked | #21340 |
| decreased | #21383 |
| maternal | #21389 |
| emerged | #21445 |
| survived | #21524 |
| confirms | #21558 |
| membrane proteins | #21585 |
| forming | #21593 |
| preserved | #21732 |
| contained | #21802 |
| previous | #21805 |
| 16 | #21813 |
| doses | #21835 |
| immunodeficiency | #21852 |
| electrophoresis | #21867 |
| mellitus type | #21871 |
| natural killer | #21877 |
| cell count | #21898 |
| prolonged | #21903 |
| heavy | #21965 |
| increasing | #21979 |
| polymeric | #22042 |
| gradually | #22067 |
| glial | #22202 |
| selecting | #22242 |
| extremely | #22248 |
| 4 | #22274 |
| opportunistic | #22307 |
| accepted | #22356 |
| emission tomography | #22395 |
| enable | #22402 |
| humans models | #22445 |
| initially | #22458 |
| microscopy confocal | #22466 |
| physiologic | #22470 |
| appears | #22488 |
| releasing | #22497 |
| suitable | #22522 |
| humans immunosuppressive | #22529 |
| confirm | #22553 |
| chemokine | #22558 |
| metabolic | #22585 |
| actins | #22597 |
| loss | #22611 |
| nf | #22756 |
| reactive protein | #22834 |
| utilizing | #22899 |
| transformed | #22917 |
| progression female | #22918 |
| detailed | #23005 |
| natural | #23089 |
| cell types | #23132 |
| sex | #23234 |
| null | #23277 |
| untranslated | #23305 |
| signaling | #23324 |
| syndrome | #23335 |
| bone | #23397 |
| necrosis factor | #23407 |
| rich | #23430 |
| cells tumor | #23467 |
| nucleic | #23501 |
| continued | #23663 |
| cellular | #23667 |
| expression gene | #23728 |
| attenuated | #23757 |
| mitogen | #23814 |
| serine threonine | #23835 |
| examine | #23864 |
| fusion proteins | #23968 |
| organ | #23990 |
| remained | #23998 |
| prevent | #24026 |
| confined | #24245 |
| oxidized | #24325 |
| called | #24330 |
| discussed | #24334 |
| genomic | #24394 |
| covering | #24485 |
| embryonic | #24490 |
| interleukin | #24583 |
| varying | #24640 |
| weeks | #24698 |
| mechanistic | #24796 |
| putative | #24897 |
| sarcoidosis | #24963 |
| detect | #24963 |
| remains | #25082 |
| controversial | #25175 |
| implies | #25192 |
| stromal | #25269 |
| type 1 diabetes | #25410 |
| enriched | #25470 |
| relation | #25543 |
| attributed | #25618 |
| 7 | #25632 |
| proteins | #25644 |
| tumor necrosis | #25683 |
| dysregulation | #25711 |
| cytoplasmic | #25732 |
| inflammatory agents | #25735 |
| energetic | #25813 |
| healthy | #25887 |
| representing | #25917 |
| challenging | #25976 |
| threonine | #25988 |
| mechanisms underlying | #26094 |
| signal | #26163 |
| tnfalpha | #26432 |
| frequent | #26487 |
| individuals | #26568 |
| antibodies viral | #26579 |
| growth factor | #26602 |
| validated | #26686 |
| lower | #26708 |
| treat | #26713 |
| 3 | #26751 |
| tolerated | #26780 |
| pathophysiology | #26782 |
| explored | #26850 |
| tumor necrosis factor | #26925 |
| comparable | #26955 |
| normal | #27016 |
| define | #27055 |
| exist | #27121 |
| presented | #27123 |
| consists | #27152 |
| intracellular | #27233 |
| invariant | #27331 |
| animals cells | #27339 |
| adaptor proteins | #27447 |
| chromosomes human | #27524 |
| associations | #27560 |
| kda | #27648 |
| tract | #27680 |
| possess | #27765 |
| exclude | #27824 |
| cell tumor | #27826 |
| attributable | #28018 |
| proteins humans | #28150 |
| heterozygote | #28266 |
| treated | #28436 |
| observe | #28472 |
| remain | #28560 |
| regulation humans | #28667 |
| threonine kinases | #28809 |
| hypothesis | #28819 |
| require | #28838 |
| examined | #29041 |
| infection | #29082 |
| 5 | #29247 |
| animals apoptosis | #29491 |
| intracellular signaling | #29517 |
| easily | #29557 |
| effective | #29656 |
| 005 | #29706 |
| fully | #29936 |
| exhibit | #29947 |
| gtp binding | #29997 |
| intravenous | #30185 |
| cell movement | #30520 |
| oxide | #30546 |
| reached | #30655 |
| active | #30908 |
| versus | #30963 |
| 1 | #31228 |
| cell differentiation | #31374 |
| vary | #31548 |
| blotting western | #31843 |
| free | #32409 |
| expression regulation | #32516 |
| needed | #32543 |
| objectives | #32805 |
| generally | #33368 |
| inhibited | #33394 |
| clinical | #33439 |
| sought | #34008 |
| reduce | #34128 |
| biological | #34247 |
| reflect | #34701 |
| separately | #34818 |
| agents | #34868 |
| assess | #34935 |
| polymerase | #35201 |
| nuclear | #35715 |
| polymerase chain | #36180 |
| formed | #36819 |
| chain reaction | #36949 |
| 001 | #36954 |
| measured | #42007 |
Bericht ausführen | |
Prominent publications by Rikard Holmdahl
KOL-Index: 15284
The purpose of the study was to map the dominant T cell epitope of the CB11 sequence of CII in RTlu haplotype rats and to determine if, when used as a synthetic peptide, it would induce tolerance to protect against CIA. A dominant epitope corresponding to residues 184-198 included in the sequence of the CB11 fragment of bovine CII was identified in proliferation assay using peptides in an epitope scanning system using synthetic peptides of 15 amino acids, overlapping by 12 amino acids. ...
| Bekannt für Mucosal Tolerance | Synthetic Peptide | Cell Epitope | Cia Cii | Collagen‐induced Arthritis |
KOL-Index: 14658
An antibody response to defined epitopes located on the triple helical portion of type II collagen (CII) is associated with the development of collagen-induced arthritis (CIA) and rheumatoid arthritis (RA). Monoclonal antibodies to epitopes associated with arthritis, but not antibodies specific for epitopes not associated with arthritis, induce arthritis in mice, the so-called collagen antibody induced arthritis (CAIA) model. We have selected monoclonal IgG antibodies specific for four ...
| Bekannt für Collagen Antibody | Induced Arthritis | Monoclonal Antibodies | Mice Inbred | Specific Epitopes |
KOL-Index: 13984
The Aq major histocompatibility complex (MHC) class II molecule is associated with susceptibility to murine collagen-induced arthritis (CIA), whereas the closely related H-2Ap molecule is not. To understand the molecular basis for this difference, we have analyzed the ability of H-2Aq and H-2Ap molecules (referred to as Aq and Ap) to bind and present collagen type II (CII)-derived glycosylated and non-glycosylated peptides. T cell clones specific for the immunodominant CII 256-270 ...
| Bekannt für Collagen‐induced Arthritis | Transgenic Models | Aq Molecule | Structural Basis | C3h Mice |
KOL-Index: 13727
BACKGROUND: Autoantibodies to cyclic citrullinated peptides (anti-CCP) are present in most patients with rheumatoid arthritis (RA), and associate with HLA-DRB1 shared epitope (SE) alleles.
OBJECTIVE: To investigate reactivities of anti-CCP to various citrullinated proteins/peptides, which represent potential autoantigens in RA, and to examine the relationship between such antibodies, and their association with genetic variants within HLA-DRB1 SE alleles.
METHODS: Serum samples from 291 ...
| Bekannt für Citrullinated Antigens | Rheumatoid Arthritis | Drb1 Alleles | Ccp Patients | Antibody Reactivities |
Localization of a critical restriction site on the I-A beta chain that determines susceptibility to collagen-induced arthritis in mice
[ PUBLICATION ]
Type II collagen-induced arthritis (CIA) in mice is an autoimmune experimental model for rheumatoid arthritis. Susceptibility to CIA is associated with certain major histocompatibility complex class II haplotypes. The two very closely related haplotypes H-2q and H-2p differ in susceptibility to CIA. Only mice of H-2q (DBA/1, B10G strains) but not mice of H-2p-expressing strains (like strain B10P) develop CIA and an autoimmune response to type II collagen (CII) after immunization with ...
| Bekannt für Mice Cia | Beta Chain | Rheumatoid Arthritis | H2q Haplotype | Type Collagen Cii |
KOL-Index: 13513
INTRODUCTION: It has previously been shown that an increased number of antibodies against citrullinated peptides/proteins (ACPA) predate the onset of rheumatoid arthritis (RA). Over time antibody positivity expands, involving more specific responses when approaching the onset of symptoms. We investigated the impact of human leukocyte antigen-shared epitope (HLA-SE) alleles and smoking on the development of ACPA, as well as in combination with ACPA during the state of quiescent ...
| Bekannt für Citrullinated Peptides | Onset Symptoms | Development Rheumatoid Arthritis | Combination Acpa | Hlase Smoking |
Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients
[ PUBLICATION ]
OBJECTIVE: High titers of specific anti-citrullinated protein antibodies (ACPAs) are frequently present in the serum of rheumatoid arthritis (RA) patients, but their presence in synovial fluid is less well characterized. The purpose of this study was to compare the levels of antibody to 4 well-defined citrullinated candidate RA autoantigens in serum and synovial fluid and to determine whether antibodies to one citrullinated antigen are dominant over another. Furthermore, we studied their ...
| Bekannt für Citrullinated Antigens | Synovial Fluid | Rheumatoid Arthritis Patients | Type Collagen | Antibodies Acpas |
Toll-like receptor 3 upregulation in macrophages participates in the initiation and maintenance of pristane-induced arthritis in rats
[ PUBLICATION ]
INTRODUCTION: Toll-like receptors (TLRs) are involved in both innate and adaptive immune responses and are likely to play a complex role in the pathogenesis of human rheumatoid arthritis (RA) and experimental arthritis. The objective of this study was to identify the key TLR in pristane-induced arthritis (PIA), a rat model for RA, and to clarify its roles in the initiation and maintenance of arthritis.
METHODS: Arthritis in DA rats was induced by pristane and the severity was evaluated ...
| Bekannt für Induced Arthritis | Tlr3 Expression | Rats Pristane | Receptor 3 | Inbred Strains Severity |
KOL-Index: 12776
Multiple sclerosis (MS) is a complex chronic neurologic disease with a suspected autoimmune pathogenesis1,2. Although there is evidence that the development of MS is determined by both environmental influences and genes, these factors are largely undefined3,4, except for major histocompatibility (MHC) genes. Linkage analyses and association studies have shown that susceptibility to MS is associated with genes in the human histocompatibility leukocyte antigens (HLA) class II region, but ...
| Bekannt für Multiple Sclerosis | Transgenic Mice | Hla Dr2 | Humanized Model | Spontaneous Disease |
KOL-Index: 12721
Polymorphism of the major histocompatibility complex (MHC) influences susceptibility to experimental autoimmune encephalomyelitis (EAE) induced by myelin basic protein (MBP) in rats. Current concepts relate such influences to the capacity of class II molecules to present relevant peptides to autoreactive T cells. We have here analyzed the MHC influence on the immune response and the development of EAE after immunization with the immunodominant peptide MBP-63-88. Analysis of MHC-congenic ...
| Bekannt für Myelin Basic Protein | Experimental Autoimmune | Major Histocompatibility | Rats Eae | Immune Response |
Multiplex Analyses of Antibodies Against Citrullinated Peptides in Individuals Prior to Development of Rheumatoid Arthritis
[ PUBLICATION ]
OBJECTIVE: The presence of antibodies against cyclic citrullinated peptides has been demonstrated to precede the onset of symptoms of rheumatoid arthritis (RA) by several years. The aim of this study was to analyze antibodies against 10 citrullinated autoantigen-derived peptides for reactivity before the onset of RA symptoms.
METHODS: A case-control study was conducted within the Medical Biobank of Northern Sweden. The study was performed in 409 individuals, 386 of whom donated 717 blood ...
| Bekannt für Citrullinated Peptides | Rheumatoid Arthritis | Onset Symptoms | Antibodies Cep1 | Type Collagen |
KOL-Index: 12510
Antibodies against type II collagen (anti-CII) are arthritogenic and have a crucial role in the initiation of collagen-induced arthritis. Here, we have determined the dependence of T and B cells in collagen-antibody-induced arthritis (CAIA) during different phases of arthritis. Mice deficient for B and/or T cells were susceptible to the CAIA, showing that the antibodies induce arthritis even in the absence of an adaptive immune system. To determine whether CII-reactive T cells could have ...
| Bekannt für Collagen Type | Arthritis Mice | Antigen Tcell | Antibodies Cii | Adaptive Immune |
KOL-Index: 12427
The nonobese diabetic (NOD) mouse spontaneously develops autoimmune-mediated diseases such as diabetes and Sjögren's syndrome. To investigate whether NOD genes also promote autoimmune-mediated arthritis we established a NOD strain with an MHC class II fragment containing the A(q) class II gene predisposing for collagen induced arthritis (NOD.Q). However, this mouse was resistant to arthritis in contrast to other A(q) expressing strains such as B10.Q and DBA/1. To determine the major ...
| Bekannt für Genetic Control | Complement Factor | Induced Arthritis | Locus Chromosome | Mice Inbred |
Schlüsselpersonen für Rheumatoid Arthritis
Top -Kols der Welt
Wählen Sie einen Suchphrase aus rheumatoid arthritis , rheumatoid arthritis patients , rheumatoid arthritis treatment , rheumatoid arthritis risk , rheumatoid arthritis study
Rikard Holmdahl:Expertenwirkung
Konzepte für welcheRikard Holmdahlhat direkten Einfluss:Rheumatoid arthritis, Induced arthritis, Experimental arthritis, Collagen type, Type collagen, Animal models, Reactive oxygen species, Autoimmune diseases.
Rikard Holmdahl:KOL -Auswirkungen
Konzepte im Zusammenhang mit der Arbeit anderer Autoren, für diefor which Rikard Holmdahl hat Einfluss:Rheumatoid arthritis, Multiple sclerosis, Autoimmune diseases, Oxidative stress, Animal models, Reactive oxygen species, Nadph oxidase.
Tools
Ist das dein Profil? Fordern Sie Ihr Profil an URL kopieren Einbetten Sie den Link zu Ihrem Profil ein |